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A major challenge for personalized medicine is to identify biomarkers that predict response 
to therapeutics. Current experience indicates that few pharmacogenetic biomarkers are 
individually predictive, since such biomarkers usually lack the sensitivity and specificity to 
achieve a clinically meaningful prediction on their own. The future is in combining multiple 
biomarkers together with clinical and other characteristics, with the aim of producing 
multivariable prediction algorithms that can serve as decision support tools for 
personalizing medicine. This PhD project approaches pharmacogenetics from two different 
angles. Firstly, we investigate specific hurdles to the adoption of genetic tests to guide 
pharmaceutical treatment. We study the characteristics of a pharmacogenetic test that 
predicts the development of a serious adverse drug reaction caused by the antipsychotic 
clozapine and model the requirements for the test to be clinically useful. In addition, we 
assess the cost-effectiveness of pharmacogenetic testing by means of a literature review 
and estimate how this would change in a future where genetic information is available at 
no additional cost at the time of prescribing, for example via an electronic health record. 
The second emphasis of this PhD is on the application of machine learning methods to 
predict pharmacogenetic responses in Phase 2 clinical trials. Genetic studies are highly 
dimensional and traditionally genetic variants are investigated independently in univariate 
analyses. Alternatively, machine learning algorithms can be used to model large numbers of 
variables simultaneously, even if these variables are correlated as is the case for genetic 
variants. These methods optimize predictive ability and a wide range of linear and non-
linear algorithms exists. Two clinical trials and one gene expression case-control study in 
different disease areas were analysed using machine learning (elastic net, random forest, 
support vector machine) and deep learning (neural network) methods with the aim of 
predicting efficacy and safety measures using genetic and clinical baseline variables. We 
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compare the predictive ability of the algorithms used and evaluate the strengths and 




1.1. Overview of pharmacogenetics 
When it comes to pharmacotherapy, one size does not fit all. Whereas some patients gain 
improvements in their condition as intended, others may fail to respond clinically or suffer 
from an adverse drug reaction (ADR), which results in treatment failure (Fig. 1). Non-
response to drug treatment and the occurrence of ADRs is a major burden on patients and 
society as a whole. On average, for 25-50% of patients, drug treatment response is 
suboptimal across a wide range of treatments (Spear, Heath-Chiozzi, & Huff, 2001). 
Furthermore, it is estimated that 3.5% of hospital admissions in Europe are caused by an 
ADR and that 10% of hospitalized patients develop and ADR (Bouvy, De Bruin, & 
Koopmanschap, 2015). On top of the health risks imposed on patients, ADRs have 
considerable economic consequences. On average ADRs increase the cost of hospitalization 
by US$2,000 or 20%, and the yearly cost of ADRs may exceed US$30 billion in the US and 
€24 billion in Europe (European Commission, 2008; Khan, 2013; Sultana, Cutroneo, & 
Trifirò, 2013). The duration of hospitalization increases by 8% in patients suffering an ADR 
(Khan, 2013). However, up to 20-30% of ADRs could be prevented by pharmacogenetic 
(PGx) testing (Alfirevic & Pirmohamed, 2017). Clearly, a predictive biomarker that 
personalizes treatment and improves response rates or prevents a proportion of ADRs from 
occurring would save health care resources and greatly improve patient experience. 
The variability in how patients respond to drugs is partly due to differences in patients’ 
characteristics such as age, sex, ethnicity and genetic make-up, and environmental factors 
such as diet, medication and alcohol and tobacco use. The research field of PGx studies the 
association between genetic markers and the variability in response to drug treatment. The 
terms pharmacogenetic and pharmacogenomic imply the study of interactions between 
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drug response and a single gene or the whole genome, respectively, but are used 
interchangeably in the literature and in this thesis (PharmGKB, 2017a). Genetic biomarkers 
have been associated with efficacy of drug treatment, risk of developing ADRs and drug 
dosage, though these distinctions are not always clear cut as toxicity may be the result of 
excessively high dosing and non-response due to inadequately low dosing. Different types 
of genetic variation exist, for example single nucleotide polymorphisms (SNPs), deletions, 
insertions or short tandem repeats, though in this PhD we mainly focus on SNPs.  
  
Figure 1. Inter-individual variability in drug response. Adapted from Samwald (2017). 
PGx variants are used as predictive biomarkers since they predict how a patient will 
respond to treatment, in contrast to prognostic biomarkers which predict disease 
progression independently of treatment. A patient’s genetic profile, alone or in 
combination with demographic details, clinical observations and environmental factors, can 
thus sometimes be used to tailor treatment to that individual patient. The hope is that 
personalized medicine will reduce the number of adverse events, and improve and quicken 
treatments by selecting the most effective drug and choosing the optimal dose (Jorgensen 
& Pirmohamed, 2011). In addition to improving patients’ health outcomes, PGx discoveries 
may increase our understanding of the pharmacodynamics and pharmacokinetics of a drug.  
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An important advantage of using DNA to personalise treatment is that DNA sequences 
largely remain unaltered over time, unlike gene expression or methylation levels and 
metabolic biomarkers. By consequence, if the genetic code of a patient is obtained once, 
this information stays relevant throughout their life. It is conceivable that whole genome 
sequencing, which currently costs approximately £1,000, would become cheap enough to 
be routinely incorporated in health records (Wetterstrand, 2016). Genotyping arrays, 
covering SNPs spread across the genome, are less costly (approximately £30-£200) and can 
also contain useful PGx information (Lu, Lewis, & Traylor, 2017). An exception to the 
unchangeable nature of DNA is somatic mutations in tumour cells. The DNA sequence of 
cancerous cells can mutate rapidly, so this can be regarded as a separate branch of PGx 
which will not be investigated in this thesis. However, there has been a lot of progress in 
this field and many cancer drugs are accompanied by PGx tests (Patel, 2016). 
The search for new predictive biomarkers often starts by investigating candidate genes, 
typically genes involved in the pharmacokinetic and pharmacodynamic pathways of a drug 
(Fig. 2). Since PGx effects of a variant only become evident after exposure to a drug, which 
may not happen for many carriers, these genes are not under selection pressure (Roden, 
Wilke, Kroemer, & Stein, 2011). Hence, PGx variants can be relatively common in the 
population. For example, the cytochrome P450 (CYP450) enzymes CYP1A2, CYP2D6, 
CYP2C9, CYP2C19 and CYP3A4 are involved in the metabolism of 60% of drugs and variants 
of these enzymes with increased or decreased enzyme activity are common in the 
Caucasian population (Table 1) (Preissner et al., 2013). A study looking at five commonly 
used drugs found that 91% of patients in the United States carries at least one variant that 
affects drug response (Van Driest et al., 2014). The drugs (and respective genes) included in 
this study were clopidogrel (CYP2C19), simvastatin (SLCO1B1), warfarin (CYP2C9 and 




Figure 2. Pharmacokinetic and pharmacodynamic pathways can be affected by genetic 
variability. Adapted from Pirmohamed & Park (2001). 
Table 1. Frequency of selected CYP variants in the Caucasian population. Adapted from 
Preissner et al. (2013) . 
CYP Allele Frequency (%) Enzyme Activity 
1A2 *1F 33.3 Higher inducibility  
 
*1D 4.82 Decrease 
2C9 *2 19.0% *1/*2; 1.6% *2/*2; 1.8 % *2/*3 Decrease 
 
*3 9 Decrease 
2C19 *2 16 Decrease 
 
*17 18 Increase 
2D6 *3 2.04 Decrease 
 
*4 20.7 Decrease 
 
*4D 3.4 Decrease 
 
*4L 4.5 Decrease 
 
*5 4.1 no enzyme 
 
*6 1.3 Non-functional 
 
*7 1 Decrease 
 
*9 2 Decrease 
 
*10 8 Decrease 
 
*41 8 decrease (expression) 
3A4 *17 2 Decrease 
 
*1B 17 increase (transcription)  
  *2 2.7 Decrease 
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It is important to note that not all statistically significant PGx biomarkers can be translated 
to clinically useful predictive tests. A PGx variant indicating a small increase in risk of 
developing an ADR or slightly lower chance of response might not have a clinical impact on 
the choice of drug. The required effect size to be of clinical relevance depends on specific 
circumstances, such as the severity of non-response or the ADR, the absolute risk of non-
response or ADR development and the availability and efficacy of alternative drugs. In order 
to have clinical utility, the effect size of a PGx variant must provide relevant and actionable 
information to the physician.  
In addition to clinical utility, the economic impact of PGx testing needs to be evaluated 
before implementing a biomarker in clinical practice. As health care resources are limited, 
the economic consequences of applying new technologies are important. Health economic 
studies compare costs and outcomes of different treatment strategies to assess which 
option is more cost-effective. A treatment is deemed cost-effective if the gain in health 
outcomes reduces total costs or comes at an affordable increase in costs. A review of the 
economics of individualized medicine found that in general personalized medicine is as 
cost-effective as other health care interventions (Hatz, Schremser, & Rogowski, 2014). This 
study included screening and prognostic biomarkers in addition to predictive genetic tests 
and also covered tests of viral or bacterial DNA. However, predictive PGx testing was more 
expensive than the use of prognostic or screening biomarkers. A second literature review of 
personalized medicine found that the majority of genetic tests were cost-effective and one 
in five tests reduced costs while providing better health outcomes (Phillips et al., 2014). The 
economics of PGx testing is a rapidly evolving field as more genetic biomarkers are 
discovered and the cost of genetic testing decreases. 
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1.1.1. Pharmacogenetic information and drug labelling 
PGx information that is deemed relevant is sometimes included on the drug label or 
package insert. The US Food and Drug Administration (FDA) curated Table of 
Pharmacogenomic Biomarkers in Drug Labeling lists 204 biomarkers on the labels of 165 
unique drugs in various treatment areas (U.S. Food and Drug Administration, 2017b). 
Information on the biomarker is included in the drug label, though not all labels provide 
guidance regarding genetic testing. One third of drugs on the FDA table are used in 
oncology (52 drugs, 32%), while psychiatry and infectious diseases are the second and third 
largest therapy areas with respectively 16% (27 drugs) and 10% (16 drugs) of PGx 
biomarkers (Fig. 3). CYP450 enzymes are involved in the metabolism of many drugs and are 
included frequently on FDA drug labels (Fig. 4). CYP2D6 has PGx associations with 44 drugs, 
while CYP2C19 is mentioned in 19 and CYP2C9 in 6 drug labels. Although CYP2D6 is the 
most quoted genetic biomarker on FDA drug labels, it has not had a significant impact on 
clinical practice (Pirmohamed, 2014). The glucose-6-phosphate dehydrogenase (G6PD) 
gene is associated with 22 drugs, among which antimalarials, analgesics and antibiotics 
(Luzzatto & Seneca, 2014). With regards to psychiatry, it is remarkable that all 27 
psychiatric drugs listed on the FDA table have PGx associations with CYP2D6, and 3 drugs 
also with CYP2C19.  
A second resource, the PharmGKB website managed by Stanford University, identifies 202 
drugs that contain PGx information on the FDA drug label and 92 with PGx details on the 
European Medicines Agency (EMA) European Public Assessment Report (Whirl-Carrillo et 
al., 2012). Genetic testing prior to use of the drug is required for 50 and 35 drugs by the 
FDA and EMA, respectively (Fig. 5). For a further five (FDA) and two (EMA) drugs genetic 
testing is recommended on the label. Differences in regulation and labelling between the 
US FDA and the European EMA could partly be due to varying allele frequencies in the 




Figure 3. Therapeutic areas of drugs listed on FDA Table of Pharmacogenomic Biomarkers in 
Drug Labeling (U.S. Food and Drug Administration, 2017b). 
 
 
Figure 4. Genes reported in labels of drugs listed on FDA Table of Pharmacogenomic 





Figure 5. Requirements on drug labels regarding PGx testing based on information from 
PharmGKB.org (PharmGKB, 2017b; Whirl-Carrillo et al., 2012). 
1.1.2. Examples of pharmacogenetic biomarkers 
There are some well-established PGx associations which are used in clinical practice as 
predictive PGx tests to improve drug safety and efficacy. An example of a safety PGx 
biomarker is the association of the HIV-1 reverse transcriptase inhibitor abacavir with a 
human leucocyte antigen (HLA) variant. About 4% of patients treated with abacavir develop 
a potentially fatal hypersensitivity syndrome (Hetherington et al., 2002; Symonds et al., 
2002). HLA-B*5701 is strongly associated with abacavir hypersensitivity syndrome with an 
exceptionally large odds ratio of 117 (Mallal et al., 2002). The clinical usefulness of HLA-
B*5701 screening has been confirmed in a clinical trial and as a result HLA-B*5701 
screening before initiation of abacavir treatment is required in the UK and US (Electronic 
Medicines Compendium, 2016b; Hughes, Hughes, Brothers, Spreen, & Thorborn, 2008; 
























Level of information 
on drug label 
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A second successful example of PGx safety associations with HLA alleles is the anti-epileptic 
drug carbamazepine. Carriers of the HLA-B*1502 allele are at high risk of developing 
Stevens-Johnson syndrome and toxic epidermal necrolysis, a severe ADR (Lim, Kwan, & Tan, 
2008). This association is very strong in Han Chinese and Taiwanese patients, with odds 
ratios exceeding 1000, and was also detected in Malay and Thai samples (Chung et al., 
2004; Hung et al., 2006). The HLA-B*1502 allele has low frequency in Japanese, Korean, 
European and African populations and occurrence of the ADR is rare in these patients (Lim 
et al., 2008). However, in Caucasian patients, HLA-A*3101 has been linked to Stevens-
Johnson syndrome and toxic epidermal necrolysis (McCormack et al., 2011). PGx testing is 
mandatory for patients of Asian descent prior to starting carbamazepine treatment in the 
US and testing is strongly recommended in the UK (Electronic Medicines Compendium, 
2015; U.S. Food and Drug Administration, 2013b) . The drug label also mentions the HLA-
A*3101 association without testing requirements.  
In addition to reducing the risk of ADRs, genetic variants may be used as efficacy 
biomarkers to identify patients who are likely to respond to a drug. Ivacaftor is used for the 
treatment of cystic fibrosis, a disease caused by over 1900 different mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) protein (Lubamba, Dhooghe, Noel, & 
Leal, 2012). The efficacy of ivacaftor depends on specific mutations in the CFTR gene. Cystic 
fibrosis patients with at least one G551D-CFTR allele benefit from ivacaftor, but the drug is 
ineffective for patients who are homozygous for the F508del-CFTR variant (Davies et al., 
2013; Flume et al., 2012; Ramsey et al., 2011). Both the FDA and the EMA require genetic 
testing before starting ivacaftor treatment (Electronic Medicines Compendium, 2016a; U.S. 
Food and Drug Administration, 2017a). 
The anti-coagulant warfarin is an example of how a PGx test can be used to establish the 
appropriate dose of a drug. The therapeutic dosing of warfarin is closely monitored by 
measuring the standardized international normalized ratio (INR), but there is wide variation 
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between patients in the dose needed to achieve a therapeutic INR. Variants of the vitamin 
K epoxide reductase complex (VKORC1), the target to which warfarin binds, and CYP2C9 
and CYP4F2, involved in the metabolism of the drug, have been associated with therapeutic 
warfarin dose. Together these genes explain around 40% to 54% of variability between 
patients (Fisch, Perry, Stephens, Horenstein, & Shuldiner, 2013). However, four clinical trials 
comparing time in therapeutic INR range between patients who were prescribed warfarin 
based on a dosing algorithm including CYP2C9 and VKORC1 genotypes and clinical variables, 
versus an algorithm based on clinical variables only did not find significant differences 
(Jonas et al., 2013; Kimmel et al., 2013; Pengo et al., 2015; Verhoef et al., 2013). A fifth trial 
concluded that the PGx algorithm lead to a higher percentage of time in therapeutic INR 
range and also that this range was reached more quickly (Pirmohamed et al., 2013). 
Although there is still uncertainty about the clinical utility of PGx guided warfarin dosing, 
the FDA recommends including CYP2C9 and VKORC1 genotype information in the 
calculation of the starting dose, if this information is available (U.S. Food and Drug 
Administration, 2016a). 
1.2. Research methods in pharmacogenetics 
The scientific methods used to investigate PGx associations have made a lot of progress, 
both in terms of the range of genetic variants studied as well as statistical rigour. The 
earliest PGx studies used the ratio between a drug and its metabolites to measure enzyme 
activity. This allowed distinguishing between genetic variants that cause different enzyme 
activity phenotypes. The assay method was for example used in the discovery of CYP2D6 
poor and ultrarapid metabolizers (Ingelman-Sundberg, 2005). In fact, phenotyping is still 




The development of the polymerase chain reaction (PCR) technique and sequencing made 
it possible to study specific candidate genes. The discovery of the HLA-B*5701 allele with 
abacavir hypersensitivity is a successful example of this approach. However, few findings 
from candidate gene studies have been replicated and many associations are likely false 
positives. This is partly due to the small sample sizes typically used in these PGx studies. In 
disease genetics studies increasing the sample size often revealed that effects estimated in 
small samples were overly optimistic (Fig. 6). In addition, candidate gene studies focused on 
one or a few variants in a gene instead of the variability in the entire gene (Pirmohamed, 
2014). Furthermore, the mechanism of action of a drug might not be fully clear and this 
complicates selection of candidate genes.  
 
Figure 6. Strength of association decreases with increasing sample sizes. Adapted from 
Ioannidis, Ntzani, Trikalinos, & Contopoulos-Ioannidis (2001). 
The question of choosing genes to study does not present itself in genome-wide association 
studies (GWAS), as they take a hypothesis free approach. Millions of variants can be 
assessed and hence p-values are compared to a strict statistical significance threshold 
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(usually 10-8) to account for multiple testing. By consequence, sample sizes need to be large 
to have sufficient statistical power to detect associations, particularly for moderate effect 
sizes. This partly explains why the success of PGx GWAS has been modest so far. GWAS of 
PGx outcomes have typically collected hundreds to thousands of patients, whereas some 
disease GWAS samples include over 100,000 individuals. In disease GWAS, increased 
sample sizes have led to more significant findings and the same is expected in PGx research 
(Fig. 7). However, it can prove difficult to recruit participants for PGx studies who not only 
need to suffer from the same disease, but also need to be treated with the same drug. In 
addition, studying a rare ADR can make it more challenging to attain a substantial sample 
size. International and multi-centre collaborations help to increase sample sizes. The field 
of PGx GWAS is not as advanced as disease genetics and fewer GWAS have been conducted 
(Fig 8). More and larger PGx GWAS are needed to confirm the associations from candidate 
gene studies and to uncover new PGx markers. Moreover, next generation sequencing 
techniques such as whole exome and whole genome sequencing allow even denser 
coverage of genetic variants (Katsila & Patrinos, 2015). This opens the door to studying a 
greatly increased number of variants, including rare variants. 
1.3. Pharmacogenetics in psychiatry 
Although various PGx associations with psychiatric drugs have been discovered, few 
associations have effects strong enough to influence clinical practice (Arranz & Kapur, 
2008). Many psychiatric drugs are metabolized by CYP450 enzymes and may inhibit or 
induce enzyme activity. CYP2D6 and CYP2C19 are the genes with the most clinically 
relevant PGx associations (Table 2) (Spina & de Leon, 2015). CYP2D6 variants are for 
example used in dosing guidelines for venlafaxine, pimozide, aripiprazole, haloperidol and 
tricyclic antidepressants. Patients treated with citalopram or escitalopram who are 
ultrarapid CYP2C19 metabolizers should receive increased doses to achieve the same level 
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of efficacy (Swen et al., 2011). Furthermore, response to antipsychotic treatment is 
associated with dopamine receptor (DRD2 and DRD3), serotonin receptor (HTR1A and 
HTR2A) and zinc-finger domain-containing protein (ZNF804A) genes (Pouget, Shams, Tiwari, 
& Müller, 2014). DRD2 and HTR2A have also been found to be associated with tardive 
dyskinesia, an ADR to antipsychotics. However, none of these genetic variants provides 
clinically relevant predictions on their own as effect sizes are small. The sample sizes 
collected in candidate gene studies have typically been small, so there is a considerable risk 
of false positive findings. Therefore, these PGx variants should be replicated, for example in 
candidate gene studies or GWAS, to provide more robust evidence for association. 
 
Figure 7. Number of independent genome-wide significant loci as a function of the numbers 
of cases in the largest meta-analysis. Cross-disorder indicates a broad psychiatric 
phenotype. AD: Alzheimer's disease; ADHD: attention deficit hyperactivity disorder; AN: 
anorexia nervosa; ASD: autism spectrum disorder; BPD: bipolar disorder; CD-IBD: Crohn's 
disease and inflammatory bowel disease; MDD: major depressive disorder; OCD: obsessive 
compulsive disorder; SCZ: schizophrenia; TS: Tourette's syndrome. Adapted from Gratten, 




Figure 8. Number of GWAS (a) in total and (b) per year in human diseases, traits and PGx. 
Adapted from Giacomini et al. (2017).  
Table 2. Dosing guidelines for psychiatric drugs using CYP2C19 and CYP2D6. Adapted from 
Spina & de Leon (2015). 





CYP2D6 PMs: ↓ dose by 50 % or select another antipsychotic 
CYP2D6 UMs: be alert to diminished serum concentrations or prescribe 
another antipsychotic 




CYP2D6 PMs: ↓ dose to 75 % 
Pimozide If prescribing >4 mg/day in adults, CYP2D6 genotyping is required by 
the US prescribing information because 4 mg/day is the maximum 
recommended dose in CYP2D6 PMs 
Tricyclic 
antidepressants 
CYP2D6 PMs: avoid TCAs or ↓ dose by 50 % and use TDM to adjust 
dosing 
CYP2D6 UMs: avoid TCAs 
CYP2C19 PMs and amitriptyline: ↓ dose by 50 % and use TDM to adjust 
dosing  
CYP2C19 UMs and amitriptyline: select another antidepressant not 
metabolized by CYP2C19  
Venlafaxine CYP2D6 PMs: select another antidepressant or use venlafaxine TDM  
CYP2D6 UMs: increase dose by a factor of 1.5  
PM: poor metabolizer; TCA: tricyclic antidepressant; TDM: therapeutic drug monitoring; 
UM: ultrarapid metabolizer 
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Most PGx studies in psychiatry, as in other therapy areas, were candidate gene studies, but 
recently GWAS have been used to expand the search for genetic variants. A GWAS of 
antipsychotic induced weight gain found a significantly associated SNP in the melanocortin 
4 receptor (MC4R) that was confirmed in 3 replication cohorts (Malhotra, Correll, et al., 
2012). Although the first GWAS studying lithium response in bipolar patients (STEP-BD 
study) did not identify any genetic associations (Perlis et al., 2009), recent studies were 
more successful. Four linked SNPs in a region containing long, non-coding RNAs on 
chromosome 21 were significantly associated with lithium response in a European and 
Asian sample (Hou et al., 2016). A GWAS in Swedish and UK samples compared lithium 
responsive patients with healthy controls and detected a SNP in the 6-
pyruvoyltetrahydropterin synthase gene (PTS), yet no SNPs were significantly associated 
with response among lithium treated patients (Song et al., 2017; Song et al., 2016). In 
addition, a two SNP signal in the glutamate decarboxylase-like protein 1 gene (GADL1) was 
associated with lithium response with an extremely significant 𝑝-value (𝑝=5.50×10-37) and 
could potentially be a highly accurate predictor of treatment response (Chen et al., 2014). 
However, this association has only been confirmed in Han Chinese sample but not in other 
populations (Pickard, 2017). Five GWAS of antidepressant response, the GENDEP, MARS, 
STAR*D, PGRN-AMPS and ISPC studies, did not find any significant associations (Biernacka 
et al., 2015; Garriock et al., 2010; GENDEP Investigators, MARS Investigators, & STAR*D 
Investigators, 2013; Ising et al., 2009; Ji et al., 2013; Uher et al., 2010). Polygenic risk scores 
also did not predict treatment response from the GENDEP to STAR*D study or vice versa 
(García-González et al., 2017). Furthermore, GWAS studying antipsychotic response (CATIE 
studies) did not detect statistically significant variants (Malhotra, Zhang, & Lencz, 2012). 
The small sample sizes used in these GWAS contribute to the lack of success in identifying 
PGx variants, though it is expected that larger studies will lead to more genome-wide 
significant findings (Giacomini et al., 2017). 
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Few PGx associations are translated to widely used predictive tests, because large effect 
sizes are needed to achieve clinical utility. A PGx test based on multiple CYP450 genes, 
serotonin transporter (SLC6A4) and serotonin receptor (5-HTR2A) genes (GeneSight test by 
Assurex Health) to guide antidepressant treatment has been developed commercially and 
claims to improve treatment response compared to treatment as usual (Altar et al., 2015; 
Hall-Flavin et al., 2012; Hall-Flavin et al., 2013; Winner, Carhart, Altar, Allen, & Dechairo, 
2013). Another test using CYP450, UGT1A1 and ABC transporter genes to guide 
antidepressant dosing (CNSDose test by CNSDose) improved remission compared to 
standard treatment (Bousman et al., 2017; Singh, 2015). Yet the utility of these tests should 
be judged with some caution, as the studies supporting the efficacy claims had small 
sample sizes (𝑛 = 227, 44 and 51 for the GeneSight test and 𝑛 = 148 and 119 for the 
CNSDose test) and have all been conducted by the companies marketing the tests. The 
AmpliChip CYP450 test (Roche Molecular Systems) identifying CYP2D6 and CYP2C19 
variants was the first FDA approved PGx test and can be used to guide antipsychotic drug 
selection (Pouget et al., 2014). However, tests for clozapine response (using the 5-HT2A and 
5-HT2C serotonin receptor, H2 histamine receptor, and the 5-HTT serotonin transporter 
genes) and clozapine-induced agranulocytosis (using a SNP in HLA*DQB1) have been 
marketed but are no longer available (Kohlrausch, 2013; Pouget et al., 2014). The moderate 
effect sizes of these tests did not lead to changes in clozapine treatment. 
1.4. Machine learning for predictive modelling 
Genetic studies collect large datasets spanning thousands or millions of variants, many of 
which are correlated. The number of study participants is often considerably smaller than 
the number of variables. These data characteristics complicate the statistical analysis of 
genetic studies. Typically, statistical methods are applied to individual genetic variants one 
by one and significance thresholds are corrected for multiple testing. However, these 
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univariate approaches do not take interactions between the variables into account. Due to 
the stringent significance thresholds applied genetic variants with weak effects can easily 
be missed. However, treatment response and ADRs could well be caused by a combination 
of multiple variants with moderate or weak effect sizes and it is possible that up to 104 
genetic variants contribute to these traits (Pouget et al., 2014). Therefore, it is appropriate 
to perform a multivariable analysis and assess several genetic variants simultaneously.  
Machine learning is a discipline integrating concepts from statistics and computer science 
to build flexible multivariable prediction models. These methods enable the analysis of 
large datasets such as genome-wide studies with millions of genetic variants in a single 
model. In addition, machine learning algorithms optimize prediction accuracy and are thus 
well suited for the development of predictive biomarkers. Some machine learning methods, 
for example elastic net, inherently perform variable selection and can help identifying 
relevant genetic variants from a genome-wide dataset.  
Several machine learning methods, including elastic net, random forest, support vector 
machines and neural networks, have been used to build prediction models for warfarin 
dosing in different populations. Machine learning algorithms proved successful in predicting 
optimal warfarin dosing based on clinical characteristics or a combination of clinical and 
genetic variables (Cosgun, Limdi, & Duarte, 2011; Grossi et al., 2014; Liu, Li, Zhang, & Zhou, 
2015; Pavani et al., 2016; Sharabiani, Bress, Douzali, & Darabi, 2015). However, other 
studies found that multiple linear regression outperformed machine learning algorithms 
(International Warfarin Pharmacogenetics Consortium, 2009; X. Li et al., 2015). Machine 
learning was also successfully applied to construct different prediction algorithms for 
tacrolimus dose in renal transplant patients (Tang et al., 2017). Furthermore, tree-based 
machine learning algorithms were able to identify patients most likely to benefit from 
pharmacotherapy in an alcohol dependence trial (Hou et al., 2015). Although machine 
learning methods can perform well with large datasets, the PGx studies mentioned above 
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included only a small set of previously associated genetic variants as predictors. A study 
combining clinical and genetic predictors used elastic net to predict antidepressant 
response to a clinically relevant degree (Iniesta et al., 2015). This study did include genome-
wide variants and allowed the algorithm to select the most relevant features for inclusion in 
the prediction model. 
In the last few years, computer processing power has increased rapidly. Combined with the 
availability of ever larger datasets, this has fostered advances in deep learning, a branch of 
machine learning covering neural networks and their variations. Deep learning applications 
are the algorithms underlying artificial intelligence and are widely used. For example, online 
recommendation systems, which apply algorithms to web traffic data and suggest items 
based on what previous users have looked at, demonstrate how deep learning is routinely 
used in everyday life (Cheng et al., 2016; Covington, Adams, & Sargin, 2016). A second well-
known example is image recognition, where deep learning algorithms can recognise and 
identify faces nearly as well as humans can (Parkhi, Vedaldi, & Zisserman, 2015; Taigman, 
Yang, Ranzato, & Wolf, 2014). Other areas where deep learning significantly progressed the 
field are speech recognition and software for self-driving cars (Deng et al., 2013; Reiley, 
2016). Medicine has been named as the next frontier in deep learning (Frey, 2016). 
Automated image classification tools can assist in diagnosis making, for example in 
oncology where neural networks could be used to detect prostate and breast cancer in 
histopathological images of biopsies (Litjens et al., 2016). Furthermore, a deep learning 
network outperformed dermatologists in classifying cancers from skin lesion images and 
the authors suggest that their algorithm could be made available on smartphones as a low-
cost diagnostic tool (Esteva et al., 2017). 
Machine learning and deep learning approaches provide novel tools for the analysis of large 
genetic datasets. A strong advantage of these methods over traditional statistical models is 
that they enable studying multiple correlated genetic variants simultaneously. Moreover, as 
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machine learning algorithms aim to optimize prediction accuracy, they can readily be 
applied as tests for personalizing treatments.  
1.5. Outline of thesis 
The research presented in this thesis is grouped in two parts. Firstly, we look into aspects 
related to the translation of PGx associations to genetic tests that are implemented in 
clinical practice to guide pharmaceutical treatment. In the second part, we apply machine 
learning techniques to genetic and gene expression datasets to predict clinical outcomes. 
1.5.1. Adoption of pharmacogenetic testing in clinical practice 
The adoption of novel PGx biomarkers in clinical practice is not self-evident. We studied 
two factors that are relevant to the transition from bench to bedside: the predictive power 
that a PGx test needs to achieve in order to be clinically useful and the economic feasibility 
of PGx testing. The research introduced in the following paragraphs led to two peer-
reviewed journal publications and an invited editorial. The research chapters in this first 
part of the thesis consist of these manuscripts. 
Firstly, we studied the characteristics of a PGx test for clozapine induced agranulocytosis, a 
rare but severe ADR. Clozapine in an effective antipsychotic, but due to the risk of 
agranulocytosis the drug is reserved for treatment resistant schizophrenia and patients 
must undergo regular haematological monitoring throughout the course of treatment. A 
PGx test that stratifies patients into agranulocytosis risk subgroups could have a big impact 
on schizophrenia pharmacotherapy. We examined the relationship between test sensitivity 
and the proportion of positive test results, which is related to the allele frequency of the 
genetic variant(s) (Verbelen, Collier, Cohen, MacCabe, & Lewis, 2015). In light of our 
findings, we revisited the previously established PGx associations with clozapine induced 
agranulocytosis and comment on the lack of clinical impact they made (Verbelen & Lewis, 
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2015). The framework we developed to assess the utility of PGx testing for clozapine 
induced agranulocytosis can readily be adapted to other settings where PGx biomarkers for 
drug response or safety are evaluated. 
Secondly, we looked at the economic arguments for PGx testing. In addition to clinical 
utility, economic criteria need to be fulfilled to warrant the use of a PGx test as standard 
practice. Healthcare budgets are limited, thus the cost of an intervention needs to be 
balanced with its benefits. Although the use of a PGx test is intended to decrease the rate 
of non-response or ADRs, this does not automatically reduce costs. In addition to the price 
of the genetic test itself, the costs and health outcomes of the treatment following the test 
result need to be considered, for example the cost and efficacy of an alternative drug. 
Economic evaluations or cost-effectiveness studies assess and compare the costs and 
benefits of different healthcare strategies. We reviewed the health-economic literature to 
form a picture of the cost-effectiveness of PGx tests (Verbelen, Weale, & Lewis, 2017). As 
the cost of genotyping keeps decreasing, it is conceivable that genetic information might 
become part of patients’ health records and could be used for PGx guidance without 
additional cost. Therefore, we estimated the impact of freely available genetic information 
on the cost-effectiveness conclusions of the reviewed publications.  
1.5.2. Machine learning prediction algorithms applied to genetic and gene expression 
studies  
The second part of this thesis emphasises the application of machine learning to study 
genetic and gene expression data. Due to the size of genetic datasets, genetic variants are 
traditionally analysed on a one by one basis. In contrast, machine learning algorithms can 
be fit with large numbers of variables and can thus be used to perform multivariable 
analyses where all genetic variants are studied in a single model. As the focus of machine 
learning models lies on prediction, these methods are ideal to build polygenic prediction 
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models, potentially including clinical variables. In addition, variable importance scores can 
be used to rank predictor variables and derive which genetic variants are most predictive of 
the outcome.  
We used machine learning methods to perform multivariable analyses of genetic and gene 
expression studies. Various statistical approaches were applied and we start by giving an 
overview of the statistical methods used. Next, we describe three studies that were 
undertaken using machine learning algorithms. 
In the first study, machine learning algorithms were built to classify schizophrenia cases 
from controls using RNA sequencing (RNA-seq) gene expression data from post-mortem 
dorsolateral prefrontal cortex (DLPFC) brain samples. The dataset was randomly split in 
training data for model building and test data for assessing the predictive accuracy of the 
algorithm. Random forests, support vector machines and neural networks were trained to 
distinguish cases from controls. The predictive performance of the algorithms was assessed 
on the test data. Using different feature selection methods, we investigated whether a 
smaller set of genes can achieve comparable or higher prediction accuracy than an 
algorithm based on the entire set of predictor variables. Thus, we tested if machine learning 
algorithms can be used to identify sets of genes of which the expression levels contribute 
most to predicting case/control status. 
Secondly, we applied linear and tree-based machine learning algorithms to a phase II anti-
diabetic clinical trial. This was a cross-over trial comparing a glucagon receptor antagonist 
(LY2409021) to placebo in type 2 diabetes patients. Our goal was to construct predictive 
PGx algorithms for five continuous anti-diabetic efficacy and safety measures using clinical 
variables and genome-wide SNPs. Again, the available data were randomly split in training 
and test subsets. Regression trees, random forest and elastic net algorithms were built 
using the training data and their predictive performance was assessed in the independent 
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test data. Furthermore, feature selection techniques were used to improve the signal to 
noise ratio in the predictor variables, which may enhance the performance of the 
algorithms. A sensitivity analysis was carried out to verify the robustness of the results 
against random sampling errors in to the training/test data splitting process.  
Thirdly, we contrasted traditional statistical analysis methods with machine learning 
algorithms for the analysis of a phase II clinical trial comparing a highly selective 
norepinephrine reuptake inhibitor (LY2216684) to placebo in patients suffering from major 
depressive disorder. We used clinical and genetic variables in candidate genes to model 
changes in the Montgomery-Åsberg depression rating scale total score (MADRS-TS), a 
measure of depression severity. The aim of this study was to identify SNPs that have an 
effect on changes in the outcome variable. First, we looked at cross-sectional methods, 
namely linear regression and elastic net, to model the change from baseline in the outcome 
variable at the end of the trial period. Next, we approached this analysis from a longitudinal 
perspective and used linear mixed models and linear mixed elastic net to model changes in 
MADRS-TS over the course of the trial. We compared the results from the traditional and 
machine learning analysis methods. In addition, we reviewed the existing software 
packages for longitudinal machine learning. 
1.5.3. Summary 
This thesis studies how genetics can be used to improve pharmacological treatment across 
a range of disorders. In the research performed, PGx biomarkers are approached from two 
different angles. Firstly, we assess the adoption of PGx associations as predictive tests in 
clinical practice. We examined the characteristics of a clinically useful PGx test for clozapine 
induced agranulocytosis and reviewed the literature of cost-effectiveness studies of PGx 
tests. Secondly, we applied machine learning algorithms to genetic and gene expression 
datasets to evaluate the utility of these methods for building algorithms that accurately 
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predict clinical outcomes. We also investigated how these methods can be used to identify 
risk variants that would play a role in response to treatment or in adverse events. 
31 
 
Part 1: Adoption of pharmacogenetic testing in clinical 
practice 
The first part of this thesis investigates aspects related to the clinical use of PGx tests. These 
chapters consist of two published peer-reviewed articles and an editorial. Firstly, we 
examined the characteristics of a PGx test for clozapine induced agranulocytosis. In the 
accompanying editorial we comment on why the known PGx associations are not yet used 
to guide clinical practice and highlight the challenges in this research area. Secondly, we 
performed a review of the pharmaco-economic literature on PGx testing to get a general 

























































Supplementary table 1a. Column headings for supplementary table 1b. 
Column name Column explanation 
Authors First author and reference to citation 
Year of publication Year of publication 
Country Country where economic evaluation was performed 
Perspective Perspective used when defining costs and effects to include in 
evaluation 
Drug Generic name of drug for which a PGx test is studied 
Gene Gene(s) used in PGx test 
Type of study The type of economic evaluation: cost-effectiveness analysis (CEA), 
cost-utility analysis (CUA) or cost-benefit analysis (CBA) 
Outcome measure The measure used to quantify the effect of treatment 
Sensitivity analysis Extent of sensitivity analysis performed in the study 
Price of genetic test 
quoted in study 
Price of the genetic test as reported be study 
Price of genetic test 
in 2014 US$ 
Price of genetic test corrected for inflation and converted to 
2014US$ 
Result Result reported by study. Incremental cost-effectiveness ratio 
(ICER) if applicable. 
Estimated result Our estimated result if genetic information was freely available. 
Estimated by taking the cost of the PGx test as reported out of the 
total costs reported by the study. 
Conclusion for PGx 
strategy 
Conclusion reached by study. Classified as: Favourable and cost 
saving (dominant), favourable (cost-effective, not cost-saving), not 
favourable (not cost-effective) or undetermined (no clear 
conclusion). 
Estimated conclusion 
for PGx strategy 
Our estimated conclusion if genetic information was freely 













 2004 UK National Health Service 
Schackman et al.
39
 2008 US Not stated 
Kauf et al.
40
 2010 US US healthcare system 
Nieves Calatrava et al.
41
 2010 Spain National Health System 
Kapoor et al.
42
 2015 Singapore Not stated 
Tavadia et al.
43
 2000 Canada Not stated 
Marra et al.
44
 2002 Canada Third party payer 
Oh et al.
45
 2004 Korea Society 
Winter et al.
46
 2004 Scotland Not stated 
Dubinsky et al.
47
 2005 US Third party payer 
Priest et al.
48
 2006 New Zealand New Zealand government and patients with 
inflammatory bowel disease 




2006 Germany, Ireland, The 




 2010 US Not stated 
Thompson et al.
51
 2014 UK UK health service 
Dong et al.
21
 2012 Singapore Not stated 
Rattanavipapong et al.
52
 2013 Thailand Society 
Tiamkao et al.
53
 2013 Thailand Not stated 
Plumpton et al.
54
 2015 UK National Health Service 
Perlis et al.
57
 2009 US Society 
Serretti et al.
58
 2011 Italy Italian National Health System 
Olgiati et al.
59
 2012 Europe Society 
Crespin et al.
60
 2011 US Medicare 
Panattoni et al.
61
 2012 New Zealand New Zealand healthcare system 
Reese et al.
62
 2012 US Private payer  
Lala et al.
26
 2013 US Payer  
Sorich et al.
25
 2013 Australia Australian healthcare system 
Kazi et al.
63
 2014 US Society 
Perlis et al.
65
 2005 US Society 
Obradovic et al.
66
 2008 US US healthcare payers 
Gold et al.
67
 2009 US Medicare payer  
Pichereau et al.
68
 2010 France Hospital 
Donnan et al.
69
 2011 Canada Healthcare system 
You et al.
70
 2004 Not clearly stated Healthcare provider 
Eckman et al.
71
 2009 US Society 
Leey et al.
72
 2009 US third-party payer 
Patrick et al.
24
 2009 US Society 
You et al.
73
 2009 Not clearly stated Healthcare provider 
Meckley et al.
74
 2010 US US third party payer 
You et al.
75
 2012 Not clearly stated Healthcare payers 
Nshimyumukiza et al.
23
 2013 Canada Public Health system 
Chong et al.
76
 2014 Thailand Healthcare system and society 
Pink et al.
22
 2014 UK National Health Service 
You
30
 2014 Not clearly stated US healthcare payers 
Mitropoulou et al.
77
 2015 Croatia Sickness Fund perspective, healthcare payers 
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Supplementary table 1b (continued). Overview of reviewed economic evaluations of PGx 
guided strategies. 
Authors Drug Gene Type of study 
Hughes et al.
38
 abacavir HLA CEA 
Schackman et al.
39
 abacavir HLA CUA 
Kauf et al.
40
 abacavir HLA CUA 
Nieves Calatrava et al.
41
 abacavir HLA CEA 
Kapoor et al.
42
 abacavir HLA CUA 
Tavadia et al.
43
 azathioprine TPMT CBA 
Marra et al.
44
 azathioprine TPMT CEA 
Oh et al.
45
 azathioprine TPMT CEA 
Winter et al.
46
 azathioprine TPMT CEA 
Dubinsky et al.
47
 azathioprine TPMT CEA 
Priest et al.
48
 azathioprine TPMT CUA 




azathioprine TPMT CEA 
Hagaman et al.
50
 azathioprine TPMT CUA 
Thompson et al.
51
 azathioprine TPMT CUA 
Dong et al.
21





 carbamazepine HLA CUA 
Tiamkao et al.
53
 carbamazepine HLA CBA 
Plumpton et al.
54
 carbamazepine HLA CUA 
Perlis et al.
57
 citalopram HTR2A CUA 
Serretti et al.
58
 citalopram 5-HTTLPR CUA 
Olgiati et al.
59
 citalopram 5-HTTLPR CUA 
Crespin et al.
60
 clopidogrel CYP2C19 CUA 
Panattoni et al.
61
 clopidogrel CYP2C19 CUA 
Reese et al.
62
 clopidogrel CYP2C19 CEA 
Lala et al.
26
 clopidogrel CYP2C19 CUA 
Sorich et al.
25
 clopidogrel CYP2C19 CUA 
Kazi et al.
63
 clopidogrel CYP2C19 CUA 
Perlis et al.
65
 clozapine H2, 5-HTTLPR, 5-HT2A, 5-HT2C CUA 
Obradovic et al.
66
 irinotecan UGT1A1 CEA 
Gold et al.
67
 irinotecan UGT1A1 CUA 
Pichereau et al.
68
 irinotecan UGT1A1 CEA 
Donnan et al.
69
 mercaptopurine TPMT CEA 
You et al.
70
 warfarin CYP2C9 CEA 
Eckman et al.
71
 warfarin CYP2C9, VKORC1 CUA 
Leey et al.
72
 warfarin CYP2C9, VKORC1 CUA 
Patrick et al.
24
 warfarin CYP2C9, VKORC1 CUA 
You et al.
73
 warfarin CYP2C9, VKORC1 CUA 
Meckley et al.
74
 warfarin CYP2C9, VKORC1 CUA 
You et al.
75
 warfarin CYP2C9, VKORC1 CUA 
Nshimyumukiza et al.
23
 warfarin CYP2C9, VKORC1 CUA 
Chong et al.
76
 warfarin CYP2C9, VKORC1 CUA 
Pink et al.
22
 warfarin CYP2C9, VKORC1 CUA 
You
30
 warfarin CYP2C9, VKORC1 CUA 
Mitropoulou et al.
77
 warfarin CYP2C9, VKORC1 CUA 
52 
 
Supplementary table 1b (continued). Overview of reviewed economic evaluations of PGx 
guided strategies. 
Authors Outcome measure Sensitivity analysis 
Hughes et al.
38
 adverse reactions avoided Univariate  
Schackman et al.
39
 QALY Univariate and multivariate  
Kauf et al.
40
 QALY Univariate  
Nieves Calatrava et al.
41
 cost per adverse reaction avoided Univariate and multivariate  
Kapoor et al.
42
 QALY Univariate and multivariate  
Tavadia et al.
43
 Canadian dollars Univariate  
Marra et al.
44
 number needed to treat to avoid one adverse event Univariate 
Oh et al.
45
 probability of not dropping out due to serious 
adverse event 
Univariate and multivariate  
Winter et al.
46
 life years saved None reported 
Dubinsky et al.
47
 time to response Univariate and multivariate  
Priest et al.
48
 QALY Univariate 




life years gained Univariate and multivariate  
Hagaman et al.
50
 QALY Univariate and multivariate  
Thompson et al.
51
 QALY Univariate 
Dong et al.
21
 QALY Univariate and multivariate  
Rattanavipapong et al.
52
 QALY Multivariate 
Tiamkao et al.
53
 Thai baht None reported 
Plumpton et al.
54
 QALY Univariate and multivariate  
Perlis et al.
57
 QALY Univariate and multivariate  
Serretti et al.
58
 QALWeek Univariate and multivariate  
Olgiati et al.
59
 QALWeek Univariate and multivariate  
Crespin et al.
60
 QALY Univariate and multivariate  
Panattoni et al.
61
 QALY Multivariate 
Reese et al.
62
 adverse events avoided Multivariate 
Lala et al.
26
 QALY Univariate and multivariate  
Sorich et al.
25
 QALY Univariate and multivariate  
Kazi et al.
63
 QALY Univariate and multivariate  
Perlis et al.
65
 QALY Univariate 
Obradovic et al.
66
 life years gained Multivariate 
Gold et al.
67
 QALY Univariate and multivariate  
Pichereau et al.
68
 number of neutropenias avoided Univariate and multivariate  
Donnan et al.
69
 life months survived Univariate and multivariate  
You et al.
70
 major bleedings averted Univariate and multivariate  
Eckman et al.
71
 QALY Univariate and multivariate  
Leey et al.
72
 QALY Multivariate 
Patrick et al.
24
 QALY Univariate and multivariate  
You et al.
73
 QALY Univariate and multivariate  
Meckley et al.
74
 QALY Univariate and multivariate  
You et al.
75
 QALY Univariate and multivariate  
Nshimyumukiza et al.
23
 QALY Univariate and multivariate  
Chong et al.
76
 QALY Univariate and multivariate  
Pink et al.
22
 QALY Univariate and multivariate  
You
30
 QALY Univariate and multivariate  
Mitropoulou et al.
77
 QALY Multivariate 
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Supplementary table 1b (continued). Overview of reviewed economic evaluations of PGx 
guided strategies. 
Authors 
Price of genetic test 
quoted in study 
Price of genetic 
test in 2014 US$ 
Hughes et al.
38
 €43.40 US$77.18 
Schackman et al.
39
 US$68.00 US$79.85 
Kauf et al.
40
 US$87.92 US$100.39 
Nieves Calatrava et al.
41
 €55.00 US$80.19 
Kapoor et al.
42
 US$277.00 US$275.73 
Tavadia et al.
43
 C$100.00 US$118.59 
Marra et al.
44
 C$100.00 US$112.95 
Oh et al.
45
 ₩60000.00 US$79.58 
Winter et al.
46
 £30.00 US$67.79 
Dubinsky et al.
47
 US$510.06 US$639.21 
Priest et al.
48
 NZ$120.00 US$128.08 







 US$300.00 US$342.54 
Thompson et al.
51
 £20.00 US$39.48 
Dong et al.
21
 US$270.00 US$293.14 
Rattanavipapong et al.
52
 ฿1000.00 US$33.03 
Tiamkao et al.
53
 ฿3000.00 US$94.12 
Plumpton et al.
54
 £54.26 US$102.39 
Perlis et al.
57
 US$500.00 US$587.15 
Serretti et al.
58
 2010 Int$233.80 US$253.84 
Olgiati et al.
59
 2009 Int$200.00 US$220.70 
Crespin et al.
60
 US$200.00 US$220.70 
Panattoni et al.
61
 NZ$175.00 US$161.17 
Reese et al.
62
 US$310.00 US$326.24 
Lala et al.
26
 US$500.00 US$542.85 
Sorich et al.
25
 AUS$46.55 US$44.90 
Kazi et al.
63
 US$235.00 US$247.31 
Perlis et al.
65
 US$500.00 US$710.50 
Obradovic et al.
66
 US$375.00 US$440.36 
Gold et al.
67
 US$102.83 US$117.41 
Pichereau et al.
68
 €71.00 US$106.01 
Donnan et al.
69
 C$459.63 US$452.73 
You et al.
70
 US$100.00 US$125.32 
Eckman et al.
71
 US$400.00 US$456.72 
Leey et al.
72
 US$250.00 US$321.65 
Patrick et al.
24
 US$575.00 US$656.54 
You et al.
73
 US$200.00 US$219.90 
Meckley et al.
74
 US$175.00 US$199.82 
You et al.
75
 US$72.00 US$74.24 
Nshimyumukiza et al.
23
 C$615.00 US$599.53 
Chong et al.
76
 ฿3000.00 US$94.12 
Pink et al.
22
 £20.00 US$35.87 
You
30
 US$75.00 US$76.22 
Mitropoulou et al.
77
 €140.25 US$189.66 
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 Dominant - €22 811/adverse reaction avoided 
Schackman et al.
39




Nieves Calatrava et al.
41
 €630/adverse reaction avoided 
Kapoor et al.
42
 US$44 649 - US$926 938/QALY 
Tavadia et al.
43
















Van Den Akker-Van Marle et al.
49
 €2 100/life year gained 
Hagaman et al.
50
 US$29 662/QALY 
Thompson et al.
51
 £256.89 expected incremental net benefit 
Dong et al.
21
 US$7 930 - US$136 630/QALY 
Rattanavipapong et al.
52
 ฿130 000/QALY for patients with neuropathic pain and ฿222 000/QALY for 
patients with epilepsy 
Tiamkao et al.
53
 ฿98 549.94 saved per 100 tested patients 
Plumpton et al.
54






 Int$2 890/QALW for 1 episode and Int$1 392/QALW for 2 recurrent episodes 
Olgiati et al.
59
 Int$1 147 - Int$1 185/QALW 
Crespin et al.
60












 Alternative strategy is cost-effective compared to PGx guided treatment 
Kazi et al.
63
 US$30 200/QALY 
Perlis et al.
65
 US$47 705/QALY 
Obradovic et al.
66












 US$5 778/major bleeding averted 
Eckman et al.
71
 US$170 000/QALY 
Leey et al.
72
 Any reduction in major bleeding would offset the higher costs of PGx testing. 
Patrick et al.
24
 ICER <US$50,000/QALY if genotyping increases time spent in therapeutic INR 
range by 9% 
You et al.
73
 US$347 059/QALY  
Meckley et al.
74
 US$60 725/QALY 
You et al.
75






 ฿1 473 852/QALY from societal perspective and ฿1 477 042/QALY from 
healthcare system perspective 
Pink et al.
22
 Alternative strategy is cost-effective compared to PGx guided treatment 
You
30
 US$2 843/QALY 
Mitropoulou et al.
77
 €31 225/QALY 
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Supplementary table 1b (continued). Overview of reviewed economic evaluations of PGx 
guided strategies. 
Authors Estimated result 
Hughes et al.
38
 Dominant - €19 811/adverse reaction avoided 
Schackman et al.
39









 Dominant - US$164 127/QALY 
Tavadia et al.
43















 Alternative strategy is cost-effective compared to PGx guided treatment 







 Not possible to estimate 
Thompson et al.
51
 Not possible to estimate 
Dong et al.
21
 US$4 416 - US$34 221/QALY 
Rattanavipapong et al.
52
 ฿94 970/QALY for patients with neuropathic pain and ฿190 104/QALY for 
patients with epilepsy 
Tiamkao et al.
53
 ฿398 549.94 saved per 100 tested patients 
Plumpton et al.
54
 £10 502/QALY 
Perlis et al.
57









 Alternative strategy is cost-effective compared to PGx guided treatment 
Panattoni et al.
61
 NZ$15 737/QALY 
Reese et al.
62






 Alternative strategy is cost-effective compared to PGx guided treatment 
Kazi et al.
63
 US$25 931/QALY 
Perlis et al.
65





















 Not possible to estimate 
Patrick et al.
24









 Alternative strategy is cost-effective compared to PGx guided treatment 
Nshimyumukiza et al.
23






 Alternative strategy is cost-effective compared to PGx guided treatment 
You
30
 US$2 450/QALY 
Mitropoulou et al.
77
 €17 512/QALY 
56 
 
Supplementary table 1b (continued). Overview of reviewed economic evaluations of PGx 
guided strategies. 
Authors Conclusion for PGx strategy Estimated conclusion for PGx strategy 
Hughes et al.
38
 Favourable, cost-saving Favourable, cost-saving 
Schackman et al.
39
 Favourable Favourable 
Kauf et al.
40
 Favourable, cost-saving Favourable, cost-saving 
Nieves Calatrava et al.
41
 Favourable Favourable, cost-saving 
Kapoor et al.
42
 Not favourable Undetermined 
Tavadia et al.
43
 Favourable, cost-saving Favourable, cost-saving 
Marra et al.
44
 Favourable, cost-saving Favourable, cost-saving 
Oh et al.
45
 Favourable, cost-saving Favourable, cost-saving 
Winter et al.
46
 Favourable Favourable, cost-saving 
Dubinsky et al.
47
 Favourable, cost-saving Favourable, cost-saving 
Priest et al.
48
 Not favourable Not favourable 




Favourable Favourable, cost-saving 
Hagaman et al.
50
 Favourable Favourable 
Thompson et al.
51
 Undetermined Not possible to estimate 
Dong et al.
21
 Favourable Favourable 
Rattanavipapong et al.
52
 Undetermined Undetermined 
Tiamkao et al.
53
 Favourable, cost-saving Favourable, cost-saving 
Plumpton et al.
54
 Favourable Favourable 
Perlis et al.
57
 Not favourable Favourable 
Serretti et al.
58
 Undetermined Favourable, cost-saving 
Olgiati et al.
59
 Undetermined Favourable, cost-saving 
Crespin et al.
60
 Not favourable Not favourable 
Panattoni et al.
61
 Favourable Favourable 
Reese et al.
62
 Favourable, cost-saving Favourable, cost-saving 
Lala et al.
26
 Favourable, cost-saving Favourable, cost-saving 
Sorich et al.
25
 Not favourable Not favourable 
Kazi et al.
63
 Favourable Favourable 
Perlis et al.
65
 Favourable Favourable 
Obradovic et al.
66
 Favourable, cost-saving Favourable, cost-saving 
Gold et al.
67
 Favourable, cost-saving Favourable, cost-saving 
Pichereau et al.
68
 Favourable Favourable 
Donnan et al.
69
 Not favourable Favourable, cost-saving 
You et al.
70
 Undetermined Not possible to estimate 
Eckman et al.
71
 Not favourable Favourable, cost-saving 
Leey et al.
72
 Favourable, cost-saving Favourable, cost-saving 
Patrick et al.
24
 Undetermined Not possible to estimate 
You et al.
73
 Not favourable Favourable, cost-saving 
Meckley et al.
74
 Undetermined Favourable, cost-saving 
You et al.
75
 Undetermined Undetermined 
Nshimyumukiza et al.
23
 Not favourable Not favourable 
Chong et al.
76
 Not favourable Favourable, cost-saving 
Pink et al.
22
 Not favourable Not favourable 
You
30
 Favourable Favourable 
Mitropoulou et al.
77
 Favourable Favourable 
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Part 2: Machine learning prediction algorithms applied to 
genetic and gene expression studies 
In the second part of this thesis, we used machine learning methods to perform 
multivariable analyses of genetic and gene expression studies. Various statistical 
approaches were applied to genetic and gene expression datasets and we start by giving an 
overview of the statistical methods used. Next, we expand on three studies that were 
undertaken using machine learning algorithms: the classification of schizophrenia cases 
from controls using brain gene expression scores, a PGx analysis of an anti-diabetic clinical 




5. Statistical methods 
A range of statistical approaches were used for the analysis of genetic and RNA-seq gene 
expression datasets. This methods chapter starts with an overview of the notation used 
throughout this thesis. Next, the traditional statistical models applied in the thesis are 
described. The key concepts of machine learning are defined and then a detailed 
introduction to the specific machine learning methods and deep learning algorithms used in 
this thesis are given. 
5.1. Notation 
Unless otherwise stated, the following notation will be used to describe statistical methods. 
For cross-sectional models with a single outcome variable:  
 𝑛 is the number of subjects or individuals in the sample.  
 𝑖 is the index used for the subjects, thus 𝑖=1, …, 𝑛. 
 𝑝 is the number of predictor variables. The terms independent variable, predictor 
variable, predictor and feature will be used interchangeably.  
 𝑗 is the index used for the predictor variables, thus 𝑗=1, …, 𝑝. 
 𝑥𝑖𝑗 is the 𝑗
th predictor variable for the 𝑖th subject.  
 𝑥0 is a constant for the intercept term, thus 𝑥𝑖0 = 1 for all 𝑖. 
 𝐗 is the 𝑛 x (𝑝 + 1) feature matrix containing the intercept and predictor variables 


















 ?̂?𝑖  is the model prediction for 𝑦𝑖  and ?̂? is the model prediction for 𝐲. 
 𝛽𝑗 is the model coefficient or model parameter for the 𝑗
th predictor variable. 𝛽0 is 
the coefficient for the intercept. 
 𝛃 is the coefficient vector with length (𝑝 + 1) containing the coefficients for the 






 ?̂?𝑗 is the estimate for 𝛽𝑗, and ?̂? is the estimate for 𝛃. 
In addition, for longitudinal analyses with repeated outcome measurements on each data 
point, we use the following notation: 
 𝑚𝑖 is the number of measurements per subject, which is variable per individual. 





 𝐗𝒊 is the 𝑚𝑖 x (𝑝 + 1) feature matrix containing the predictor variables for all 𝑚𝑖 






 𝐲𝒊 is the outcome vector with length 𝑚 containing the outcomes 𝑦𝑖  for all 𝑚𝑖 








5.2. Statistics versus machine learning 
Both statistics and machine learning are tools for data analysis. Although the two fields 
overlap, there are some distinctions between them. A key difference between traditional 
statistics and machine learning is in the way data analysis problems are approached. 
Traditional statistics hypothesises that the observed data were generated by a certain 
mechanism, and uses the data to test how likely that hypothesis is true. Typically, statistical 
tests return a p-value which is compared to a significance threshold to determine whether 
or not the data support the hypothesis. The validity of statistical models depends on certain 
conditions, for example the assumption of normality of the error terms in linear regression. 
In contrast, machine learning does not make such hypotheses and assumptions but aims to 
build prediction models by learning from the data what the parameters of those prediction 
models are (Breiman, 2001a). The usefulness of a machine learning model is assessed by 
how well the algorithm predicts the outcome in a test dataset. Although it is possible to 
compute empirical p-values, for example through permutation tests, this is not common 
practice in the machine learning community. Machine learning is often criticised for being a 
‘black box’ solution which does not shed any light on the relationship between predictors 
and outcome. However, many machine learning algorithms provide variable importance 
scores or perform variable selection and thus allow distinguishing important predictors 
from trivial variables.  
A practical distinction between the two fields is how they cope with large datasets. 
Traditional statistical models struggle with large datasets, especially when the number of 
predictor variables exceeds the number of subjects (the 𝑛 < 𝑝 case). As a rule of thumb 
linear regression requires 10 times as many subjects as there are covariates, whereas 
logistic regression needs at least 10 events per covariate (Miller & Kunce, 1973; Peduzzi, 
Concato, Kemper, Holford, & Feinstein, 1996; VanVoorhis & Morgan, 2007). Machine 
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learning has a strong advantage here as its methods are applicable to high dimensional 
datasets. For large datasets, such as genetic studies, machine learning allows the 
simultaneous multivariable analysis of many predictors, which is not possible using 
traditional statistics.  
Statistical models and machine learning algorithms can be broadly grouped into methods 
for supervised or unsupervised learning. Supervised learning refers to research problems 
where the aim is to make predictions on a certain outcome variable and a dataset 
containing the predictor variables and outcome labels is used to train the algorithm. On the 
other hand, the term unsupervised learning is used for problems where there is no 
outcome variable and the goal is to detect clusters of similarity in the observations. In this 
thesis we exclusively use supervised approaches and our discussion on statistical methods 
is thus limited to supervised models. 
5.3. Traditional statistical methods 
The statistical methods covered in the following paragraphs are linear and logistic 
regression for cross-sectional data and linear mixed models for repeated measurements.  
5.3.1. Linear regression 
Linear regression is a commonly used method for the analysis of continuous outcome 
variables. This model relies on the assumption that there is a linear relationship underlying 
the observed predictor variables and the outcome. Moreover, it is assumed that the 
residual error terms are random, independent, normally distributed and have constant 
variance. A linear regression model can be expressed as 
𝑦𝑖 = 𝛽0 + 𝛽1𝑥𝑖1 + ⋯+ 𝛽𝑝𝑥𝑖𝑝 + 𝜀𝑖 




When the equations of all 𝑛 subjects are stacked the model can be written in matrix 
notation as: 
𝐲 = 𝐗𝛃 + 𝛆 
with 𝛆 being an 𝑛-dimensional vector of error terms. 
The model parameters are estimated by minimizing the residual sum of squares (RSS), 
which is the sum of the squared differences between the observed outcomes (𝐲) and the 
outcome values predicted by the regression model (𝐗𝛃).  





‖𝐲 − 𝐗𝛃‖2 
Thus, the least squares estimate for the model parameters is 
?̂? = argmin
𝛃
(‖𝐲 − 𝐗𝛃‖2) 
For linear regression, the same estimates are obtained by maximum likelihood estimation, 
which returns the parameter values that maximize the likelihood of observing the 
outcomes 𝐲. The significance of parameter estimates, i.e. whether a parameter is different 
from zero, can be assesed using t-tests and type III F-tests. 
5.3.2. Logistic regression 
Bivariate outcomes can be analysed using logistic regression. Outcome predictions from a 
linear regression are real numbers, which is not suitable for categorical outcomes. Logistic 
regression provides a solution to this by modelling the probability of belonging to a certain 
class. For a binary outcome with levels A and B, logistic regression models the log odds of 
belonging to class A as opposed to class B, given the observed predictor variables,  
𝑙𝑜𝑔 (
𝑃(𝑦𝑖 = 𝐴|𝑥𝑖1, 𝑥𝑖2, … , 𝑥𝑖𝑝)
𝑃(𝑦𝑖 = 𝐵|𝑥𝑖1, 𝑥𝑖2, … , 𝑥𝑖𝑝)
) = 𝛽0 + 𝛽1𝑥𝑖1 + ⋯+ 𝛽𝑝𝑥𝑖𝑝. 
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As 𝑃(𝑦𝑖 = 𝐵|𝑥𝑖1, 𝑥𝑖2, … , 𝑥𝑖𝑝) = 1 − 𝑃(𝑦𝑖 = 𝐴|𝑥𝑖1, 𝑥𝑖2, … , 𝑥𝑖𝑝), the probability of belonging 
to class A is given by 




From this equation it is clear that the model appropriately predicts probabilities in the 
range between 0 and 1. 
The predictor variables have a linear effect on the log odds, i.e. for a unit increase in 𝑥𝑗 the 
log odds increases by 𝛽𝑗. However, the change in the probability 𝑃(𝑦𝑖 = 𝐴|𝑥𝑖1,  𝑥𝑖2, … ,  𝑥𝑖𝑝) 
due to a change in 𝑥𝑗 depends on the current value of 𝑥𝑗. As there is a linear effect of the 
predictor variables on a function of the outcome, logistic regression belongs to the class of 
generalized linear models. No closed form expression for estimating the model parameters 
𝛽𝑗 exists and estimates are obtained by applying iterative algorithms such as the Newton-
Raphson method to maximize the likelihood function. Wald tests and likelihood-ratio tests 
can be used to formally test the statistical significance of predictor variables. 
5.3.3. Linear mixed models for longitudinal repeated measures 
Some studies, for example clinical trials, follow a group of subjects over a period of time 
and make repeated observations. A linear regression will not suffice to analyse longitudinal 
data as it does not take the sequential nature of the observations into account nor the fact 
that observations on the same subject are likely to be correlated. Linear mixed models 
capture the correlation between multiple outcome observations and can accommodate 
unbalanced data, both in terms of the number of observations per subject (𝑚𝑖) as well as 
the measurement time points. For the context of clinical trials, this is a useful property as 
patients who dropped out of the study or missed appointments can still be included in the 
analysis. Assuming that any missing data points are missing at random, the model provides 
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valid inference on the model parameters (Molenberghs et al., 2004; Verbeke & 
Molenberghs, 2000).  
Linear mixed models are multivariate regression models that model population-level effects 
and at the same time allow subject-specific deviations from the average trend. The 
regression terms that capture the average trend in the population are the fixed effects, 
whereas the subject-specific deviations are modelled by the random effects. Typically, 
random intercepts and random time effects are considered when modelling longitudinal 
data.  
For 𝑛 subjects, where the number of data points per subject (𝑚𝑖) is variable, a linear mixed 
model with 𝑝 + 1 fixed effects (the intercept and 𝑝 predictor variables) and 𝑞 random 
effects is specified by 
𝐘𝑖 = 𝐗𝑖𝛃 + 𝐙𝑖𝐛𝑖 + 𝛆𝑖. 
where 𝐘𝑖 is a 𝑚𝑖 dimensional vector of longitudinal outcome observations on the 𝑖
th 
subject, 𝐗𝑖 is a 𝑚𝑖  x (𝑝 + 1) dimensional matrix of fixed predictor variables, 𝐙𝑖  is a 𝑚𝑖 x 𝑞 
dimensional matrix of random predictor variables, β is a (𝑝 + 1) dimensional vector of fixed 
effects parameters, 𝐛𝑖 is a 𝑞 dimensional vector of subject specific random effects 
parameters and 𝛆𝑖 is a vector of residual error terms. Furthermore, 𝐛𝑖~𝑁(0,𝐃) where 𝐃 is 
a 𝑞 x 𝑞 dimensional variance-covariance matrix and 𝛆𝑖~𝑁(0, 𝚺𝑖) where 𝚺𝑖 is a 𝑚𝑖 x 𝑚𝑖 
dimensional variance-covariance matrix. 
The fixed effects model the average trend in the data, whereas the random effects account 
for the correlation between observations within the same subject through the variance -
covariance matrix 𝐃, and any remaining variability is captured in the residual variance-
covariance matrix 𝚺𝑖. The model parameters can be estimated using maximum likelihood 
(ML) or restricted maximum likelihood (REML) (Verbeke & Molenberghs, 2000). 
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Often interest lies mainly in the estimation of the fixed effects parameters and the random 
effects are regarded as nuisance parameters. In that case, the marginal perspective of the 
linear mixed model is sufficient for inference on the fixed effect model parameters. The 
outcomes are assumed to follow a normal distribution with the fixed effects defining the 
mean, and where the random effects only appear in the variance term, 
𝐘𝑖~𝑁(𝐗𝑖𝛃 ,  𝐙𝑖𝐃𝐙𝑖
′ + 𝚺𝑖) 
Two types of standard errors can be calculated for the fixed effects parameter estimates. 
Model-based standard errors depend on the variance of 𝐘𝑖, 𝑉𝑎𝑟(𝐘𝑖), and assume that the 
covariance matrix of the marginal model is correctly specified. However, choosing the right 
random effects structure, i.e. which random effects to include in the model and their 
covariance matrix, is not straightforward. Mistakes in the random effects structure 
invalidate inference relying on model-based standard errors. Alternatively, empirical 
standard errors can be used which replace 𝑉𝑎𝑟(𝐘𝑖) by the squared residuals (𝐘𝑖 − 𝐗𝑖?̂?)
2
. 
The advantage of empirical standard errors is that they are robust against misspecification 
of the random effects structure given that the fixed effects are correctly defined (Liang & 
Zeger, 1986; Verbeke & Molenberghs, 2000). Including the right random effects and 
specifying their covariance matrix correctly is thus not essential for valid inference, 
although it improves efficiency of the model. As in the case of linear regression, fixed 
effects parameters can be formally tested for significance using t-tests and type III F-tests. 
5.4. Machine learning 
In the next paragraphs, some key concepts of machine learning are introduced. We 
describe the use of independent training and test data and different measures of predictive 
performance. Next, cross-validation is presented as a method to optimize the 
hyperparameters of machine learning algorithms and the practice of feature selection to 
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reduce the dimensionality of the data is explained. Finally, the machine learning methods 
applied in this thesis, regularised regression, tree-based algorithms and support vector 
machines, are introduced. 
5.4.1. Independent training and test data 
Predictive machine learning algorithms are evaluated on their predictive performance. To 
obtain an unbiased estimate of predictive ability, an algorithm is tested on a dataset 
independent of the data used to build the model. It should be noted however that all 
variables present in the training data are also required in the test data. In the absence of an 
independently collected test dataset, the available data can be randomly split in two 
subsets, one of which is used for algorithm training and the other set aside for measuring 
test set predictive performance. In this case, the number of observations used for training 
the model and the number used for accurate prediction assessment are balanced against 
each other. Commonly used proportions for data splitting are 70 - 80% for training and 20 - 
30% for testing. However, this is an arbitrary choice and the available sample size should be 
considered.  
5.4.2. Measuring predictive performance 
A wide range of statistics can be used to measure predictive ability and compare different 
machine learning algorithms. Optimizing the predictive performance of an algorithm is 
equivalent to minimizing the prediction error. The measure used depends on the type of 
outcome variable and should be decided upon before starting model optimization and 
selection. In the next paragraphs the measures used in this thesis are introduced, but this 
list is by no means exhaustive. Depending on the research question, ad hoc performance 
measures may be defined. 
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5.4.2.1. Continuous outcome  
When predicting a continuous outcome, a widely used statistic to assess predictive 

















 is an equivalent statistic.  
Another popular measure for predicting continuous outcomes is the 𝑅2 statistic. The 𝑅2 is 
given by 
𝑅2 = 1 −
∑ (𝑦𝑖 − ?̂?𝑖)
2𝑛
𝑖=1












This statistic expresses the proportion of variability in the outcomes that is explained by the 
model. By definition the 𝑅2 ranges between 0 and 1 and higher values correspond to better 
prediction. 
5.4.2.2. Binary outcome 
For binary outcome variables, a 2x2 confusion matrix contrasts observed outcomes with 




accuracy =  
True positives + True negatives
𝑛
. 
The accuracy can also be extended to the context of a multi-class categorical outcome. 
Other measures that can be derived from the confusion matrix are sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV). However, these 
statistics are not suitable for assessing the predictive ability of an algorithm. While 
sensitivity and specificity can reach 100% by classifying every data point as positive or 
negative, respectively, the PPV and NPV focus on one outcome class only. These 
classification measures are examined in more detail in part 1 of the thesis in the context of 
a PGx test for clozapine induced agranulocytosis. 
When the prediction algorithm outputs a probability rather than a classification decision, 
observations can be classified as positive when the predicted probability exceeds a 
specified threshold and negative otherwise. A receiver-operator characteristic (ROC) curve 
plots 1-specificity against sensitivity for varying decision threshold values (Fig. 9). The area-
under-the-curve (AUC) is a measure of how well the model predicts and ranges between 0 
and 1. High AUC scores indicate better prediction, while a value of 0.5 corresponds to a 
random chance classifier. 






Positive True positives False negatives 





Figure 9. ROC curves of three hypothetical prediction models. Model A is a perfect classifier 
with AUC=1, model B has an AUC=0.85 and model C classifies randomly resulting in 
AUC=0.5. Adapted from Zou et al. (2007). 
5.4.3. Validation and cross-validation 
Many machine learning algorithms depend on one or more tuning parameters or 
hyperparameters. Choosing the tuning parameter value that leads to optimal prediction in 
the training data likely overfits the algorithm to the training data. To increase 
generalizability, an independent validation dataset can be used select to the 
hyperparameter value that maximizes prediction accuracy (Fig. 10). Given a list of possible 
values for the hyperparameter, the training data are used to construct models for each 
value in that list. The algorithm that achieves the best prediction in the validation data is 
selected and in a final step an unbiased estimate of predictive performance is obtained by 
applying the algorithm to a test dataset. As the training data, validation data and test data 




Figure 10. Hyperparameter tuning using validation data. 
Alternatively, cross-validation on the training data can be used to set the value of tuning 
parameters without need for a validation dataset. Again, a list of possible values for the 
hyperparameter to be tuned is defined. Then, for 𝑘-fold cross-validation the training data is 
split in 𝑘 equally sized subsamples or folds. Each fold is used to test how well a model fitted 
on the remaining 𝑘-1 folds performs (Fig. 11). This step is repeated for each possible value 
of the tuning parameter and the value that leads to the best prediction performance 
averaged across all folds is selected. Finally, the algorithm is fit on the entire training data 
with the hyperparameter set to the selected value and the prediction of this model is 
measured in independent test data. When the machine learning algorithm has multiple 
hyperparameters, a grid of tuning values is cross-validated to select the optimal 
combination. 
Training data 
Step 2: Use training data to build model for each value of 𝜆  
Step 1: Define possible values for tuning parameter 𝜆 =  𝜆1,  𝜆2,  … ,  𝜆𝑣. 
Step 3: Apply models to independent validation data and choose 𝜆 that 
maximizes prediction accuracy.  






Figure 11. Hyperparameter tuning using five-fold cross-validation. 
As cross-validation requires repeatedly fitting the model to a subset of the data, it is 
computationally expensive. Typical values for 𝑘 are 5 and 10, though a different number of 
folds may be used balancing the computational cost of repeating the analysis 𝑘 times and 
Training data 
Step 2: Split training data in five subsets. 
Step 1: Define possible values for tuning parameter 𝜆 =  𝜆1,  𝜆2,  … ,  𝜆𝑣. 
Fold 1 
Step 3: Set 𝜆 =  𝜆1. For each fold, build model on blue out-of-fold data, 
test performance on yellow in-fold data.  
Validation accuracy 
82% 
Fold 2 85% 
Fold 3 83% 
Fold 4 88% 
Fold 5 84% 
Average accuracy for 𝜆1 = 84.4% 
Step 4: Repeat step 3 for 𝜆 =  𝜆2,  … ,  𝜆𝑣.  
Step 5: Choose 𝜆 that maximizes average accuracy across folds. 
Step 7: Measure prediction accuracy in independent test data. 
Test data 




the size of each fold. Moreover, smaller values of 𝑘 result in less bias but more variance in 
the predictive power estimate (James, Witten, Hastie, & Tibshirani, 2013). The 𝑘-fold cross-
validation process can be repeated a certain number of times, which is more robust but 
evidently even more computationally expensive. A special case of 𝑘-fold cross-validation is 
leave-one-out cross-validation, where 𝑘 equals the number of samples in the training data.  
For linear models like lasso and elastic net, the Akaike information criterion (AIC) and 
Bayesian information criterion (BIC) can be used for hyperparameter tuning as an 
alternative to cross-validation (Ninomiya & Kawano, 2016). These statistics are calculated 
on the entire training sample and do not require repetitive model fitting. Asymptotically, 
AIC is equivalent to leave-one-out cross-validation and BIC to leave-𝑚-out cross-validation, 
where 𝑚 is a function of the sample size (Shao, 1997; Stone, 1977). 
5.4.4. Feature selection 
In large datasets with many predictor variables, it is likely that only a subset of features 
contribute to prediction whereas other features are irrelevant. Variable selection or feature 
reduction removes these redundant predictors and thus leads to more sparse algorithms. 
Moreover, removing noise variables from the model can improve prediction accuracy and 
avoid overfitting (Guyon & Elisseeff, 2003; Saeys, Inza, & Larrañaga, 2007). In addition, 
identifying the subset of relevant predictors may increase understanding of the biological 
mechanisms of the phenotype studied. Three main classes of feature reduction methods 
exist (Saeys et al., 2007). The simplest technique is applying a filter method. The features 
are ranked using parametric or non-parametric tests and the top scoring variables are 
carried forward as features in the prediction model. Machine learning methods such as 
random forest and SVM can even be used to rank and select features prior to fitting a 
separate machine learning model. Filter methods are fast and scalable but independent of 
the prediction algorithm. Secondly, wrapper techniques can be applied. Here, the 
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prediction algorithm is incorporated in the variable selection process. For example, 
recursive feature elimination (RFE) iteratively removes features by repeatedly fitting an 
algorithm excluding one variable at a time. Then, the variable with the least impact on 
model performance is excluded from the feature set. This process is repeated until all 
variables are exhausted. Wrapper methods take dependencies between the features into 
account but quickly become computationally expensive as the number of features grows. 
Lastly, some machine learning methods have embedded feature selection properties. For 
example elastic net and decision trees inherently perform variable selection. Embedded 
variable selection is computationally efficient but not available for all machine learning 
algorithms. As for all model building steps, feature reduction should be carried out on the 
training data only. 
5.4.5. Regularized regression models 
Traditional linear regression models run into overfitting problems when modelling datasets 
with many correlated variables, but penalized regression - a machine learning extension of 
generalized linear regression - provides a way around this problem. 
The expected error of linear regression predictions, i.e. the squared difference between the 
estimated outcome and the true outcome, can be decomposed into 
E[(𝑦𝑖 − ?̂?𝑖)
2] = 𝜎2 + 𝐵𝑖𝑎𝑠2 + 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 =  𝜎2 + 𝑀𝑆𝐸. 
The variance in prediction estimates is due to the randomness in the training data, whereas 
the bias reflects the deviation of the average predictions from the true average (Fig. 12) 
(Hastie, Tibshirani, & Friedman, 2009). 𝜎2 is the irreducible error of the test set outcomes. 
The MSE of the predictions is the sum of the squared bias and the variance.  
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Maximum likelihood estimates for 𝛽𝑗 are unbiased and the variance is the only factor 
contributing to the MSE. However, sometimes accepting a small bias can lower the MSE by 
reducing the variance. This balance is referred to as the bias-variance trade-off.  
As in the case of linear regression, a least squares procedure is used to optimize model 
coefficients (𝛃), but penalized regression models introduce some bias by adding a penalty 
term to the RSS. 
?̂? = argmin
𝛃
(‖𝐲 − 𝐗𝛃‖2 + 𝑝𝑒𝑛𝑎𝑙𝑡𝑦) 
Here, the concept of penalized regression is explained in a linear regression context but it 
can easily be extended to logistic regression and other generalized linear models by 
maximizing the penalized log-likelihood (Hastie et al., 2009). 
 
Figure 12. Bias and variance of predictions. Crosses represent the predicted values, whereas 




In the lasso model (least absolute shrinkage and selection operator), the residual sum of 
squares is minimized subject to the 𝑙1-norm or lasso penalty on the absolute size of the 
coefficients. The lasso model coefficient estimates are obtained by 
?̂?𝐿 = argmin
𝛃




In the above equation, 𝜆 is a tuning parameter controlling the strength of the penalty. The 
value of 𝜆 is positive and can be set by cross-validation.  
The lasso optimization problem can also be rewritten as 
?̂?𝐿 = argmin
𝛃




where 𝑠 has a one-to-one relationship with 𝜆. Larger values of 𝜆 correspond to smaller 
values of 𝑠. 
The lasso shrinks the coefficients towards zero and sets some of them equal to exactly zero, 
thereby in effect dropping them from the model. The lasso thus automatically performs 
feature selection. The larger the value of 𝜆 is, the more sparse the lasso model is. A 
disadvantage of lasso is that the model only retains one predictor from a set of correlated 
variables while excluding the rest. In addition, in the 𝑛 < 𝑝 case, the lasso is restrained by 
the sample size of the training data and can select a maximum of 𝑛 features (H. Zou & 
Hastie, 2005). The left panel of Figure 13 shows a graphical representation of the lasso 
coefficient optimization for a model with two features. The least squares or ML estimate 
?̂? = (?̂?1, ?̂?2) is marked on the plot. The elliptical contours around ?̂? represent values of 𝛽1 
and 𝛽2 that result in the same RSS, while the blue area is the region where 𝛽1 and 𝛽2 
comply with the lasso constraint |𝛽1| + |𝛽2| ≤ 𝑠. Thus, the lasso estimate ?̂?
𝐿 is the point in 
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the blue diamond with the lowest RSS. In this example, the lasso model selects only the first 
variable and excludes the second by setting 𝛽2 equal to 0. 
5.4.5.2. Ridge regression 
Ridge regression applies an 𝑙2-norm or ridge penalty to the coefficient least squares 
procedure, restraining the size of the coefficients. The ridge estimates are obtained by 
?̂?𝑅 = argmin
𝛃





Again, 𝜆 is a tuning parameter to be optimized by cross-validation. Larger values of 𝜆 
impose a stronger penalty, thus coefficients are more shrunk towards zero. 
In analogy with the lasso penalty, the ridge regression optimization can be expressed as 
?̂?𝑅 = argmin
𝛃





Ridge regression shrinks the coefficients towards zero and each other. Unlike lasso, ridge 
regression does not set any coefficient to zero and thus does not perform variable 
selection. All features are retained in the model. The estimated coefficients of correlated 
variables have similar sizes, as if the effect is spread across the correlated predictors. The 
right part of Figure 13 symbolizes ridge regression coefficient optimization for a model with 
two features. The blue circle indicates the area where 𝛽1
2 + 𝛽2
2 ≤ 𝑠. The ridge estimate 
?̂?𝑅 is the point within the blue circle with the lowest RSS. 
For both lasso and ridge regression, the size of the blue constraint area depends on the 
value of 𝜆. Smaller values of 𝜆 result in larger blue regions, thus less penalization. When 𝜆 is 
sufficiently small, ?̂? is included in the constraint area and ?̂?𝐿 and ?̂?𝑅 will be equal to the 
least squares estimate. In the case of 𝜆 = 0, ridge regression and lasso reduce to a 




Figure 13. Coefficient estimation subject to lasso (left) and ridge (right) penalty. ?̂? indicates 
the location of the least squares estimate. The red ellipses represent values of 𝛃 that result 
in constant RSS. The blue shapes are the regions were 𝛃 complies with the constraints of 
|𝛽1| + |𝛽2| ≤ 𝑠 for lasso and  𝛽1
2 + 𝛽2
2 ≤ 𝑠 for ridge regression. ?̂?𝐿 indicates the lasso 
estimate and ?̂?𝑅 the ridge estimate. Adapted from James et al. (2013). 
5.4.5.3. Elastic net 
The elastic net is a penalized regression model that combines the advantages of lasso and 
ridge regression. The elastic net performs grouped feature selection, retaining important 
variables while excluding irrelevant predictors, and selects correlated variables in or out of 
the model as a group (Zou & Hastie, 2005). Unlike lasso, the number of features that can be 
selected is not limited by the size of the training sample. 
The elastic net penalty is a weighted average of the 𝑙1 and 𝑙2-norm. The model coefficients 
are estimated by 
?̂?𝐸𝑁 = argmin
𝛃







The elastic net has two hyperparameters: λ determines the strength of the penalty whilst 𝛼 
is limited to values between 0 and 1 and is a mixing factor between the 𝑙1 and 𝑙2-norm. 
Cross-validation can be used to select the values for α and λ.  
It is clear that ridge regression and lasso are special cases of elastic net when 𝛼 = 0 and 
𝛼 = 1, respectively. A visual comparison of the elastic net constraint area with the lasso 
and ridge regression is shown in Figure 14. The curvature of the elastic net constraint area 
depends on 𝛼, whereas the size is determined by λ. 
 
Figure 14. Contours of the constraint area for model coefficient estimates.  
indicates the shape of the ridge penalty,  of the lasso penalty and  of the 
elastic net penalty with 𝛼 = 0.5. Adapted from Zou and Hastie (2005). 
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5.4.5.4. Penalized linear mixed models 
As the 𝑙1 and 𝑙2 penalties can be added to the log-likelihood of a model for penalized 
coefficient estimation, it follows that penalized regression can also be extended to the 
multivariate case. Such models are of interest for the analysis of longitudinal data with a 
large number of predictor variables. We discuss the concept of penalized linear mixed 
models without going into technical details. Although longitudinal statistical learning is still 
an emerging field, a few penalized linear mixed models have been developed (Table 4). 
These models vary in the penalty applied to the coefficient estimation and the estimation 
algorithm that is used. Furthermore, feature selection can be performed on the fixed or 
random effects, or on both at the same time (Chen, Grant, Wu, & Bowman, 2014). The 
penalized linear mixed models listed here are all slightly different models and each method 
can be fitted with the appropriate software. 
For the longitudinal analysis of an antidepressant clinical trial (chapter 8) we used the 
lassop software to estimate a linear mixed elastic net, because it permits an elastic net 
penalty to be imposed on a linear mixed model (Rohart, 2016; Rohart, San Cristobal, & 
Laurent, 2014). When fitting this model, the random effects are treated as missing values 
and the ML estimation of the fixed effects is subject to an elastic net penalty. A limitation of 
the lassop software is that the model can select at maximum the same number of 
predictors as there are observations in the data. The software can thus not fit a ridge 
regression, which retains all predictor variables, when the number of predictors exceeds 
the number of subjects (the n < p case). In n < p situations REML cannot be used to estimate 
model coefficients and thus ML is the only estimation procedure supported by the lassop 





Table 4. Software packages for penalized linear mixed model analysis. 
Method Penalty Variable selection on  Suitable for n < p Software Reference 
lassop Elastic net  Fixed effects Yes R package: MMS (Rohart et al., 2014) 
lmmlasso Lasso  Fixed effects Yes R package: lmmlasso (Schelldorfer, Bühlmann, & 
Van De Geer, 2011) 
glmmixedlasso Lasso  Fixed effects Yes R package: glmmixedlasso (Schelldorfer, Meier, & 
Bühlmann, 2014) 
glmmLasso Lasso  Fixed effects No R package: glmmLasso (Groll & Tutz, 2014) 
Pen.LME Adaptive lasso  Fixed and random effects 
simultaneously 
No R code (Bondell, Krishna, & Ghosh, 
2009; Bondell, Krishna, & 
Ghosh, 2010) 
Indep. selection  Elastic net First fixed effects, then 
random effects 




5.4.6. Tree-based prediction algorithms 
5.4.6.1. Decision trees 
When the relationship between predictor variables and the outcome is non-linear, 
regression models fail to fit this adequately, and tree-based machine learning methods 
perform better (Fig. 15). 
 
Figure 15. Top row: A binary classification example where the true decision boundary is 
linear. A linear model (left) captures the relationship perfectly but a decision tree (right) 
struggles to classify the two categories. Bottom row: When the true decision boundary is 
non-linear a decision tree (right) can distinguish the classes whereas the linear model (left) 
fails to do so. Adapted from James et al. (2013). 
A decision tree is an algorithm that recursively splits observations using the values of 
predictor variables (Fig. 16). Decision trees are greedy algorithms, because at each step the 
best split is considered without taking future splitting steps into account. Split points in the 
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tree are referred to as internal nodes, whereas the subsets at the end of the branches are 
external nodes or leaves. At each node, the feature space is split in two subregions based 
on the value of a predictor variable. Continuous features can separate the predictor space 
by splitting on a value 𝑡. All observations with 𝑥𝑗 ≤ 𝑡 are assigned to the left subregion 
whereas all observations with 𝑥𝑗 > 𝑡 go to the right subregion. Categorical splitting 
variables place observations with certain classes in one subregion and the remaining classes 
in the other subregion. In Figure 16, predictors 𝑥1and 𝑥2 are continuous, whereas 𝑥3is a 
categorical predictor with three classes. Predictor variables can be used in more than one 
node of the decision tree, for example two distinct values of a continuous predictor can be 
used as split points in different nodes. 
 
Figure 16. Example of a decision tree with four internal nodes where the sample is split, 
resulting in five terminal nodes corresponding to five subregions in the predictor space (𝑅1 
to 𝑅5). 𝑥1 and 𝑥2 are continuous predictors, 𝑥3 is a categorical predictor with classes A, B 
and C.  
A decision tree can be applied to predict categorical (classification tree) as well as 
continuous outcomes (regression tree) and in both cases the algorithm optimizes the purity 
of the nodes. Classification trees aim to separate the outcome categories by searching for 
𝑥1 ≤ 𝑡1 
𝑥3 ∈  𝐴,  𝐶  
𝑅1 𝑅2 𝑅3 
𝑅4 𝑅5 
𝑥1 > 𝑡1 
𝑥2 ≤ 𝑡2 𝑥2 > 𝑡2 
𝑥2 ≤ 𝑡4 𝑥2 > 𝑡4 
𝑥3 ∈  𝐵  
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the predictor variable that leads to the cleanest split in each node. Purity of a node can be 
measured by the classification error rate  
𝐸 = 1 − max
𝑘
?̂?𝑘 . 
where ?̂?𝑘is the proportion of training observations that belong to the 𝑘
th class, for a 
categorical outcome with 𝐾 classes. Two alternative measures that are more sensitive than 
the classification error are the Gini index  




and the cross-entropy 




Smaller values of 𝐺 and 𝐶 indicate a more pure split in the node and thus the algorithm 
aims to minimize these quantities.Classification trees make predictions using the most 
common class seen in the training data in each terminal node. Predictions for a test sample 
are made by following the branches of the classification tree and placing the new 
observation is a terminal node. The predicted class for the test observation is the most 
common class in the training data in that terminal node. 
Regression trees aim to minimize the RSS between the observed outcomes and the node 
predictions. For a continuous outcome 𝑦, a piecewise constant regression tree splits the 
training data in subregions and models the outcome by taking the mean of 𝑦 within each 
node. The predictor values used for splitting the nodes are chosen so that RSS in the 
subregions is minimized. Some decision tree algorithms can fit more complex regression 
models in the nodes. For example, the Generalized, Unbiased, Interaction Detection and 
Estimation (GUIDE) decision tree algorithm fits a regression model in each node and the 
residuals are grouped by positive or negative value. Then, the predictor variable that results 
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in the best split between the two groups of residuals is selected. The regression models 
within the nodes can be constant models (intercept only), simple or multiple linear 
regression models. To make predictions using a regression tree, a new observation is run 
through the tree until it reaches a terminal node. The predicted outcome is the mean 
outcome of the training data in that terminal node. 
In both classification and regression decision trees, splitting of the nodes is repeated until 
the terminal nodes contain less than a pre-specified number of observations. To prevent 
overfitting the tree to the training data, decision trees can be pruned, i.e. recursively 
removing the least important node from the tree. The appropriate number of nodes is a 
tuning parameter that can be determined using cross-validation.  
An advantage of decision trees is that they are easily interpretable and can be graphically 
displayed. Moreover, decision trees perform variable selection, except in the scenario 
where all predictor variables are used in the splitting process. Although the simplicity of 
decision trees makes them attractive prediction models, their predictive performance is 
generally lower than that of more sophisticated algorithms such as random forest (James et 
al., 2013). 
5.4.6.2. Random forest 
The random forest algorithm aggregates multiple decision trees, which can substantially 
improve the predictive power compared to a single decision tree (Breiman, 2001b). A 
bootstrapped sample of the training data is drawn and used in the construction of each 
individual tree (Fig. 17). Furthermore, for each tree only a random subset of predictors is 
considered. Typically, the number of predictor variables considered in the construction of 
each tree (𝑟) is √𝑝 for classification forests and 𝑝/3 for regression forests, though 𝑟 is a 
hyperparameter that can be tuned (Hastie et al., 2009). The randomness introduced when 
building the individual trees assures that the trees in the random forest are uncorrelated. 
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For prediction, a new observation is run through each of the decision trees in the random 
forest and the predicted outcome is obtained by majority-voting (classification) or 
averaging across trees (regression). Averaging across trees reduces the prediction variance, 
which is further reduced by the low correlation between the trees (Hastie et al., 2009). A 
useful feature of random forests is the fact that bootstrapping the training data creates 
out-of-bag (OOB) samples. These can be used as validation data to get a prediction 
estimate: for each observation a prediction is made using only trees for which that 
observation was not included in the bootstrapped sample. The OOB prediction estimate 
provides an alternative to cross-validation without any additional computational cost. 
Furthermore, the gain in OOB predictive performance can be monitored as trees are added 
to the random forest. Once the OOB prediction accuracy or the OOB prediction error 
stabilizes the random forest training can be stopped. An additional advantage is that adding 
more trees to the forest does not overfit the model, thus the size of the random forest is a 
hyperparameter that does not need to be tuned. The degree of pruning applied to the 
individual trees can be optimized, though in practice this parameter does not have a large 
impact on the model performance (Hastie et al., 2009). Importance scores for predictor 
variables can be calculated by averaging the reduction in RSS or Gini index across all trees in 
the random forest. Alternatively, the OOB samples can be used to construct importance 
scores by permuting the values of a single predictor variable and measuring the reduction 
in prediction accuracy. A special case of random forest is bagging, where 𝑟 = 𝑝. In bagging, 
all predictors are considered in the construction of each decision tree and by consequence 
the trees are correlated. For datasets where the proportion of relevant predictors is small, 
bagging can outperform random forest. In that case the probability of including a relevant 





Figure 17. Graphical representation of the random forest algorithm. 
5.4.7. Support vector machine 
The support vector machine (SVM) is a powerful machine learning technique for binary 
classification. The SVM searches for the hyperplane in high dimensional feature space that 
separates the outcome classes with the largest margin. A linear SVM uses the data in 𝑝-
dimensional space, where each dimension represents one of 𝑝 predictor variables. Each 
observation is thus a vector in the feature space. The observations situated closest to the 
separating hyperplane are called the support vectors (Fig. 18). The decision boundary is 
found by maximizing the margin, i.e. the perpendicular distance from the support vectors 
to the hyperplane. This means that the location of the decision boundary depends only on 

























Figure 18. In the left panel, the red and green classes are separated by a small margin. In 
the right panel, the margin is large. 
5.4.7.1. Perfect linear separation 
We first introduce the SVM for the scenario of a perfectly linearly separable classification 
problem (Fig. 19). For a binary outcome with two classes 𝑦𝑖 ∈  −1, 1  a hyperplane is 
defined as 
𝐻(𝑥) = 𝛽0 + 𝛽1𝑥𝑖1 + ⋯+ 𝛽𝑝𝑥𝑖𝑝 = 0. 
The observations are classified by their location relative to the hyperplane, thus 
𝛽0 + 𝛽1𝑥𝑖1 + ⋯+ 𝛽𝑝𝑥𝑖𝑝 > 0 if 𝑦𝑖 = 1 
and  
𝛽0 + 𝛽1𝑥𝑖1 + ⋯+ 𝛽𝑝𝑥𝑖𝑝 < 0 if 𝑦𝑖 = −1. 
This is equivalent to  
𝑦𝑖(𝛽0 + 𝛽1𝑥𝑖1 + ⋯+ 𝛽𝑝𝑥𝑖𝑝) > 0. 





Figure 19. In the left panel, the red and green classes are linearly separable. The right panel 
shows an example of non-linearly separable data. 
The distance between a data point  𝑥𝑖 (a 𝑝-dimensional vector) and a hyperplane 𝐻(𝑥) is 




with ‖𝛃‖ = ∑ 𝛽𝑗
2.𝑝𝑗=1  Note that the intercept 𝛽0 is excluded in ‖𝛃‖. 
The optimal separating hyperplane maximizes the margin 𝑀 between the hyperplane and 
the support vectors 
𝑦𝑖(𝛽0 + 𝛽1𝑥𝑖1 + ⋯+ 𝛽𝑝𝑥𝑖𝑝)
‖𝛃‖
≥ 𝑀 
where 𝑀 > 0. However, given the hyperplane 𝐻(𝑥) = 0, every 𝑘𝐻(𝑥) = 0 with 𝑘 ≠ 0 is 






Thus, maximizing 𝑀 is equivalent to minimizing ‖𝛃‖ subject to 𝑦𝑖(𝛽0 + 𝛽1𝑥𝑖1 + ⋯+
𝛽𝑝𝑥𝑖𝑝) ≥ 1, which is a convex optimization problem (Hastie et al., 2009). It can be derived 
Linearly separable Not linearly separable 
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using Lagrange multipliers that the solution for 𝛃 is a linear combination of the support 
vectors. The location of the hyperplane thus only depends on the data points closest to it.  
It is useful to note that the only term in the Lagrange function that uses the training data 
consists of the inner product between the observations. The inner product between two 
data points 𝑥𝑎 and 𝑥𝑏 is defined as 




This feature will prove helpful when we discuss non-linear SVMs. 
5.4.7.2. Non-separable classification 
In situations where it is not possible to perfectly separate outcome classes by a hyperplane, 
it is useful to allow some flexibility. To tolerate some observations to fall in the margin or 
even on the wrong side of the hyperplane, the maximum margin equation can be modified 
to  
𝑦𝑖(𝛽0 + 𝛽1𝑥𝑖1 + ⋯+ 𝛽𝑝𝑥𝑖𝑝)
‖𝛃‖
≥ 𝑀(1 − 𝜖𝑖) 
where 𝜖𝑖 = 0 if the 𝑖
th observation is on the correct side of the hyperplane and outside of 
the margin, 1 > 𝜖𝑖 > 0 if it falls on the correct side but inside the margin and 𝜖𝑖 > 1 if it is 





where C is the cost-parameter controlling how strictly the separation between the classes is 
enforced. A hard margin (𝐶 = 0) requires all items to be correctly classified, whereas a soft 
margin (large 𝐶) allows some objects to be misclassified (Cortes & Vapnik, 1995). Allowing 
some flexibility increases the generalizability of the algorithm to test data.  
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5.4.7.3. Non-linear separation 
Not all classification problems can be solved using a linear separating hyperplane. As an 
alternative to linear separation, the input data can be projected to higher dimensional 
space (Fig 20). In fact, because the optimization function only depends on the inner product 
of the training data, the transformation function does not need to be known explicitly. A 
kernel function computing the inner product of the transformed data points is sufficient,  
𝐾(𝑥𝑎 , 𝑥𝑏) = 〈ℎ(𝑥𝑎), ℎ(𝑥𝑏)〉 
where ℎ(𝑥) is the transformation function applied to the input data. This is known as the 
kernel trick. Popular kernel functions are radial and polynomial kernels 
𝑅𝑎𝑑𝑖𝑎𝑙: 𝐾(𝑥𝑎 , 𝑥𝑏) = exp(−𝛾‖𝑥𝑎 − 𝑥𝑏‖
2) 
𝑃𝑜𝑙𝑦𝑛𝑜𝑚𝑖𝑎𝑙: 𝐾(𝑥𝑎 , 𝑥𝑏) =  (𝛾〈𝑥𝑎 , 𝑥𝑏〉 + 𝑟)
𝑑 
where 𝛾, 𝑟 and 𝑑 are kernel specific hyperparameters. The separating hyperplane is linear 
in higher dimensional space, but translates to a non-linear decision boundary in the original 
input space.  
5.4.7.4. Practical notes on the SVM 
Training an SVM requires tuning the hyperparameters, namely the cost parameter C and 
the kernel function. In addition, some kernels have kernel-specific hyperparameters, for 
example the degree of a polynomial kernel. For an SVM with linear kernel, the model 
parameters 𝛽1, … , 𝛽𝑝 can be interpreted as feature importance scores. There is no 
straightforward way to extract importance scores from non-linear SVMs. The SVM 
algorithm can also be adapted to regression problems, though a discussion of support 




Figure 20. In the original input space the observations are not linearly separable. However, 
by transforming to higher dimensional space the red and green classes can be separated by 
a linear hyperplane. 
5.5. Deep learning 
Neural networks are a class of machine learning algorithms also referred to as deep 
learning. Although the first neural networks were developed in the 1960s, training neural 
networks, especially with many layers, was a computationally challenging task given the 
large number of parameters in these models. The deep learning field has made a lot of 
progress in the last few years thanks to the increase in computational power and speed 
achieved by graphics processing units (GPUs) and the availability of very large datasets. 
Neural networks are highly flexible classification and regression algorithms and have 
outperformed other machine learning approaches in various research fields (LeCun, Bengio, 
& Hinton, 2015; Schmidhuber, 2015) . 
5.5.1. Perceptron and artificial neurons 
The building stones of neural networks are perceptrons and artificial neurons. A perceptron 
is relatively simple model that takes multiple input variables and returns a single binary 
output. Each feature has a weight and the weighted sum of the input variables determines 
Input space High dimensional feature space 
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the output. The perceptron returns 1 when the weighted sum exceeds a certain threshold 














+ 𝑏 > 0
 
where 𝑤𝑗 is the weight for the 𝑗th feature and 𝑏 is the negative of the threshold. 𝑏 is also 
called the bias of the perceptron. The terminology used by the deep learning and statistics 
community is different, but weights correspond to model coefficients, whereas the bias 
term can be seen as the intercept. We refer to the weighted sum of input features plus the 





In fact, a perceptron is equivalent to a linear SVM, although both algorithms typically use 
different optimization techniques (Collobert & Bengio, 2004). The binary nature of the 
perceptron output is a limitation of this model. Changes in the input features either result 
in a reversal of the output or no change at all. Artificial neurons are modified perceptrons 
that apply an activation function to the input 𝑧 and produce a continuous outcome, 
allowing for a more nuanced response to changes in the input features. A sigmoid neuron 
applies the logistic function to 𝑧 
𝑓(𝑧) =
1
1 + exp (−𝑧)
. 
The output from a sigmoid neuron is thus a continuous number between 0 and 1, and can 
be interpreted as the probability of belonging to outcome class 1. Other activation 
functions include the hyperbolic tangent, linear and rectified linear functions (Table 5). A 
graphical representation of an artificial neuron helps explain its similarities with a biological 
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neuron (Fig. 21). The input features can be compared to dendrites, through which 
information is received, the circle depicting the activation function is similar to the soma or 
cell body and the output arrow is the equivalent of the axon, which fires when the electrical 
potential in the cell surpasses a threshold.  
Table 5. Activation functions in artificial neurons. 




  [0, 1]  
Hyperbolic tangent 𝑓(𝑧) = tanh(𝑧)  [−1, 1]  
Linear 𝑓(𝑧) = 𝑧  ]−∞,∞[  
Rectified linear 𝑓(𝑧) = max(0, 𝑧)  [0,∞[  
Softmax  






  [0, 1] and ∑ 𝑓(𝑧)𝑘
𝐾
𝑘=1 = 1 
 
 
Figure 21. Artificial neuron with three input features, applying activation function 𝑓(𝑧) to 
the weighted sum of features 𝑧𝑖  to produce outcome 𝑦𝑖. 
5.5.2. Neural network 
The output of a neuron can be used as input feature to another neuron and several 
neurons can be connected to form a network. The result is a highly flexible non-linear 

















arranged in layers (Fig. 22). The input features are drawn as circles, which form the input 
layer of the network. In the next layers, circles represent artificial neurons. The layers of 
neurons from which the output serves as input for the subsequent layer of neurons are 
called hidden layers. The number of hidden layers and the number of neurons in each one 
are hyperparameters of the neural network. Finally, the last layer is called the output layer. 
For a binary outcome, the output layer consists of a single sigmoid neuron, predicting the 
probability of outcome class 1. If the outcome is categorical with K categories, a layer of 
K softmax neurons can be used (Table 5). The kth softmax neuron gives the probability of 
the outcome belonging in the kth category. A continuous outcome is most suitably modelled 
by a single linear output neuron. Each connecting arrow in the neural network graph has a 
weight attached to it and each neuron is associated with a bias term. It is obvious that the 
number of parameters in a neural network rapidly grows with the complexity of the model 
and that fitting a neural network can be computationally expensive.  
With the exception of a single perceptron or artificial neuron it is not straightforward to 
interpret the weights and biases and derive feature importance scores from a neural 
network. This limitation implies that these algorithms are not suitable for analysis problems 
where understanding how the predictor variables interact is important. On the other hand, 
neural networks are very flexible classification and regression models and often outperform 
other machine learning approaches for the modelling of large datasets. 
The weights and biases of a neural network are iteratively updated during the model 
training process using mini-batch gradient descent, an iterative optimization algorithm. To 
compute the gradient of the cost function, backpropagation is used, which is an efficient 
algorithm that backwardly propagates the error through the neural net. Each gradient 
descent iteration involves a forward pass through the network to compute the cost 
function and a backward pass to compute the derivative of the cost function and update 
the model parameters.  
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Whereas other machine learning algorithms are usually trained using cross-validation, the 
neural network community has a preference for the training-validation-test data approach, 
whereby algorithms are fit on the training data, then the model that achieves the best 
prediction in the validation data is selected and in a final step that model is assessed on the 
test data. This approach avoids the computationally expensive part of cross-validation, 
namely the model fitting, but requires larger sample sizes as the data are split in three 
independent subsets. 
 
Figure 22. A neural network with three input features, two hidden layers of four hidden 
neurons each and a single output neuron. 
With the large number of model coefficients, neural networks can easily overfit to the 
training data. One way to prevent overfitting is early stopping; the model training is 
stopped as soon as the prediction accuracy in the validation data does not improve further. 
A second strategy is applying drop-out during model fitting, where a random selection of 



















iteratively excluding parts of the neural network, the model is forced to learn more robust 
patterns (Srivastava, Hinton, Krizhevsky, Sutskever, & Salakhutdinov, 2014). Another 
alternative is to add a regularization penalty to the cost-function which is minimized. 
The design of a neural network, i.e. defining the structure of the network, including the 
number of hidden layers, the number of hidden neurons and the connections between the 
neurons, choosing the activation functions and deciding the gradient descent parameters 
(number of iterations, mini-batch size, learning rate) is not a straightforward task. There is 
no consensus in the field of the preferred strategy to optimize hyperparameters, though a 
pragmatic approach is to build a relatively small network that achieves some prediction and 
then try to improve its performance by repeatedly tuning the hyperparameters one by one 
(Nielsen, 2015). Alternatively, a grid search can be performed but this involves many 
repetitions of fitting a computationally intensive model. A random search, where 
hyperparameter values are randomly sampled provides a faster way to explore 
hyperparameter settings (Bengio, 2012).  
The neural network described in the preceding paragraphs is sometimes referred to as a 
feedforward multi-layer perceptron (MLP), even though the neurons need not be 
perceptrons and are usually sigmoid neurons. In the MLP each layer is fully connected to 
the next one. More complex architectures of neural networks exist, which take the nature 
of the input data into account. For example, convolutional networks are well suited for 
image recognition (Krizhevsky, Sutskever, & Hinton, 2012). Images are translated into 
matrices of pixel intensities. Convolutional networks have hidden layers which are 
organized in parallel and each layer scans the input image to detect a visual feature. The 
network learns the weights of the hidden layers from the data and thus automatically 
learns visual features that are useful for classification. The architecture of convolutional 
networks reduces the number of coefficients compared to a fully connected MLP and 
makes these algorithms faster to train. A second example is recurrent neural networks. 
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These networks have cyclic connections between neurons and are ideal for the analysis of 
sequential data. Given a sequence of input data, a recurrent neural network predicts the 
next item. Recurrent neural networks have been successful in speech recognition (Graves, 
Mohamed, & Hinton, 2013). 
5.6. Summary 
Traditional statistical methods like linear and logistic regression are limited in the number 
of variables a single model can fit and struggle when predictor variables are correlated. By 
consequence, large genetic datasets are analysed in a univariate way and a subsequent 
correction for multiple testing is applied. In contrast, machine learning and deep learning 
algorithms can model a large number of correlated predictor variables simultaneously. 
These methods optimize prediction precision and can be used to build multivariable 
prediction models for continuous or categorical outcomes. We applied the methods 




6. Diagnostic classification using machine learning and deep 
learning applied to brain gene expression data 
6.1. Introduction 
Schizophrenia is a psychiatric complex disorder affecting nearly 1% of the population. It is a 
highly heritable condition with heritability estimates up to 80% (Gejman, Sanders, & Duan, 
2010). GWAS has proven a successful approach for discovering genetic variants that are 
associated with schizophrenia risk. In the largest GWAS on schizophrenia to date, 
conducted by the Psychiatric Genetics Consortium (PGC), 128 SNPs in 108 independent 
genetic loci were identified (Schizophrenia Working Group of the Psychiatric Genomics 
Consortium, 2014). Many of the implicated associations mapped to genes expressed in the 
brain and to genes involved in the immune response. 
It is often not straightforward to derive the molecular effects of a SNP, particularly for 
variants that lie outside protein coding regions. In addition to the genetic code, gene 
expression levels can be studied to investigate differences between cases and controls. 
Various techniques can be used to measure expression levels, including RNA-seq, a next-
generation sequencing technique covering the whole transcriptome. Whereas the genetic 
code in DNA is constant, gene expression levels change over time and are tissue specific. 
RNA-seq thus takes a snapshot of gene expression in a tissue at a specific point in time. 
Furthermore, differences in gene expression may be causal to the disease studied or on the 
contrary may be the consequence of the disease.  
Differential gene expression studies compare the expression of each gene between cases 
and controls and correct the statistical significance threshold for multiple testing. Several 
genes have been shown to be differently expressed in post-mortem brains of schizophrenia 
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cases and controls (Bray, 2008; Xin Li & Teng, 2015). Genes related to immune response 
were upregulated in the hippocampus and dorsolateral prefrontal cortex (DLPFC) of 
schizophrenia patients (Fillman et al., 2013; Hwang et al., 2013). Differentially expressed 
genes have also been reported in other tissues, including fibroblasts and peripheral blood 
cells of schizophrenia patients (Cattane et al., 2015; Sainz et al., 2013).  
Machine learning approaches enable large multivariable analyses and can thus be used to 
simultaneously examine the expression of many genes in a single model. Moreover, these 
algorithms optimize the accuracy of predicting the outcome of interest, for example 
diagnostic class. The aim of this study was to classify schizophrenia cases and controls using 
RNA-seq gene expression data from DLPFC brain tissue. We applied machine learning and 
deep learning classification algorithms using brain gene expression scores as predictor 
variables. Three different algorithms, SVM, random forest and neural networks, were 
trained and their predictive accuracy on test data was compared.  
6.2. Methods 
6.2.1. Data 
The BrainSeq consortium is a collaboration between the Lieber Institute for Brain 
Development (LIBD) and seven pharmaceutical industry partners, including Eli Lilly and 
Company, investigating the molecular mechanisms through which genetic variants 
associated with psychiatric disorders act (Lieber Institute for Brain Development, 2017; 
Schubert et al., 2015). In addition to genetic data, the BrainSeq project also generates and 
analyses epigenetic and transcriptomic datasets from different brain regions and will make 
them publicly available after completion of the primary analyses. Differential RNA-seq 
expression analysis of the DLPFC brain region has recently been completed and the results 
are currently submitted for publication. 
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Through Eli Lilly, a founding member of BrainSeq, we gained access to the DLFPC gene 
expression dataset prior to public release. RNA-seq was performed on RNA extracted from 
the DLPFC of post-mortem human brain tissue donated to the LIBD. The raw sequencing 
reads (FASTQ files) generated by LIBD were processed using a proprietary pipeline 
developed and used at Eli Lilly. The RNA-seq pipeline uses open-access and bespoke 
software and checks for data integrity and potential errors. The raw sequencing reads were 
put through pre-alignment QC, aligned against human reference genome build 19 and 
subjected to post-alignment QC (Fig. 23). Next, the expression counts were summarized at 
the gene level and normalised using log normalisation. Further quality checks included the 
generation of summary statistics for each normalised sample and a visual inspection of the 
distributions of all gene expression scores in the data, the variability of the median values 
and skewness of the samples. The resulting gene expression scores used in our analysis are 
continuous variables without missing values, each variable corresponding to one gene. In 
addition to gene expression scores, demographics and sample quality related measures 
were available (Table 6). There were 408 samples from individuals with schizophrenia and 
healthy controls in the LIBD dataset. 
6.2.2. Statistical methods 
6.2.2.1. Data splitting and pre-processing 
Three different machine learning and deep learning algorithms were applied to predict 
schizophrenia case/control status from brain gene expression data. The predictive accuracy 
of a classification algorithm, i.e. the proportion of subjects that are correctly classified, is 
assessed on a test dataset independent from the data used to train the model. Therefore, 
the LIBD dataset was randomly split in training (80%) and test (20%) subsets. The training 
data were used to build the machine learning models, which were then applied to the 




Figure 23. Eli Lilly RNA-seq quality control pipeline. QC: quality control. 
The gene expression scores were adjusted for demographic and sample related variables to 
control for confounding covariates (Table 6). The effect of the covariates on gene 
expression was estimated using linear regression in the training set control samples. By only 
modelling the covariates in the controls we separate the covariate effects from differences 
caused by the disease status (Dukart, Schroeter, Mueller, & Alzheimer's Disease 
Neuroimaging Initiative, 2011). Subsequently, these regression models were used to correct 
the gene expression scores in the training and the test data. 
Input data 
• Exon level read count FASTQ files 
Output data 
• Normalize gene expression scores 
• Visual quality checks of distributions 
Pre-alignment QC 
• Base quality/Base composition 
• Heterologous organisms 
• rRNA/mitochondrial/viral/adapter content 
Mapping 
• Alignment against human reference genome build 19 
• Using Genomic Short-read Nucleotide Alignment Program (GSNAP) 
(GSNAP) 
Counting 
• Count for each exon with ≥ 2 reads 
• Sum exon counts per gene and return single number per gene 
Post-alignment QC 
• Gene/location type count summary 
• Template length 
• Ethnicity 
• DNA genotype/RNA genotype match 
• Sample relatedness/intermixing 
• 3’ bias 
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Table 6. Demographics and sample quality measures controlled for in gene expression 
analyses. 
Covariate Description 
Age Age in years 
Sex Sex of the patient 
Ethnicity Ethnicity of the patient 
Smoking status Whether the patient consumed tobacco. When this 
information was not available it was derived from nicotine 
and cotinine toxicology analysis.  
pH Acidity of cerebellar tissue, a measure relating to basic 
tissue quality. 
RNA integrity number (RIN) RNA quality measure capturing RNA degradation. Ranges 
from 1 (degraded) to 10 (intact). 
Post mortem interval (PMI) Time in hours between death of the patient and freezing of 
the brain. RNA degrades over time thus shorter PMI is 
preferable. 
 
6.2.2.2. Machine learning algorithms 
SVM, random forest and neural network algorithms were trained to classify schizophrenia 
cases from controls (Fig. 24). The SVM algorithm has previously been successfully applied to 
gene expression data in an antidepressant response study and therefore we chose this 
machine learning classifier for our study (Malki et al., 2017). We compared the SVM to 
random forest, another well-established classifier for high dimensional data. Neural 
networks are highly flexible classification algorithms which have outperformed other 
machine learning methods in various fields. Hence, we explored the use of this deep 
learning method on gene expression data.  The hyperparameters of the algorithms were 
optimized using five-fold cross-validation. 
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An SVM separates the outcome classes by defining a decision boundary and maximizing the 
distance between the data and that boundary (for details of the SVM algorithm, see section 
5.4.7. on page 86). Different kernels can be applied to project the input variables to higher 
dimensional space and compute non-linear decision boundaries. The cost-parameter of an 
SVM determines how strictly the separation between the classes is enforced. Five-fold 
cross-validation was used to tune the kernel type, kernel specific parameters and the value 
of the cost-parameter (Table 7).  
Table 7. Hyperparameters of machine learning algorithms.  
Algorithm Hyperparameter Values tested in tuning 
process 
SVM Kernel type Linear, radial, polynomial 
 Cost  0.01, 1, 100 
 Degree of polynomial kernel (kernel 
specific parameter) 
2, 3, 4 
 𝛾 (kernel specific parameter) 10-4, 10-5, 10-6 
Random forest 𝑟 (number of predictors randomly 
selected for tree building) 
log(𝑝), √𝑝, 𝑝 
Neural network Number of hidden layers 1, 2, 3 
 Number of hidden neurons per hidden 
layer 
500, 1,000, 2,000, 5,000, 
10,000 
𝑝 = total number of predictors 
A random forest is an ensemble of decision trees (for details of the random forest 
algorithm, see section 5.4.6.2. on page 84). Each tree is constructed using a bootstrapped 
sample and a random selection of predictor variables. The number of predictors that is 
randomly selected for the construction of each tree (𝑟) was optimized using five-fold cross-
validation (Table 7). We built random forests with 1,000 trees. Including more trees does 
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not induce overfitting of the model to the training data, and it is thus not necessary to tune 
this hyperparameter. 
Lastly, neural networks were applied to solve the classification problem (for details of the 
neural network algorithm, see section 5.5.2. on page 93). These are highly flexible 
algorithms with a large number of parameters. As the computational cost of neural 
networks increases rapidly with the complexity of the design, a pragmatic approach was 
used for hyperparameter tuning. Instead of defining a list of hyperparameter values to be 
evaluated prior to cross-validation, we started by training a simple neural network with 1 
hidden layer of 500 neurons. We then then increased the complexity of the model by 
varying the number of hidden layers and hidden neurons whilst taking guidance from the 
cross-validated prediction accuracy (Table 7). The parameters of backpropagation, the 
iterative optimization method used to estimate neural network parameters, were fine 
tuned for each complexity level of the algorithm. To prevent overfitting we applied drop-
out to the input (10%) as well as hidden layers (30%), which means that in each training 
iteration a randomly selected proportion of neurons is excluded. 
6.2.2.3. Variable selection 
Big datasets may contain a large proportion of variables irrelevant to predicting the 
outcome of interest. Different variable selection techniques can be used to reduce the 
complexity of the data and improve the signal-to-noise ratio. Including variable selection in 
the model building process leads to more sparse models and may improve prediction 
accuracy (Guyon & Elisseeff, 2003).  
Initially, machine learning algorithms including the full set of gene expression predictors 
were built to tune the hyperparameters of the model. After the values of the 
hyperparameters had been fixed, four different variable selection methods were applied to 
SVM and random forest models and the results were compared. Three filter methods were 
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used, where the predictor variables are ranked using t-tests (parametric), Mann-Whitney U 
tests (non-parametric) or information gain (Kraskov, Stögbauer, & Grassberger, 2004). The 
top 10, 25, 50, 100, 250, 500, 750, 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,500, 10,000, 
12,500, 15,000 and 20,000 genes were taken forward as predictors in the machine learning 
algorithms. The fourth variable selection technique was recursive feature elimination (RFE). 
This method iteratively excludes the variables that have the smallest impact on the 
algorithm’s prediction accuracy. RFE was used to build SVM and random forest algorithms 
with 10, 25, 50, 100, 250, 500, 750, 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,500, 10,000, 
12,500, 15,000 and 20,000 genes as predictors.  
In addition, we selected genes based on previously published knowledge. The PGC 
Schizophrenia GWAS detected 108 significant loci and mapped these to genes 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). We used the 
list of mapped genes from the PGC study to select genes for inclusion as predictor variables 
in SVM and random forest models. The PGC mapped the GWAS results to 351 protein 
coding genes, of which 322 corresponded to genes in our study. Genes were matched 
through their Entrez GeneID (Maglott, Ostell, Pruitt, & Tatusova, 2011). 
No variable selection was applied prior to neural network modelling. As neural networks 
take interactions between predictors into account, it is less meaningful to exclude 
predictors on an individual basis. Moreover, historically neural networks were built without 
variable selection.  
6.2.2.4. Prediction accuracy in independent test set 
For each machine learning approach, the model containing all genes and the model that 
achieved the highest cross-validated prediction accuracy after variable selection were taken 
forward. These algorithms were applied to classify schizophrenia case/control status is the 




All analyses were performed in Python 2.7.12. The SVM and random forest algorithms were 
built using the scikit-learn Python library (Pedregosa et al., 2011). The neural net analyses 
were carried out using the theano and lasagne Python libraries (Bergstra et al., 2010; 
Dieleman et al., 2015).  
 
Figure 24. Analysis plan for building machine learning classification models for 




6.3.1. Data description 
The LIBD gene expression dataset contained DLPFC brain gene expression scores for 24,383 
genes on 408 samples. For one individual the smoking status was missing and could not be 
estimated, and this sample was excluded from the analysis. No other covariates were 
missing. There were more controls (55.0%) than schizophrenia cases (45.0%) in the dataset. 
Most samples were male (67.8%) and the age of the subjects in the dataset ranged 
between 17 and 97 years (Table 8). The data were randomly split in independent training 
(80%) and test (20%) sets.  
Table 8. Description of outcome and covariates in LIBD training and test data. 
Variable LIBD Training set LIBD Test set 
Outcome class, count (%)   
Case 149 (45.8) 34 (41.5) 
Control 176 (54.2) 48 (58.5) 
Sex, count (%)   
Male 226 (69.5) 50 (61.0) 
Female 99 (30.5) 32 (39.0) 
Smoking status, count (%)   
Yes 159 (48.9) 36 (43.9) 
No 166 (51.1) 46 (56.1) 
Ethnicity, count (%)   
Caucasian 159 (48.9) 34 (41.5) 
African American 151 (46.5) 43 (52.4) 
Other 15 (4.6) 5 (6.1) 
Age in years, mean (s.d.) 45.8 (15.3) 48.7 (16.2) 
PMI in hours, mean (s.d.) 33.8 (18.2) 34.1 (24.4) 
pH, mean (s.d.) 6.5 (0.3) 6.5 (0.3) 
RIN, mean (s.d.) 8.2 (0.8) 8.1 (1.0) 
Sample size 325 82 
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6.3.2. Machine learning prediction algorithms 
Three different machine learning approaches were applied to classify schizophrenia cases 
from controls using brain gene expression data. After the hyperparameters of the SVM and 
random forest were tuned, different variable selection techniques were applied to reduce 
the number if inputs. No variable selection was performed on neural networks. 
6.3.2.1. Support vector machine 
The hyperparameters of the SVM were tuned in a model including the full set of genes as 
predictor variables. The linear kernel reached 83.38% accuracy in the cross-validation, 
which was higher than the polynomial or radial kernel and was thus carried forward (Table 
9). The value of the cost-parameter had little influence and was set to the default value of 
one. 
Next, different variable selection methods were applied to the linear SVM (Fig. 25). 
Recursive feature elimination retained slightly higher cross-validation accuracy in the 
training data than t-test and mutual information based ranking. The method using Mann-
Whitney U-tests to rank and select variables performed substantially worse than the other 
methods when lower numbers of variables were selected.  
The best predicting model in training set cross-validation was the SVM with 10,000 genes 
selected by RFE, which predicted with 84.92% accuracy. This is marginally higher than the 
accuracy achieved by the full set of genes (83.38%). Similar levels of accuracy are obtained 
by more sparse models, for example an SVM including 250 genes selected by RFE reached 






Table 9. Cross-validated prediction accuracy of SVM hyperparameter values, ordered by 









prediction accuracy (%) 
Linear 1 - - 83.38 
Linear 0.01 - - 83.38 
Linear 100 - - 83.38 
Radial 0.01 - 10-5 80.92 
Polynomial 1 2 10-5 80.00 
Polynomial 1 3 10-4 73.85 
Radial 1 - 10-4 70.77 
Polynomial 0.01 2 10-5 70.46 
Polynomial 0.01 3 10-5 65.23 
Polynomial 100 3 10-5 64.62 
Radial 0.01 - 10-6 63.38 
Radial 100 - 10-5 62.46 
Polynomial 0.01 2 10-4 62.46 
Polynomial 0.01 4 10-5 58.15 
Polynomial 1 3 10-5 57.85 
Polynomial 1 3 10-6 56.62 
Polynomial 0.01 3 10-4 56.62 
Polynomial 100 3 10-4 55.08 
Polynomial 0.01 4 10-4 55.08 
Polynomial 1 4 10-6 55.08 
Polynomial 1 2 10-4 54.15 
Polynomial 100 2 10-4 54.15 
Radial 100 - 10-4 54.15 
Polynomial 1 2 10-6 54.15 
Polynomial 1 4 10-5 54.15 
Polynomial 100 2 10-6 54.15 
Polynomial 0.01 3 10-6 54.15 
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Table 9 (continued). Cross-validated prediction accuracy of SVM hyperparameter values, 









prediction accuracy (%) 
Radial 1 - 10-6 54.15 
Polynomial 100 3 10-6 54.15 
Radial 100 - 10-6 54.15 
Radial 1 - 10-5 54.15 
Polynomial 100 2 10-5 54.15 
Polynomial 100 4 10-4 54.15 
Polynomial 1 4 10-4 54.15 
Polynomial 100 4 10-5 54.15 
Radial 0.01 - 10-4 54.15 
Polynomial 0.01 2 10-6 54.15 
Polynomial 0.01 4 10-6 54.15 
Polynomial 100 4 10-6 54.15 




6.3.2.2. Random forest 
Overall, the prediction accuracy obtained from random forest algorithms was lower than 
from SVMs. The only hyperparameter of the random forest, 𝑟 (the number of randomly 
selected predictors for construction of the individual trees), was cross-validated and set to 
the total number of predictors (24,383 genes) (Table 10). Allowing each tree to choose from 
the full set of genes thus performed better in cross-validation than selecting a random 
subset of predictors. This method is a special case of random forest also called bagging. 
With 𝑟 = 𝑝, the cross-validated prediction accuracy was 75.38%. 
Table 10. Cross-validated prediction accuracy of random forest hyperparameter values, 
ordered by decreasing cross-validated prediction accuracy. 
𝑟 parameter 
5-fold cross-validated 
prediction accuracy (%) 
𝑝  75.38 
√𝑝  72.92 
log(𝑝)  69.54 
𝑝: total number of predictor variables. 
Four different variable selection methods were used to reduce the number of genes in the 
random forest (Fig. 26). The difference between RFE, t-test based ranking or mutual 
information based ranking was trivial. However, variable selection using Mann-Whitney U-
test based ranking lead to markedly lower accuracy scores. The accuracy of random forest 
algorithms built using RFE or t-test based ranking ranged between 72.92% and 76.62% and 
was roughly constant irrespective of the number of predictors included. The model with 
322 genes from the PGC GWAS study reached 70.15% accuracy.  
Several random forests achieved the maximum cross-validated accuracy of 76.62%: the 
models with 4,000 and 10,000 genes selected based on mutual information ranking and the 
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models with 250, 2,000 and 6,000 genes selected by RFE. The random forest with 250 genes 
selected using RFE was carried forward because this was the sparsest model achieving 
maximal prediction accuracy. 
Figure 26. Cross-validated prediction accuracy for random forest using different variable 
selection methods.  
6.3.2.3. Neural network 
The tuning parameters of the neural network were optimized using five-fold cross-
validation. We started with a network with one hidden layer of 500 hidden neurons and 
expanded the design complexity by increasing the number of neurons and the number of 
hidden layers. Adding more hidden neurons to a model with a single hidden layer had no 
notable effect on the cross-validated accuracy (Table 11). When a second hidden layer was 
added, the accuracy decreased by approximately six percentage points. Again, the number 
of neurons in the hidden layers had a trivial effect on the accuracy of two-layer neural 
networks. Increasing the number of hidden layers to three substantially lowered the 
prediction accuracy, after which we concluded the network design. The neural network that 
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achieved maximal cross-validated prediction accuracy (79.06%) had 1 hidden layer of 2,000 
hidden neurons. Thus, the best prediction accuracy achieved by neural networks was higher 
than the accuracy of random forests, but lower than that of SVMs. No variable selection 
was applied to the neural network algorithms; these models were built using all 24,383 
genes as predictor variables. 
Table 11. Cross-validated prediction accuracy for neural networks with varying design 
complexity, ordered by decreasing cross-validated prediction accuracy. 
Number of hidden 
layers 
Number of hidden 
neurons per layer 
5-fold cross-validated 
prediction accuracy (%) 
1 2,000 79.06 
1 10,000 79.05 
1 5,000 78.14 
1 500 77.83 
1 1,000 77.22 
2 5,000 72.91 
2 1,000 72.30 
2 10,000 72.00 
2 500 71.98 
2 2,000 71.98 
3 500 56.32 
6.3.3. Validation of predictive power in independent test set 
Selected algorithms were taken forward and applied to classify schizophrenia cases from 
controls in independent test data. The prediction accuracy of the SVM, random forest and 
neural net algorithms including the full set of 24,383 genes as predictor variables, the SVM 
and random forest models that achieved the highest accuracy after variable selection and 
the sparse SVM model with 250 genes selected by RFE were assessed in the test dataset. 
The machine learning algorithms score high prediction accuracy in the test set, ranging 
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between 69.51% and 78.05% (Table 12). The test set prediction accuracy was however 
lower than estimated by cross-validation in the training data. The SVM algorithms scored 
highest in the cross-validation and also ranked highest when applied to the test set. 
Examining the predictive characteristics of the SVM with 10,000 variables selected through 
RFE (the highest ranking algorithm in cross-validation) applied to the test set indicates that 
misclassification is balanced between cases and controls. The sensitivity and specificity of 
the algorithm were 73.53% and 79.17%, respectively (Table 13). 
Table 12. Prediction accuracy of selected algorithms in independent test data, ordered by 
decreasing cross-validated prediction accuracy. 









SVM 10,000 RFE 84.92 76.83 
SVM 24,383 None 83.38 78.05 
SVM 250 RFE 80.31 75.61 
Neural network 24,383 None 79.06 73.17 
Random forest 250 RFE 76.62 69.51 
Random forest 24,383 None 75.38 69.51 
CV: cross-validated; RFE: recursive feature elimination; SVM: support vector machine. 
Table 13. Classification measures of SVM with 10,000 variables selected through RFE 
applied to test set. 






NPV: negative predictive value; PPV: positive predictive value 
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6.3.4. Summary of results 
All algorithms achieved high prediction accuracy in the cross-validated training set and in 
the independent test set. The SVM outperformed the random forest and neural network in 
terms of prediction accuracy. Furthermore, RFE yielded slightly better results than the 
other variable selection methods we applied. The best performing algorithm in cross-
validation was an SVM with 10,000 genes selected through RFE, which achieved 76.83% 
accuracy in the test data. 
6.4. Discussion 
Three different machine learning methods were used to classify schizophrenia cases from 
controls using gene expression data from the DLPFC brain region. All methods were 
successful in predicting case/control status, with accuracy scores up to 78.05% in the 
independent test dataset. The SVM models achieved the highest accuracy in the cross-
validation of the training data and also when applied to test data. Neural network was the 
second most accurate method, followed by random forest, which still classified nearly 70% 
of test samples correctly.  
Overall, the accuracy in the test data is lower than the accuracy estimated by cross-
validation in the training data. This is to be expected. Although cross-validation splits the 
data is separate folds and the accuracy is estimated from predicting how algorithms score 
on left-out folds, across the entire process each sample is used in both the training in 
testing folds. Furthermore, cross-validation is performed in order to choose the model 
parameters that result in the highest accuracy. Precisely because the algorithm is selected 
based on the highest accuracy, this estimate of the prediction accuracy is likely to be overly 
optimistic. To obtain an unbiased, generalizable estimate of prediction accuracy, the 
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algorithm needs to be evaluated on an independent test set and these test data must not 
be involved in any step of the algorithm training process.  
Variable selection is used to reduce the dimensions of the predictor space and to improve 
prediction accuracy. In this study, four different techniques for variable selection were 
compared. None of the methods led to marked improvements in accuracy, although 
sparser models that achieved approximately the same accuracy as the models with 24,383 
genes were identified. RFE was the method that performed best when training SVM 
algorithms. For random forests, RFE, t-test and mutual information based ranking methods 
achieved similar results. Variable selection based on the non-parametric Mann-Whitney U-
test ranking clearly performed worse than the other methods.  
RFE variable selection on the SVM algorithm identified a set of 250 genes which achieves 
approximately the same accuracy as all 24,383 genes. This hints that most predictive power 
can be summarized in 250 genes. The list of genes can be investigated in more detail using 
bioinformatics approaches such as gene enrichment analysis and pathway analysis. In this 
way, genes selected by machine learning may increase our understanding of the biological 
processes underlying schizophrenia.  
Traditionally, RNA-seq data are analysed in differential expression studies, where the 
expression of genes in cases and controls is compared statistically. Each gene is 
independently tested and the significance of the difference in expression is assessed. In 
contrast, we used machine learning to select a set of 250 genes which combined hold most 
predictive power to classify cases from controls. This list of genes was obtained from an 
SVM algorithm that models all genes simultaneously. It is important to note these 
methodological differences when interpreting our results and comparing them to the 
differential expression literature. The list of genes identified by machine learning and by 
differential expression analysis may show little or no overlap. The strength of machine 
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learning lies in its ability to pick up combinations of genes that optimize the prediction of 
the outcome of interest, although these genes may not have a large effect individually.  
In addition to performing variable selection, which is based on information in the training 
data, we also evaluated SVM and random forest models which included 322 genes derived 
from the PGC schizophrenia GWAS study as predictors. The cross-validated accuracy of the 
PGC list SVM was in the range of what can be expected for this number of predictors, based 
on the results from t-test and mutual information variable selection methods. However, 
RFE outperformed the PGC gene list algorithm substantially. In the random forest models 
the differences in predictive performance were smaller, but again variable selection 
techniques resulted in models with higher accuracy than the PGC list random forest. 
Nevertheless, this suggests that information from a study of variability in genetic sequence 
contains some signal that translates to gene expression levels. This is an encouraging 
finding, as the link between genetic variability and gene expression is not self-evident. A 
gene expression study looking at 5 genes identified through GWAS (ZNF804A, OPCML, 
RPGRIP1L, NRGN and TCF4) found no difference in gene expression levels in brain samples 
of schizophrenia cases and controls (Umeda-Yano et al., 2014). Moreover, in addition to the 
type of data studied (DNA variants versus RNA gene expression), there are important 
methodological differences between the PGC GWAS and our study. In the GWAS SNPs are 
studied univariately, whereas we used a machine learning approach to model all gene 
expression scores simultaneously. 
Neural networks are very flexible models and have been successfully put to use in many 
advanced applications such as computer vision and speech recognition. In several fields 
they have outperformed classic machine learning approaches such as the SVM (LeCun et al., 
2015). In our study, neural networks ranked second best in terms of prediction accuracy, 
after SVM. The limited sample size in our study may be an explanation for this. The training 
data contained 325 individuals. In comparison, successful applications of neural networks 
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are often trained on large datasets with thousands or millions of training examples. It is 
possible that the strengths of the neural network approach might come into play in larger 
datasets and that with larger samples neural networks may outperform SVM in gene 
expression studies. Yet, the expectation that larger training datasets will increase the 
usefulness of the algorithm holds for all machine learning approaches.  
In conclusion, gene expression data from the DLPFC region in human brain tissue can 
classify schizophrenia cases from controls using machine learning algorithms. SVM was the 
most accurate approach, followed by neural network and random forest. Variable selection 
was applied to identify a small subset of genes that have the same predictive power as the 
full set of genes. A set of 322 genes derived from a large schizophrenia GWAS achieved 
lower accuracy than our best variable selection method, which utilizes the machine learning 
algorithm itself. Larger sample sizes will further increase the utility of machine learning in 
gene expression studies. 
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7. Machine learning algorithms for pharmacogenetic 
prediction in an anti-diabetic clinical trial 
7.1. Introduction 
Type 2 diabetes mellitus (T2DM) is an endocrinologic condition in which blood sugar levels 
are increased due to insulin resistance and insufficient insulin secretion. In addition to 
lifestyle changes, T2DM is treated with drugs such as metformin, sulphonylureas, 
thiazolidinediones and gliptins. A few PGx associations with anti-diabetics have been 
discovered and replicated to date. Glycated hemoglobin (HbA1c) levels, a measure 
indicative of the three-month average plasma glucose concentration, show PGx association 
with several anti-diabetic drugs: ATM variants are associated with HbA1c levels in 
metformin treatment, TCF7L2, KCNJ11 and CYP2C9 with sulfonylureas, PPARG with 
thiazolidinediones and CTRB1/2 with gliptins. Furthermore, SLC22A1 is associated with 
metformin induced gastrointestinal adverse effects, and GSTT1 and CYP2C19 are associated 
with troglitazone induced hepatotoxicity. CYP2C9 loss-of-function variants lead to higher 
sulfonylurea drug levels and are associated with hypoglycaemia. Although these are robust, 
replicated genetic associations, the effect sizes are not large enough to be of clinical utility 
as a biomarker to guide treatment (Daniels et al., 2016; Zhou, Pedersen, Dawed, & Pearson, 
2016). Discovery of genetic biomarkers with clinical relevance will be very valuable given 
the increasing prevalence of T2DM (World Health Organization, 2016). 
Most PGx studies in anti-diabetics were candidate gene studies, focusing on a small number 
of genes selected based on prior biological knowledge. Genome-wide studies expand the 
search for associations across the whole genome and thus take a hypothesis-free 
perspective, though typically genetic variants are analysed independently. Considering that 
PGx effects could well be due to a combination of multiple variants with moderate or weak 
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effect sizes, it is appropriate to perform a multivariable analysis and assess several genetic 
variants simultaneously. Unlike traditional statistical models, machine learning can handle 
datasets with large numbers of variables, even if these variables are correlated.  
In this study we apply regression trees, random forest and elastic net to an anti-diabetic 
cross-over clinical trial, with the aim of predicting PGx changes in efficacy and safety 
measures. The glucagon receptor antagonist LY2409021 (adomeglivant) was developed for 
the treatment of T2DM by Eli Lilly. Two randomized, double-blind, placebo controlled Phase 
2 clinical trials found that LY2409021 significantly lowered glycated haemoglobin (HbA1c) 
and fasting blood glucose (FBG) levels. These studies also noted moderate increases in 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, indicators of 
hepatic safety, following LY2409021 administration (Kazda et al., 2016). A further Phase 2 
trial confirmed the superior efficacy of LY2409021 compared to placebo, and similar 
efficacy when compared to an active comparator sitagliptin. However, the safety aspect of 
the study showed that the LY2409021 treated group had increased weight, hepatic fat, 
hepatic ALT and AST levels and systolic blood pressure (SBP) (Guzman et al., 2017). Finally, a 
6-week multicentre, randomized, double-blind, placebo-controlled Phase 2 cross-over trial 
was conducted to assess the safety and efficacy of LY2409021. This study found that 
LY2409021 indeed lowered HbA1c and FBG, but increased SBP and aminotransferase levels 
(ALT and AST) (Kazda et al., 2017). Although LY2409021 lowers glucose related measures, 
there are some safety concerns that may impact its usefulness for chronic antidiabetic 






Through our collaboration with Eli Lilly we received permission to analyse clinical and 
genetic data from the cross-over clinical trial (ClinicalTrials.gov Identifier: NCT02091362) in 
a machine learning analysis (Kazda et al., 2017). Trial participants received a daily 20mg 
dose of LY2409021 or placebo for six weeks, followed by a four week washout period and a 
second six week period of the other treatment (Fig. 27). Our analysis included patients who 
received at least one dose of both treatments and were genotyped on an Affymetrix-Axiom 
platform. The primary outcome of the trial was change from baseline to six weeks in mean 
24-hour SBP and we extended our study to the secondary outcomes of change HbA1c, FBG, 
ALT and AST. In addition to clinical descriptives, the data included genotypes of 745,401 
SNPs, which we converted to minor allele counts. Our aim was to predict the absolute 
difference in these five outcome measures after six weeks of LY2409021 and six weeks of 
placebo treatment using SNPs and clinical baseline variables.  
 













Placebo LY2409021 20mg 
Placebo 
6 weeks 6 weeks 4 weeks 
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7.2.2. Statistical methods 
Three different machine learning methods were applied to predict PGx differences in SBP, 
HbA1c, FBG, ALT and AST levels: decision trees, random forest and elastic net. The 
predictive power of these algorithms was evaluated in an independent test set (Fig. 28). 
7.2.2.1. Data splitting and predictive performance assessment 
To obtain an unbiased estimate of the predictive performance of an algorithm, it must be 
assessed on a dataset independent of the data used to build the model. Therefore, the data 
were randomly split into separate training (75%) and test (25%) subsets. The training set 
was used to build the prediction algorithms and subsequently the test set was used to 
measure the predictive performance on independent data.  
The 𝑅2 statistic,  
𝑅2 = 1 −
∑ (𝑦𝑖 − ?̂?𝑖)
2𝑛
𝑖=1




with 𝑦𝑖  the observed outcome for subject 𝑖, ?̂?𝑖the estimated outcome for subject 𝑖 and ?̅? 
the average of the observed outcomes, measures the proportion of variation in the 
outcome explained by the algorithm and was used to assess predictive performance. The 
machine learning algorithms were applied to the test subset to predict the outcome 
variables and the test set 𝑅2 was calculated. In addition, to determine if the models fit the 
training data well, the 𝑅2 on the prediction of the training set outcomes was computed. If 
an algorithm fails to accurately predict the data it was built with, this indicates poor 
predictive power and the model is unlikely to perform well on independent test data.  
7.2.2.2. Quality control and data pre-processing 
Quality control (QC) is an essential step prior to the analysis of genetic data to ensure 
validity. To make sure that the test data are completely independent from the model 
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building process, QC was performed on the training data only and extrapolated to the test 
data. In the training set, the following QC steps were carried out for SNPs and individuals 
(Weale, 2010): 
 Individual missingness: exclude individuals with call rate < 95%. 
 Sex checks: exclude individuals with mismatch between reported sex and genotype 
sex, using the inbreeding coefficient, F. 
 Cryptic relatedness: exclude the individual with lowest call rate from pairs that 
appear related based on the identity-by-descent (IBD) statistic. 
 Population stratification: exclude individuals who are outliers in principal 
components analysis (PCA). 
 Heterozygosity and inbreeding: exclude individuals with outlying heterozygosity F 
statistic. 
 SNP missingness: exclude SNPs with call rate < 95%. 
 Minor Allele Frequency (MAF): exclude SNPs with MAF < 2%. We applied a lenient 
threshold as the generally used 5% MAF threshold would exclude half of SNPs in 
this sample. 
To perform QC in the test subset, the patients in the test set were scored on the PCA of the 
training data. Given these factor loadings, the individual level QC steps can be carried out in 
the test data independently. The SNPs that passed QC in the training sample were retained 
in the test set and no additional SNP-level QC steps were carried out. Hardy-Weinberg 
equilibrium tests were not used to exclude SNPs since all study participants suffer from 
T2DM and association with disease can induce deviations from Hardy-Weinberg equilibrium 
(Anderson, 2011). 
Furthermore, to control for population stratification, the first four principal components 
were regressed out of the outcome variables and the adjusted outcomes were used as 
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target variables in all analyses. Principal components were not therefore included in any 
subsequent models for genetic association of the target variables.  
The elastic net and random forest algorithms require complete data. Hence, missing clinical 
variables were imputed using k-nearest neighbours (KNN) and mean imputation and the 
imputed datasets were compared by fitting random forest and elastic net models with 
clinical predictors only. As there was no evident difference between the two imputation 
methods, the KNN imputed clinical variables were taken forward to the analyses combining 
clinical and genetic predictors. Missing genotypes were imputed based on linkage 
disequilibrium (LD) information in PLINK (Purcell et al., 2007). When insufficient LD 
information is present, this method reduces to imputation with the most common 
genotype. Our analysis was based on genotyped SNPs and imputation to large reference 
panels was not performed. As imputation is based on the correlation structure between 
SNPs, imputed SNPs can introduce a systematic pattern of bias. Multivariable machine 
learning algorithms can latch on to the imputation pattern, resulting in overfitting and 
inflated prediction accuracy. Furthermore, adding more features does not necessarily 
increase the predictive ability of a machine learning model. 
7.2.2.3. Machine learning algorithms 
The three machine learning algorithms (decision trees, random forest and elastic net) were 
built on the training data to predict changes in the five outcome variables and subsequently 
the prediction accuracy was evaluated in the independent test data (Fig. 28).  
Decision trees are non-linear machine learning models (for details of decision trees, see 
section 5.4.6.1. on page 81). The Generalized, Unbiased, Interaction Detection and 
Estimation (GUIDE) algorithm is an adaptation of the classic decision tree algorithm, 
developed by a collaboration between the University of Wisconsin-Madison and Eli Lilly, 
with some specific advantages. Firstly, GUIDE performs unbiased variable selection, 
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meaning that it does not favour splitting on variables with many levels, unlike other 
decision tree algorithms (Loh, 2002, 2009). In addition, GUIDE has the ability to detect local 
interactions between predictor variables. The algorithm can be applied to classification as 
well as regression trees. As Eli Lilly had previous experience with GUIDE and was interested 
in exploring the use of this method, we applied this machine learning algorithm to our 
dataset. We constructed GUIDE regression trees to predict changes in the outcome 
variables and fitted constant (intercept only), simple regression and stepwise multiple 
regression models in the nodes. The residuals from the node specific regression models are 
used to split the data in each node into two branches. To prevent overfitting of the models 
to the training data, the trees were pruned by 10-fold cross validation. The GUIDE algorithm 
handles missing observations in the predictor variables automatically by imputing with the 
node means when fitting regression models to the nodes. A limitation of the software used 
for fitting these trees is that it cannot manage large genome-wide datasets, so the number 
of genetic predictors was restricted to 1,000 for these analyses.  
Random forests are ensembles of decision trees and often outperform single tree 
algorithms, hence we compared the performance of GUIDE decision trees and random 
forests (for details of the random forest algorithm, see section 5.4.6.2. on page 84). We 
built random forests with 1,000 trees, randomly selecting 1/3rd of predictors for inclusion in 
each tree. The individual trees were constructed using a bootstrapped sample of the data 
and were not pruned. The random forest algorithm requires complete data, thus missing 
predictor variables were imputed as described above. 
Finally, elastic net models were applied to build linear prediction algorithms and offer an 
alternative to the non-linear tree based methods described above. If the true relationship 
between predictor variables and the outcome is linear rather than non-linear, a linear 
machine learning algorithm like elastic net may fit better than non-linear tree based 
models. Elastic net is a penalized regression model that performs grouped variable 
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selection (for details of the elastic net algorithm, see section 5.4.5.3. on page 77). The 
tuning parameters 𝛼 and 𝜆, which control the strength of the elastic net penalty, were 
selected by 10-fold cross validation. As this machine learning algorithm is restricted to 
numeric predictors, categorical variables were converted to dummy variables. Again, elastic 
net requires complete data so missing predictor variables were imputed. 
 
Figure 28. Analysis plan to build machine learning algorithms for the prediction of PGx 
changes in SBP, HbA1c, FBG, ALT and AST. PCs: principal components; PCA: principal 
components analysis; QC: Quality Control 
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7.2.2.4. Variable selection 
Some machine learning methods, for example elastic net, inherently perform variable 
selection. Variable selection or feature reduction removes redundant predictors and thus 
leads to more sparse models and can improve prediction accuracy (Guyon & Elisseeff, 
2003). Four different methods were compared to select genetic variables for inclusion in 
the machine learning algorithms using the training subset. Firstly, the SNPs were tested for 
association with the outcome variables using t-tests and ranked by increasing p-value. The 
top 10, 50, 100, 250, 500, 1,000, 10,000, 50,000, 100,000, 250,000 and 500,000 SNPs were 
included in random forest and elastic net models. In GUIDE decision trees, only the top 10, 
50, 100, 250, 500 and 1,000 SNPs were used due to software restrictions on the number of 
predictor variables. Secondly, linear regression models were used to test the association of 
the SNPs with the outcomes, including clinical predictor variables as covariates. The SNPs 
were ranked by t-statistic p-value and the same numbers of top SNPs were selected. Lastly, 
both the t-test and regression model ranked SNP lists were clumped using LD (𝑟2 threshold 
= 0.2) and the top 10, 50, 100, 250, 500, 1,000, 10,000, 50,000, 100,000 and 250,000 
independent SNPs were taken forward. The clumped SNP set contained less than 500,000 
SNPs, so this bucket was excluded for clumped feature selection. Machine learning 
algorithms were built using clinical predictors, genetic predictors and clinical and genetic 
predictors combined. The hyperparameters of the elastic net models were tuned separately 
for each set of predictor variables. 
7.2.2.5. Sensitivity analysis 
Randomly splitting the data in training and test subsets could by chance lead to extremely 
precise or poor prediction. Therefore, we performed a sensitivity analysis where the 
random data splitting, algorithm construction and test set predictive accuracy assessment 
was repeated 10 times (Fig. 29). This repetition enables evaluation of the reliability of the 
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predictive performance of the primary analyses. To facilitate automation of the sensitivity 
analysis, QC, data pre-processing and feature selection were carried out on the entire 
dataset before the repeated random splitting into training and test sets. 
 
Figure 29. Analysis plan for sensitivity analysis. QC and data pre-processing were performed 
on the full dataset. Random splitting in training and test subsets, algorithm building and 
predictive performance assessment was repeated 10 times. PCs: principal components; 




GUIDE models were built using GUIDE software, downloadable from the University of 
Wisconsin-Madison, Department of Statistics website (Loh, 2002, 2009, 2017). Random 
forest and elastic net analyses were carried out in R version 3.2.5. using the randomForest 
and glmnet packages, respectively (Friedman, Hastie, & Tibshirani, 2010; Liaw & Wiener, 
2002; R Development Core Team, 2015). 
7.3. Results 
7.3.1. Data description 
There were 270 participants randomized in the clinical trial, though our study included only 
the 213 individuals who had at least one observation in the LY2409021 and placebo 
treatment period and had genome-wide genetic information available. These patients were 
randomly split into a training subset (n=160) and test subset (n=53). After excluding 
subjects who failed QC, the number of patients in the training and test samples was 157 
and 51, respectively (Table 14). There were slightly more males (56.2%) than females 
(43.8%) in the sample. The sample was predominantly Caucasian (67.3%) and subjects 
ranged between 34 and 79 years of age (median = 58). Baseline covariates and mean 
outcome levels are reported for the training and test sets in Table 15. 
Table 14. Number of subjects excluded in the individual-level QC steps in the training and 
test sets. 
QC step Training subset (n=160) Test subset (n=53) 
Individual missingness 0 0 
Sex checks 0 0 
Cryptic relatedness 1 0 
Population stratification 1 2 
Heterozygosity and inbreeding 1 0 
Number of subjects retained after QC 157 51 
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Table 15. Description of outcomes and covariates in training and test data. 
Variable Training set (n=157) Test set (n=51) 
Outcomes   
Change in SBP in mmHg, mean (s.d.) 3.08 (8.32) 0.72 (9.72) 
Change in HbA1c in %, mean (s.d.) -0.49 (0.56) -0.46 (0.5) 
Change in FBG in mg/dL, mean (s.d.) -22.61 (32.48) -23.20 (32.2) 
Change in ALT in IU/L, mean (s.d.) 11.27 (17.73) 12.22 (19.37) 
Change in AST in IU/L, mean (s.d.) 7.51 (11.01) 7.25 (10.23) 
Covariates   
Sex, count (%)   
Male 87 (55.4) 30 (58.8) 
Female 70 (44.6) 21 (41.2) 
Race, count (%)   
Caucasian 107 (68.2) 33 (64.7) 
African American 20 (12.7) 3 (5.9) 
Other 30 (19.1) 15 (29.4) 
Ethnicity, count (%)   
Hispanic 75 (47.8) 25 (49.0) 
Not Hispanic 71 (45.2) 24 (47.1) 
Not reported 11 (7.0) 2 (3.9) 
Age in years, mean (s.d.) 58.22 (8.91) 58.57 (7.83) 
Body weight in kg, mean (s.d.) 85.83 (14.96) 89.75 (16.02) 
Baseline triglycerides in mg/dL, mean (s.d.) 168.70 (97.19) 153.08 (66.94) 
Baseline glucagon in pmol/L, mean (s.d.) 12.91 (5.79) 13.3 (7.13) 
Baseline SBP in mmHg, mean (s.d.) 129.09 (10.7) 130.55 (11.02) 
Baseline HbA1c in %, mean (s.d.) 7.30 (0.63) 7.28 (0.58) 
Baseline FBG in mg/dL, mean (s.d.) 144.88 (30.82) 137.23 (27.06) 
Baseline ALT in IU/L, mean (s.d.) 28.85 (16.74) 25.78 (12.2) 
Baseline AST in IU/L, mean (s.d.) 24.08 (10.46) 21.96 (8.35) 





The participants were genotyped on 745,401 SNPs, of which 41,437 had more than 5% 
missingness, 78,843 were mono-allelic and 106,231 had MAF less than 2%. Consequently, 
518,890 SNPs passed QC and were included as genetic predictor variables in the machine 
learning algorithms. 
The level of missingness in the clinical variables was low: the baseline glucagon and 
baseline SBP measurements of respectively two and one subject were missing in the 
training set, and the baseline glucagon measurement of one subject was missing in the test 
set. Due to this low number of missing values, the KNN and mean imputation methods 
resulted in virtually identical predictive performance of the clinical random forest and 
elastic net models (Table 16). We used the KNN imputed clinical variables when combining 
clinical and genetic predictors. 
Table 16. 𝑅2 in test set outcome predictions from clinical variable only models using mean 
and KNN imputation. 
Model  Imputation method SBP HbA1c FBG ALT AST 
Elastic net Mean -0.057 -0.030 -0.009 -0.368 -0.386 
 
KNN -0.057 -0.030 -0.008 -0.369 -0.386 
Random forest Mean -0.158 0.004 0.028 -0.256 -0.518 
  KNN -0.172 0.008 0.018 -0.262 -0.527 
 
7.3.2. Machine learning prediction algorithms 
The machine learning algorithms were used to predict the training data outcomes as a 
measure of model fit. The predictive power of the algorithms was assessed by applying the 
models to predict the outcomes in the independent test set and calculating the variability 
explained (𝑅2 statistic). An 𝑅2 value of one indicates perfect prediction, whereas 𝑅2 equal 
to zero means a model has no predictive power. Although most models perform well when 
 132 
 
predicting the training data, none of the algorithms had meaningful predictive ability in the 
test data. The method used to select the genetic predictors had a trivial impact on the 𝑅2 
achieved in all models. 
The results of the different machine learning analyses are displayed graphically in Figures 
30-35. In each plot, the vertical axis shows the prediction 𝑅2, whereas the horizontal axis 
specifies the number of SNPs that were included in each model. The colours indicate the 
different feature selection methods that were applied to select SNPs for inclusion, and the 
plotting symbols represent the type of predictors used in the models (clinical only, genetic 
only or clinical and genetic combined).The model with clinical predictor variables only 
(represented by the ∗ symbol) thus corresponds to zero genetic predictors on the left of 
each graph. The clinical predictors only model and the models including all SNPs are plotted 
in black as feature selection is not applicable for those models.  
7.3.2.1. GUIDE regression tree 
The prediction accuracy of the constant, simple and stepwise multiple GUIDE regression 
trees on the training data for each of the five different outcome variables are displayed in 
Figure 30. In general, GUIDE regression trees including genetic variables (represented by 
the ● and □ symbols) achieved higher 𝑅2 and predicted the training data more accurately 
than GUIDE models based on clinical predictors only (represented by the ∗ symbol with zero 
genetic predictors). Furthermore, stepwise multiple regression trees (bottom row of Fig. 
30) predicted the training data more closely than the simple and the constant regression 
trees and resulted in more stable 𝑅2 patterns. In the stepwise multiple trees, the predictive 
performance on the training data improved when more SNPs were included in the models. 
The constant and simple models showed an inconsistently increasing and decreasing 𝑅2 
pattern as more genetic predictors were included. For several constant models (top row of 
Fig. 30) the 𝑅2 was equal to zero, which corresponds to no predictive power.  
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In the independent test data, none of the GUIDE algorithms achieved meaningful 
predictions (Fig. 31). The maximum 𝑅2 reached by any tree is 0.12 though most GUIDE 
models resulted in negative 𝑅2, which indicates the algorithms have no predictive ability. 
There was large variability in the 𝑅2 values, which did not depend on the number of genetic 
predictors included. We note that in the GUIDE trees predicting FBG, HbA1c and SBP, the 
algorithms with clinical variables only (represented by the ∗ symbol with zero genetic 
predictors) predicted better (higher 𝑅2) than most models including genetic variables, 
though not to a relevant degree. Given the instability seen in the results, it is difficult to 
comment meaningfully on the effect of the different variable selection methods used.  
7.3.2.2. Random forest 
The random forest algorithms predicted the outcomes in the training set closely (Fig. 32). 
When 10 SNPs and no clinical variables were included as predictors (represented by the ● 
symbol with 10 genetic predictors), the algorithms achieved lower 𝑅2 values, but predictive 
power was restored when the 10 SNPs were combined with clinical predictors (represented 
by the □ symbol with 10 genetic predictors). The random forests performed optimally with 
100 to 1000 SNPs, and the inclusion of higher numbers of SNPs decreased the 𝑅2 slightly. 
There was no effect of the method used to select the genetic predictors.  
In contrast, the random forest algorithms demonstrated little predictive performance in the 
test data (Fig. 33). The 𝑅2 fluctuated around zero and was markedly negative in some AST 
and SBP algorithms, meaning none of the models predicted the outcomes. Again, there was 
no difference between the variable selection methods. 
7.3.2.3. Elastic net 
The elastic net algorithms achieved high predictive accuracy in the training data (Fig. 34). 
The models with clinical predictors only (represented by ∗) performed poorly but the 𝑅2 
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improved steadily when more genetic predictors were included. The inclusion of all 518,890 
SNPs in the elastic net models (black ● and □ plotting symbols) reduced the 𝑅2 to zero, 
except for the HbA1c prediction algorithms. All feature selection methods led to similar 
results. 
In the test set, none of the elastic net models had predictive power (Fig. 35). The 𝑅2 of the 
algorithms to predict ALT, AST, HbA1c and SBP improved when more SNPs were added, but 
did not meaningfully exceed zero. The 𝑅2 achieved by the FBG prediction algorithms 
fluctuated around zero irrespective of the number of genetic predictors. The variable 
selection methods used to select SNPs had again no notable effect on the results. 
7.3.2.4. Summary of results 
Although the stepwise multiple GUIDE trees, random forest and elastic net algorithms 
predicted the five different outcomes reliably in the training data (high 𝑅2), the models did 
not retain their predictive power in the test data (zero and negative 𝑅2). There was no 
noticeable difference between the variable selection methods used to select SNPs for 







Figure 30. 𝑅2 in training set prediction by GUIDE constant, simple and stepwise multiple regression trees (rows) for each of the five outcome variables 






























7.3.3. Sensitivity analysis 
The sensitivity analysis was carried out to assess the robustness of the results of the 
primary analyses. Repeating the random data splitting step provides an empirical way to 
determine the scale of the prediction 𝑅2 that can be achieved in this dataset, and 
circumvents unbalanced data splitting by chance. The 𝑅2 values obtained in the primary 
GUIDE, random forest and elastic net analyses were within the range of those observed in 
the sensitivity analyses (Fig. 36-41). The mean 𝑅2 achieved in the sensitivity analyses 
followed the same trends as that in the primary analyses, with negative 𝑅2 values obtained 







Figure 36. Sensitivity analysis: mean and standard deviation of 𝑅2 in training set prediction by GUIDE constant, simple and stepwise multiple regression 







Figure 37. Sensitivity analysis: mean and standard deviation of 𝑅2 in test set prediction by GUIDE constant, simple and stepwise multiple regression trees 




Figure 38. Sensitivity analysis: mean and standard deviation of 𝑅2 in trainig set prediction 





Figure 39. Sensitivity analysis: mean and standard deviation of 𝑅2 in test set prediction by 





Figure 40. Sensitivity analysis: mean and standard deviation of 𝑅2 in training set prediction 





Figure 41. Sensitivity analysis: mean and standard deviation of 𝑅2 in test set prediction by 





Machine learning prediction algorithms are a flexible approach for the linear and non-linear 
analysis of large datasets. These methods have the advantage that they allow the 
simultaneous analysis of many predictor variables - even more variables than there are data 
points - unlike traditional statistical models. Therefore, these algorithms are ideal for 
predictive studies of large genome-wide data, whether or not combined with other 
variables such as clinical descriptives. Machine learning methods have previously been 
successfully applied to PGx problems, though often using a small set of pre-selected SNPs as 
genetic predictor variables (Cosgun et al., 2011; Iniesta et al., 2015; X. Li et al., 2015; Liu et 
al., 2015).  
In this study, the machine learning algorithms applied were not able to predict PGx changes 
in SBP, HbA1c, FBG, ALT or AST reliably in independent test data. When predictor variables 
are not associated with the outcome, an 𝑅2 statistic around zero is expected. However, 
many algorithms resulted in a negative prediction 𝑅2, indicating that the algorithms do not 
have any predictive power. The most likely explanation for the negative 𝑅2 scores is 
overfitting of the models to the training data, even though cross-validation was used to 
select model parameters and prune GUIDE trees. A second factor that may be contributing 
to poor performance is the sample size (training set 𝑛=157, test set 𝑛=51). Typical sample 
size calculations rely on the assumptions underpinning traditional statistical models and do 
not apply to machine learning methods. It is thus difficult to determine how large the 
training dataset needs to be in order to achieve clinically useful predictions if there exist 
true PGx associations with the outcomes studied. Generally, machine learning methods 
perform optimally when trained on large samples. 
The sensitivity analysis confirmed that predictive GUIDE, random forest or elastic net 
algorithms could not be built in this dataset. However, it is important to note some 
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methodological differences between in the primary and sensitivity analyses. QC of the 
genetic data is difficult to automate, thus for practical purposes QC was performed on the 
entire dataset, instead of repeating it separately on the training and test data for each 
iteration of the sensitivity analysis. As some individual-level QC steps use information 
across subjects (cryptic relatedness and principal components analysis), the consequence is 
that training and test sets are not strictly independent in the sensitivity analysis. 
Furthermore, each iteration of data splitting and algorithm building leads to different 
predictor variables being selected and it is not straightforward to choose the optimally 
predicting variables. Nevertheless, we do not expect these methodological differences to 
have a noticeable impact on the prediction accuracy. Our research strategy was to 
construct prediction algorithms in the primary analysis and to estimate how reliable the 
test set predictive performance is in the sensitivity analysis.  
A few PGx associations with anti-diabetic drugs have been discovered and replicated (Zhou 
et al., 2016). Metformin, sulfonylureas, thiazolidinediones and gliptins have a PGx 
association with HbA1c levels, though in our study SNPs could not predict changes in this 
outcome. The genetic variants described in the PGx literature do not have effects strong 
enough to guide anti-diabetic treatment (Taber & Dickinson, 2015). Sulphonylureas are the 
only antidiabetics with a PGx mention on their FDA drug label: patients with glucose 6-
phosphate dehydrogenase (G6PD) deficiency are at risk of haemolytic anaemia, though 
genetic testing is not mandatory before initiating sulphonylurea treatment (U.S. Food and 
Drug Administration, 2013a, 2016b). It is estimated that 415 million people worldwide have 
diabetes and as this number is expected to increase there is a strong need to develop 
predictive biomarkers and improve anti-diabetic treatment (International Diabetes 
Federation, 2015; Maruthur, 2013; World Health Organization, 2016). 
The discovery of polygenic PGx biomarkers to guide anti-diabetic treatment in T2DM 
patients will require large datasets. Machine learning enables the study of multiple genetic 
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variants simultaneously, on a genome-wide scale and in combination with clinical 




8. Analysis of pharmacogenetic studies: comparing 
traditional statistical inference with machine learning  
8.1. Introduction 
Major depressive disorder is a complex disorder with a lifetime prevalence of 
approximately 15% (Kessler & Bromet, 2013). Patients are treated with a combination of 
psychotherapy and pharmacotherapy. The response rates for antidepressant is estimated 
at 55-75%, which means a large group of patients do not respond adequately to treatment 
(Drago, De Ronchi, & Serretti, 2009).  
Although it is estimated that common genetic variants account for 42% of the variance in 
antidepressant response, few robust PGx associations have been discovered to date 
(Tansey et al., 2013). Candidate gene studies into PGx associations with antidepressant 
response were mostly disappointing due to small effect sizes studied in small samples. 
Some of the candidate genes with PGx associations that have been replicated include 
antidepressant targets such as the serotonin transporter gene SLC6A4 and the serotonin 
receptor gene HTR2A, metabolizing enzymes CYP2D6 and CYP2C19, and the drug 
transporter gene ABCB1, though variants in these genes do not achieve significant results in 
GWAS (Fabbri, Crisafulli, Calabrò, Spina, & Serretti, 2016). Several GWAS of antidepressant 
response have been conducted, mainly in Caucasian patients, but no SNPs reached 
genome-wide significance (Biernacka et al., 2015; GENDEP Investigators et al., 2013; Ji et 
al., 2013). Polygenic risk scores predicted 0.5% of the variance in percentage improvement 
on a clinician rated depression scale and 1.2% of the variance in remission, though different 
rating scales and definitions of remission were used in the various samples combined in this 
study (GENDEP Investigators et al., 2013). Machine learning approaches combining several 
clinical and genetic predictors explained nearly 4% of the variance in depression severity in 
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escitalopram and nortriptyline treated patients, which increased to more than 15% of 
variance explained when both drugs were studied separately (Iniesta et al., 2015). Despite 
these findings, PGx has not made a relevant impact on depression treatment and more 
research in this area is necessary.  
In this study, we used traditional statistical methods and machine learning algorithms to 
examine PGx associations with LY2216684 (edivoxetine), a highly selective norepinephrine 
reuptake inhibitor developed by Eli Lilly as an antidepressant. One clinical trial found that 
LY2216684 was superior to placebo measured on the Montgomery-Åsberg depression 
rating scale total score (MADRS-TS) (Pangallo et al., 2011). However, a second trial failed to 
show that LY2216684 treated patients improved more on the Hamilton depression rating 
scale than those treated with placebo (Dubé et al., 2010). In 2013, Eli Lilly announced that 
the drug failed Phase III clinical trials where it was compared to placebo as an add-on to 
selective serotonin reuptake inhibitor treatment, measured on the MADRS-TS (Eli Lilly and 
Company, 2013). Although not efficacious in a general population of patients suffering from 
major depressive disorder, LY2216684 might be beneficial for a subset of patients with 
certain genetic variants, hence our interest in the PGx analysis of this drug. 
8.2. Methods  
8.2.1. Data 
The data were collected in a randomized, double-blind clinical trial which found that 
LY2216684 was superior to placebo for the treatment of major depressive disorder 
(ClinicalTrials.gov Identifier: NCT00795821) (Pangallo et al., 2011). Participants were 
assessed at 1, 3, 5, 7 and 10 weeks after the start of the trial. The primary efficacy measure 
was the clinician rated MADRS-TS, which ranges from 0 to 60 and increases with severity of 
depression (Montgomery & Asberg, 1979). The MADRS-TS is the sum of 10 questionnaire 
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items reflecting depression symptoms such as apparent and reported sadness, 
concentration difficulties and pessimistic thoughts, and each symptom is scored on a 0 to 6 
scale. In addition to the outcome measure, the patient characteristics and baseline clinical 
variables listed in table 17 were included in our study. Patient inclusion criteria and further 
details of this trial were described previously (Pangallo et al., 2011).  
Table 17. Demographic and baseline variables. 
Effect Description 
Treatment LY2216684 or placebo treatment 
Sex Sex of the patient 
Age Age in years  
Country Argentina, Finland, Poland, Russia or United States 
Alcohol Whether or not the patient is an alcohol consumer at baseline 
Tobacco Whether or not the patient is a tobacco consumer at baseline 
Baseline MADRS-TS MADRS-TS at baseline 
Baseline QIDS Quick Inventory of Depressive Symptomatology (QIDS) score at 
baseline 
 
Although 495 trial participants were randomized, we limited our analysis to 319 white 
patients for whom genotype data were collected to achieve a more homogeneous sample. 
1423 SNPs in 32 candidate genes were genotyped. Standard quality control (QC) 
procedures were applied to the data set, excluding SNPs with minor allele frequency less 
than 5% and genotyping rate less than 90%. Hardy-Weinberg Equilibrium tests were carried 
out and SNPs with significant p-values were flagged but not excluded in QC as all 
participants suffer from major depressive disorder and deviations from Hardy-Weinberg 
Equilibrium amongst cases do not necessarily imply genotyping errors. Patients with more 
than 10% missing SNPs were also excluded from the analyses. The relatively small number 
of SNPs in our sample did not allow stable principal components analysis or 
multidimensional scaling to control for population stratification (Price, Zaitlen, Reich, & 
Patterson, 2010).  
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8.2.2. Statistical methods 
Our study tested two hypotheses: (1) that SNPs are associated with change from baseline in 
MADRS-TS at the end of the trial, and (2) that SNPs are associated with the evolution of 
change from baseline in MADRS-TS over time.  
Both hypotheses were approached using traditional statistical models which investigate 
each SNP separately, and machine learning techniques that allow the analysis of all SNPs in 
a single model (Table 18). Although machine learning is often used to develop prediction 
models, here we applied it to simultaneously analyse a large number of SNPs and identify a 
set of SNPs associated with changes in the outcome variable. Penalized regression 
algorithms can be regarded as machine learning analogues of linear regression models and 
therefore elastic net and linear mixed elastic net were compared to their traditional 
statistical counterparts, linear regression and linear mixed models, respectively.  
Table 18. Analysis approaches used in this study. 
Modelling approach Outcome variable 
 
Endpoint change in 
MADRS-TS 
Longitudinal change in 
MADRS-TS 
Traditional statistics: 
SNPs modelled separately 
Linear regression Linear mixed model 
Machine learning: 
SNPs modelled simultaneously 
Elastic net Linear mixed elastic net 
 
Baseline covariates were included in the traditional and machine learning models through 
backward selection and the treatment groups were analysed separately as well as 
combined. The machine learning algorithms used require complete data, thus missing 
genotypes were imputed using LD in PLINK (Purcell et al., 2007). If LD informed imputation 
was not possible, genotypes were imputed by the mean allele count of that SNP. There 
were no missing baseline covariates. Machine learning models were built on the entire 
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dataset, as the sample size was deemed too small to split the data in separate training and 
testing subsets.  
In addition, we performed a simulation analysis to gain insight into the power that the 
methods used in the endpoint analyses have to detect genetic associations in this sample. 
8.2.2.1. Endpoint analyses 
To test the first research hypothesis, we investigated the association of SNPs with change in 
MADRS-TS from baseline at the end of the trial. Linear regression models (see section 5.3.1. 
on page 61) were used to evaluate the association of each single SNP with the outcome, 
whereas an elastic net approach (see section 5.4.5.3. on page 77) allowed the analysis of all 
SNPs simultaneously. For patients who did not complete the trial missing endpoint MADR-
TS observations were imputed using a linear mixed model as described below. Baseline 
covariates to be included in the genetic analyses were determined via backward elimination 
from a linear regression model including all baseline variables (Table 17) but no genetic 
variables. 
Linear regression model 
For each SNP a linear regression model was fitted including an intercept, additive genotypic 
effect and significant baseline covariates. Thus, the model can be represented as 
𝑦𝑖 = 𝛽0 + 𝛽1𝑥1𝑖 + ⋯+ 𝛽𝑚𝑥𝑚𝑖 + 𝛽𝑆𝑁𝑃𝐺𝑖 + 𝜀𝑖 
where 𝑦𝑖  is the endpoint change in MADRS-TS, 𝑥1to 𝑥𝑚 are 𝑚 baseline clinical covariates 
and 𝐺𝑖  is the genotype of a single SNP for the 𝑖th individual. 
Significance of the genetic effect was evaluated using a t-test for each SNP with a 
Bonferroni type adjustment for multiple testing based on the effective number of 
independent tests, which accounts for linkage disequilibrium between SNPs (M.-X. Li, 




Linear elastic net was used to model the effect of all SNPs simultaneously,  
𝑦𝑖 = 𝛽0 + 𝛽1𝑥1𝑖 + ⋯+ 𝛽𝑚𝑥𝑚𝑖 + 𝛽𝑆𝑁𝑃1𝐺1𝑖 + ⋯+ 𝛽𝑆𝑁𝑃𝑔𝐺𝑔𝑖 + 𝜀𝑖   
where 𝑔 is the number of SNPs. In addition to SNPs, baseline covariates were included in 
the elastic net model but their parameter estimates were not penalized. The optimal values 
for the tuning parameters 𝛼 and 𝜆 were selected from a grid by 100 times repeated five-








as performance measure. We preferred the RMSE over 𝑅2 because this is a measure that 
can easily be carried forward to the longitudinal setting.  
8.2.2.2. Longitudinal analyses  
A study of genetic associations with change in MADRS-TS measurements over time was 
used to answer the second research hypothesis. SNP main effects and SNP by time (in 
weeks since start of the trial) interactions were modelled. The latter term captures a 
potential association with change in outcome over time. Single SNP associations with 
longitudinal change in MADRS-TS since baseline were analysed using a linear mixed model 
(see section 5.3.3. on page 63). The joint effect of all genetic variables was investigated with 
linear mixed elastic net (see section 5.4.5.4. on page 79). Both methods allow unbalanced 
observations, so no imputation of missing MADRS-TS data was required. Baseline covariates 
were selected via backward elimination from a linear mixed model including all baseline 
variables (Table 17) and baseline MADRS-TS and baseline QIDS by time interaction terms. 
Main effects were always retained if their interaction terms were significant, even if the 
main effect itself was not significant. 
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Linear mixed model 
Linear mixed models are well suited for the analysis of longitudinal data, as they take the 
correlation between consecutive MADRS-TS observations on the same patient into account. 
The fixed effects structure of the linear mixed model was built via backward elimination 
starting from all baseline covariates, baseline MADRS-TS and baseline QIDS by time 
interaction terms and a quadratic time effect, but no genetic variables. Random intercepts, 
linear and quadratic time effects were considered as random effects. Thus,  
𝐘𝑖 = 𝐗𝑖𝛃𝑩𝑳 + 𝐙𝑖𝐛𝑖 + 𝛆𝑖 .  
with 𝐘𝑖 is the vector of longitudinal changes in MADRS-TS, 𝐗𝑖 is the matrix of baseline fixed 
effects and 𝐙𝑖  is the matrix that contains the random intercept and time effects.  
Likelihood ratio tests were used to compare the unstructured covariance matrix - which 
puts no restrictions on the parameters of the random effects covariance matrix - to more 
parsimonious structures and to test for significance of the random effects (Table 19). The 
resulting linear mixed model was used to impute missing MADRS-TS observations at week 
10 for the endpoint analyses and as a starting point for the longitudinal SNP by SNP 
analysis.  
To test the association of a single SNP with the change in MADRS-TS over time, an additive 
SNP effect and SNP by time interaction were added (in the matrix 𝐆𝑖) to the fixed effects 
structure of the mixed model equation, 
𝐘𝑖 = 𝐗𝑖𝛃𝑩𝑳 + 𝐆𝑖𝛃𝑺𝑵𝑷 + 𝐙𝑖𝐛𝑖 + 𝛆𝑖.  
The vector 𝛃𝑺𝑵𝑷 has thus 2 components, namely the SNP main effect and the SNP by time 
interaction. Significance of the SNP by time effect was determined via type III F-tests with a 
Bonferroni correction for the effective number of SNPs tested (M.-X. Li et al., 2012). REML 
was used to estimate the parameters of the linear mixed model. 
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Linear mixed elastic net  
A linear mixed elastic net model was built starting with the fixed effects structure from the 
linear mixed model, and adding fixed SNP and SNP by time interaction terms for all genetic 
variants. The equation for the linear mixed elastic net is the same as for the linear mixed 
model with the exception that the matrix 𝐆𝑖 and the vector 𝛃𝑺𝑵𝑷 now represent the effects 
of 𝑔 SNPs and thus have 2𝑔 entries. 
As was the case in the linear elastic net, baseline covariates were excluded from 
penalization. Due to computational complexity, some simplifications were made to the 
random effects structure: the random quadratic time effect was dropped and an 
independent covariance structure, assuming zero covariance between the random effects, 
was used for the random effects (Table 19). Nevertheless, we assume that the estimates for 
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the fixed effects are robust to misspecification of the random effects as is the case in the 
traditional linear mixed model (Verbeke & Molenberghs, 2000). Model parameters were 
estimated using ML, as the software used (the lassop function of the MMS R package) does 
not support REML (Rohart, 2011; Rohart et al., 2014). Five times repeated five-fold cross-
validation was used to select the tuning parameters that minimize the RMSE.  
8.2.2.3. Simulation study 
To gain insight in the power that linear regression and elastic net have to detect genetic 
associations in this sample we performed a simulation study. We simulated a single SNP 
associated with the observed change in MADRS-TS at the trial endpoint, appended it to the 
dataset and tested if the simulated SNP was significantly associated with outcome in the 
linear regression or selected in the elastic net. SNP effect sizes between 0% and 20% 
heritability were evaluated, and 1000 simulations were performed at each effect size. The 
power to detect genetic effects of a given effect size was defined as the proportion of 
simulations where the simulated SNP was significant (linear regression) or selected (elastic 
net). Although simulation is a standardly used approach to determine the power of a novel 
analysis method in genetic studies, most studies simulate phenotypic values from 
genotypes. Here, we wished to use existing phenotype values (change in MADRS-TS from 
baseline), and simulate genotype. No standard methods or software exists for this, and full 
algebraic details of the simulation framework are given in the following paragraphs. A 
comparable simulation analysis for the longitudinal analyses was not performed due to the 






Algebraic details of simulation study 
To simulate a SNP that is associated with the change in MADRS-TS at the endpoint, the 
following linear model was assumed: 
𝑦𝑖 = 𝛼 + 𝛽𝐺𝑖 + 𝜀𝑖     𝑤𝑖𝑡ℎ  𝜀𝑖~𝑁(0, 𝜎𝑒
2) (Eq. 1) 
where 𝑦𝑖  is the outcome at the end of the trial, α is the intercept, 𝐺𝑖  is the genotype and 𝛽 
its effect size. We assume an additive genetic effect, so 𝐺𝑖  is coded as 0, 1 or 2 minor allele 
counts and the minor and major allele frequencies are 𝑝 and 𝑞, respectively. 
The total variance can be decomposed into the variance explained by the genotype and the 
residual error variance,  
𝜎2 = 𝜎𝐺
2 + 𝜎𝑒
2 (Eq. 2) 
The variance explained by the genotype can be computed from the additive effect size and 
the minor allele frequency: 
𝜎𝐺
2 = 2𝛽2𝑝𝑞 (Eq. 3) 
Bayes’ theorem allows us to calculate the probability for each genotype conditional on the 
observed change in the outcome,  
𝑃(𝐺 = 𝑔|𝑦) =
𝑃(𝑦|𝐺 = 𝑔)𝑃(𝐺 = 𝑔)
𝑃(𝑦)
 (Eq. 4) 
Thus, to calculate 𝑃(𝐺 = 𝑔|𝑦) the following quantities are required: 
a) Probability of the genotype 𝐆: 𝑃(𝐺 = 𝑔) 
Assuming Hardy-Weinberg equilibrium,  
𝑃(𝐺 = 0) = 𝑞2 
𝑃(𝐺 = 1) = 2𝑝𝑞 





b) Probability of observing the outcome 𝐲 conditional on the genotype 𝐆: 𝑃(𝑦|𝐺 = 𝑔)  
𝑦|𝐺 = 𝑔 follows a normal distribution with mean: 
𝐸(𝑦|𝐺 = 0) = 𝐸(𝛼 + 𝜀) = 𝛼 
𝐸(𝑦|𝐺 = 1) = 𝐸(𝛼 + 𝛽 + 𝜀) = 𝛼 + 𝛽 
𝐸(𝑦|𝐺 = 2) = 𝐸(𝛼 + 2𝛽 + 𝜀) = 𝛼 + 2𝛽 
(Eq. 6) 
From the law of total probability, we infer the value of 𝛼, 
𝐸(𝑦) = 𝜇 
= 𝐸(𝑦|𝐺 = 0)𝑃(𝐺 = 0) + 𝐸(𝑦|𝐺 = 1)𝑃(𝐺 = 1) + 𝐸(𝑦|𝐺 = 2)𝑃(𝐺 = 2) 
= 𝛼𝑞2 + (𝛼 + 𝛽)2𝑝𝑞 + (𝛼 + 2𝛽)𝑝2 
= 𝛼(𝑞2 + 2𝑝𝑞 + 𝑝2) + 𝛽(2𝑝𝑞 + 2𝑝2) 
= 𝛼 + 2𝛽𝑝(𝑞 + 𝑝) 
= 𝛼 + 2𝛽𝑝 
(Eq. 7) 
Thus, 𝛼 = 𝜇 − 2𝛽𝑝 and the means of the conditional distributions of 𝑦 are   
𝐸(𝑦|𝐺 = 0) = 𝐸(𝛼 + 𝜀) = 𝛼 = 𝜇 − 2𝛽𝑝 
𝐸(𝑦|𝐺 = 1) = 𝐸(𝛼 + 𝛽 + 𝜀) = 𝛼 + 𝛽 = 𝜇 − 𝛽(2𝑝 − 1) = 𝜇 − 𝛽(𝑝 − 𝑞) 
𝐸(𝑦|𝐺 = 2) = 𝐸(𝛼 + 2𝛽 + 𝜀) = 𝛼 + 2𝛽 = 𝜇 − 2𝛽(𝑝 − 1) = 𝜇 + 2𝛽𝑞 
(Eq. 8) 
Assuming that the variance of 𝑦 conditional on 𝐺 is constant, it is equal to 𝜎𝑒
2. 
Combining equations 2 and 3 gives  
𝜎𝑒
2 = 𝜎2 − 2𝛽2𝑝𝑞 (Eq. 9) 
In equation 8 and 9, the quantities 𝜇 and 𝜎2 can be approximated by the mean 𝑦 and 
variance ?̂?2 of the observed outcomes. 
Thus, the conditional distributions of 𝑦 are the following,  
𝑦|𝐺 = 0 ~ 𝑁(𝜇 − 2𝛽,   𝜎2 − 2𝛽2𝑝𝑞) 
𝑦|𝐺 = 1 ~ 𝑁(𝜇 − 𝛽(𝑝 − 𝑞),   𝜎2 − 2𝛽2𝑝𝑞) 




and 𝑃(𝑦|𝐺 = 𝑔) is simply the probability density function of these normal 
distributions,  






















c) Probability of the outcome 𝒚: 𝑃(𝑦) 
The law of total probability allows straightforward calculation of 𝑃(𝑦),  
𝑃(𝑦) = 𝑃(𝑦|𝐺 = 0)𝑃(𝐺 = 0) + 𝑃(𝑦|𝐺 = 1)𝑃(𝐺 = 1) + 𝑃(𝑦|𝐺 = 2)𝑃(𝐺 = 2) (Eq. 12) 
the elements of which have all been defined previously (Eq. 5 and 11). 
Thus, by specifying the genetic effect size (𝛽) and minor allele frequency (𝑝), 𝑃(𝐺 = 𝑔|𝑦) 
can be calculated for each value g (Eq. 4). For each subject in the dataset, the probabilities 
of the genotypes conditional on the observed outcome were calculated. The SNP genotype 
was then simulated from a multinomial distribution. 
8.2.3. Software 
Linear regression analyses were performed using PLINK, version 1.07 (Purcell et al., 2007). 
Linear mixed model analyses were carried out using proc mixed in SAS software, version 9.3 
(SAS Institute, Cary, NC). Linear elastic net and linear mixed elastic net algorithms were 
modelled in R version 3.1.2 using the caret and glmnet, and MMS packages, respectively 
(Friedman et al., 2010; Kuhn, 2008; R Development Core Team, 2015; Rohart, 2016; Rohart 




8.3.1. Data description  
No SNPs had less than 90% genotyping rate, but 285 SNPs were removed because their 
minor allele frequencies were less than 5%, reducing the number of SNPs analysed to 1,138 
(Table 20). Five SNPs deviated significantly from Hardy-Weinberg Equilibrium (rs908867, 
rs4713908, rs2601608, rs512131 and rs11186300) but where nevertheless included in the 
analyses.  No individuals had more than 90% SNPs missing, thus all 319 patients were 
included in the analyses. There were no significant differences in demographics or baseline 
characteristics between the LY2216684 and placebo treated patients (Table 21). 
8.3.2. Endpoint analyses 
8.3.2.1. Outcome variable 
For 10% of patients the week 10 outcome observation was missing and imputed using a 
linear mixed model. The mean and median change in MADRS-TS at the trial endpoint were  
-11.20 and -11, respectively (Fig.42). It should be noted that negative outcome values 
reflect improvements in the patient’s condition as lower MARDS-TS scores indicate less 
severe depression symptoms. At the end of the trial period, 35.4% of patients achieved 
response to treatment (decrease in MADRS-TS≥50%) and 21.0% reached remission 
(MADRS-TS≤10).  
8.3.2.2. Baseline covariates 
The linear regression model including only baseline covariates revealed that baseline 
MADRS-TS, patient age and treatment were significantly associated with change in MADRS-
TS at week 10 in the full sample (Table 22). In the treatment specific analyses, only baseline 
MADRS-TS remained significantly associated with the outcome variable. These variables 
were thus included in the linear regression and elastic net analyses. As negative outcome 
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scores reflect patient improvement, negative parameter coefficients imply a beneficial 
effect, whereas positive coefficients denote a disadvantageous effect on patient wellbeing.  
Table 20. List of candidate genes studied and the number of SNPs typed in each gene.  
Gene Chromosome Number of SNPs before QC Number of SNPs after QC 
KCNK2 1 238 192 
RGL1 1 2 2 
ADRA2B 2 6 5 
DRD3 3 48 32 
ADRA2C 4 2 2 
ADRB2 5 15 13 
DRD1 5 11 11 
HTR1A 5 6 4 
NR3C1 5 70 61 
FKBP5 6 61 54 
UST 6 5 5 
DDC 7 116 95 
LEP 7 1 1 
ADRA1A 8 155 123 
DBH 9 41 35 
ADRA2A 10 10 8 
ADRB1 10 6 6 
HTR7 10 65 62 
BDNF 11 37 27 
DRD2 11 69 65 
DRD4 11 3 3 
GRIK4 11 6 6 
HTR3A 11 26 14 
TH 11 8 8 
TPH1 11 26 25 
HTR2A 13 128 114 
SLC6A2 16 117 79 
SLC6A4 17 36 24 
GRIK1 21 1 1 
COMT 22 36 25 
MAOA X 34 28 
MAOB X 38 8 
Total count - 1423 1138 
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Table 21. Demographics and baseline clinical characteristics by treatment group. 
Characteristics LY2216684 (n=157) Placebo (n=162) p-value 
Age in years, mean (s.d.) 45.33 (11.89) 46.93 (11.53) 0.22 
Sex, count (%)   0.41 
Male 55 (35.03) 64 (39.51)  
Female 102 (64.97) 98 (60.49)  
Country, count (%)   0.94 
Argentina 10 (6.37) 11 (6.79)  
Finland 36 (22.93) 39 (24.07)  
Poland 36 (22.93) 33 (20.37)  
Russia 8 (5.1) 6 (3.7)  
United States 67 (42.68) 73 (45.06)  
Alcohol use, count (%)   0.32 
No 109 (69.43) 104 (64.20)  
Yes 48 (30.57) 58 (35.80)  
Tobacco use, count (%)   0.13 
No 114 (72.61) 105 (64.81)  
Yes 43 (27.39) 57 (35.19)  
Baseline MADRS-TS, mean (s.d.) 29.31 (3.97) 29.95 (4.12) 0.16 
Baseline QIDS, mean (s.d.) 14.34 (3.82) 15.05 (3.55) 0.09 
s.d.: standard deviation 
Table 22. Significant covariates in baseline regression model. 















-3.84 <.0001 - - - - 
Age 0.08 0.049 - - - - 






Figure 42. Histogram of change in MADRS-TS at the end of the trial. 
8.3.2.3. Linear regression analysis 
No SNPs were significantly associated with change in MADRS-TS at the end of the trial in 
either dataset after correction for multiple testing (Table 23). The effective number of tests 
were 383 in the full sample, 371 in the LY2216684 treated subset and 364 in the placebo 
treated subset, so significance thresholds were 1.31*10-4, 1.35*10-4 and 1.37*10-4 
respectively. 
SNPs in ADRA1A and HTR2A achieve low p-values across different analyses (Table 20). For 
each sample, SNPs within the same gene represent a single association, but there is little 
overlap between the different analyses. The full sample SNPs in HTR2A are in strong LD 
(rLD²>0.82), as are the SNPs in ADRA1A (rLD²>0.94). The ADRA1A SNPs from the LY2216684 
analysis are in LD with each other (rLD²>0.99), but not with the full sample SNPs in the same 
gene (rLD²<0.15). Similarly, the HTR2A SNPs from the placebo analysis are in strong LD with 
each other (rLD²>0.92), but in much weaker LD with the full sample HTR2A SNPs (rLD²<0.58). 
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In both genes a large number of SNPs was genotyped relative to the other genes in the 
analysis. 
8.3.2.4. Elastic net analysis 
The full sample elastic net with baseline covariates only had a mean cross-validation RMSE 
of 8.30. When SNPs were added, the full sample elastic net selected 23 SNPs for inclusion in 
the model, reducing the mean cross-validation RMSE to 8.27 (Table 24). The treatment 
specific elastic net models did not retain any SNPs. Looking at the tuning parameters of the 
full sample elastic net, we note that the model chosen by five-fold cross-validation was 
closer to a ridge regression than a lasso (𝛼=0.2) and that the penalty was strong to 
encourage variable selection (𝜆=4.8).  
The SNPs identified in the full sample analysis showed consistency with the linear 
regression results (Table 25). From the 30 SNPs with lowest p-values in linear regression, 20 
were selected by the elastic net, including the top 8 SNPs. All SNPs selected by the elastic 
net ranked 50th or higher in the linear regression results sorted by ascending p-value. 
Inspection of the linkage disequilibrium between the SNPs revealed that the elastic net 
indeed performed grouped variable selection in some groups of correlated SNPs, but not in 
all. For example, on chromosome 11, SNPs rs7128320, rs12800734 and rs2276319 are 
highly correlated (rLD²>0.99) and all 3 were included in the elastic net. On the contrary, on 
chromosome 10, rs2420203 is in strong LD (rLD²>0.96) with 2 other SNPs but it is the only 






Table 23. SNPs with the five lowest p-values in the full sample (main effect and SNP by 
treatment interaction models), LY2216684 and placebo linear regression analyses. For the 
LY2216684 and placebo analyses we also report the top 5 SNPs from the full sample SNP by 








Full sample analysis (n=319) - SNP main effect 
rs17288723 G HTR2A 13 46883558 3.01 (0.89) 0.0008 
rs731779 C HTR2A 13 46877903 2.71 (0.83) 0.0013 
rs505138 A ADRA1A 8 26869465 3.66 (1.13) 0.0013 
rs17287961 A HTR2A 13 46862976 2.86 (0.89) 0.0015 
rs580644 A ADRA1A 8 26862973 3.63 (1.14) 0.0015 
Full sample analysis (n=319) – SNP by treatment interaction 
rs11841433 A HTR2A 13 47434733 -9.06 (2.76) 0.0011 
rs1328674 A HTR2A 13 47441707 -8.89 (2.78) 0.0015 
rs7326071 A HTR2A 13 47438668 -8.93 (2.80) 0.0016 
rs3785151 C SLC6A2 16 55712519 5.49 (1.87) 0.0036 
rs2025296 A HTR2A 13 47463819 -6.26 (2.17) 0.0042 
LY2216684 analysis (n=157) - SNP main effect 
rs12121815 G KCNK2 1 215187382 5.22 (1.78) 0.0038 
rs511662 G ADRA1A 8 26848689 -2.72 (1.00) 0.0071 
rs12521436 A NR3C1 5 143438042 -3.18 (1.19) 0.0080 
rs577366 G ADRA1A 8 26839848 -2.57 (1.00) 0.0111 
rs13282250 C ADRA1A 8 26836875 -2.57 (1.00) 0.0111 
rs11841433 A HTR2A 13 47434733 -4.06 (1.65) 0.0149 
rs1328674 A HTR2A 13 47441707 -3.94 (1.68) 0.0203 
rs7326071 A HTR2A 13 47438668 -4.02 (1.71) 0.0200 
rs3785151 C SLC6A2 16 55712519 1.37 (1.31) 0.2961 
rs2025296 A HTR2A 13 47463819 -3.26 (1.43) 0.0242 
Placebo analysis (n=162) - SNP main effect 
rs2770298 G HTR2A 13 46872712 3.50 (1.03) 0.0009 
rs2770296 G HTR2A 13 46866425 3.28 (1.03) 0.0017 
rs12249377 A HTR7 10 90833199 4.14 (1.39) 0.0033 
rs4711429 A FKBP5 6 35715771 3.27 (1.12) 0.0040 
rs2420203 G HTR7 10 90748106 3.96 (1.39) 0.0050 
rs11841433 A HTR2A 13 47434733 5.15 (2.26) 0.0242 
rs1328674 A HTR2A 13 47441707 5.15 (2.26) 0.0242 
rs7326071 A HTR2A 13 47438668 5.15 (2.26) 0.0242 
rs3785151 C SLC6A2 16 55712519 -3.68 (1.35) 0.0069 
rs2025296 A HTR2A 13 47463819 2.97 (1.67) 0.0763 
s.e.: standard error 
 169 
 








RMSE: baseline covariates 8.30 7.90 8.69 
RMSE: baseline covariates + SNP 8.27 7.90 8.69 
Number of SNPs selected 23 0 0 
α 0.2 - - 
λ 4.8 - - 
 




Gene Chromosome Position 
Parameter 
estimate 
rs12121815 G KCNK2 1 215187382 0.52 
rs4711429 A FKBP5 6 35715771 0.07 
rs9377186 A UST 6 148986631 0.25 
rs7770997 G UST 6 149010203 0.08 
rs556793 G ADRA1A 8 26841550 0.005 
rs498917 A ADRA1A 8 26862186 0.31 
rs580644 A ADRA1A 8 26862973 0.31 
rs505138 A ADRA1A 8 26869465 0.34 
rs2420203 G HTR7 10 90748106 0.10 
rs12249377 A HTR7 10 90833199 0.47 
rs12259062 G HTR7 10 90850288 0.06 
rs2070762 A TH 11 2165105 0.35 
rs908867 A BDNF 11 27724217 -0.001 
rs7128320 G GRIK4 11 120964537 -0.04 
rs12800734 G GRIK4 11 120966045 -0.06 
rs2276319 G GRIK4 11 120967112 -0.10 
rs17069005 G HTR2A 13 46849983 0.33 
rs17287961 A HTR2A 13 46862976 0.07 
rs9316235 A HTR2A 13 46871568 0.13 
rs9526245 C HTR2A 13 46871832 0.12 
rs731779 C HTR2A 13 46877903 0.08 
rs17288723 G HTR2A 13 46883558 0.41 




8.3.3. Longitudinal analyses 
8.3.3.1. Outcome variable 
MADRS-TS measurements were available for all patients at week 1, after which the 
proportion of missing observations increased gradually to 10% at week 10 (Table 26). The 
mean change in MADRS-TS from baseline decreased over time, with a slope that flattens 
towards the end of the trial period (Fig.43). Negative outcome values reflect improvements 
in the patient’s condition. 
Table 26. Proportion of missing outcome observations. 
Weeks since 










Figure 43. Change in MADRS-TS over trial period per patient (grey) and mean trend (black). 
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8.3.3.2. Baseline covariates 
In the longitudinal analysis of baseline covariates, a significant quadratic time effect 
captured the increase in change in MADRS-TS over time (Table 27). Baseline MADRS-TS and 
QIDS, as well as the baseline MADRS-TS by time interaction were associated with the 
outcome variable in all analysis samples. In addition, treatment and the interaction term of 
treatment by time were significant in the full sample model. Therefore, treatment, baseline 
MADRS-TS and their interaction terms with time, and baseline QIDS were included as 
covariates in the longitudinal analyses. Due to the nature of the outcome variable, negative 
parameter coefficients reflect a positive change in patient health state and vice versa.  
All random effects were significant and the unstructured random effects covariance matrix 
could not be simplified to a more parsimonious structure.  
Table 27. Significant covariates in baseline covariates only linear mixed model. 








Time -0.32 0.476 -1.08 0.076 -0.08 0.897 
Time² 0.09 <.0001 0.11 <.0001 0.08 <.0001 
LY2216684 
treatment 




-0.54 <.0001 - - - - 
Baseline 
MADRS-TS 




-0.05 0.001 -0.04 0.026 -0.05 0.015 




8.3.3.3. Linear mixed model analysis 
In the linear mixed model of change in MADRS-TS over time in a SNP-by-SNP analysis, none 
of the SNPs had a significant effect (Table 28). The significance threshold correcting for the 
effective number of SNPs tested are 1.31*10-4 in the full sample, 1.35*10-4 in the 
LY2216684 sample and 1.37*10-4 in the placebo sample. 
SNPs in the HTR2A gene came up in the top 5 results from each analysis (Table 28). The 
HTR2A SNPs in the full sample and placebo analyses are in mild LD (rLD²>0.65), including one 
overlapping SNP (rs9316235). The HTR2A SNPs from the LY2216684 analysis however are 
not correlated with the SNPs from other analyses (rLD²<0.03). Furthermore, the two 
ADRA1A SNPS in the LY2216684 model are in perfect LD (rLD²=1) but the SLC6A2 SNPs from 
the placebo model are not correlated (rLD²<0.03).  
There is similarity in the results of linear regression and linear mixed model analyses in 
terms of which SNPs have the lowest p-values (Fig.44).  
 
Figure 44. QQ-plots comparing the p-values for SNP effect from linear regression analysis 





Figure 44 (continued). QQ-plots comparing the p-values for SNP effect from linear 




Table 28. SNPs with the five lowest p-values for the SNP by time (weeks since start of trial) 
interaction effect in the full sample and treatment specific linear mixed models. For the 








Full sample analysis (n=319)  
rs9534501 A HTR2A 13 46865841 0.29 (0.08) 0.0005 
rs9567743 G HTR2A 13 46866665 0.29 (0.08) 0.0005 
rs731779 C HTR2A 13 46877903 0.31 (0.09) 0.0006 
rs9316235 A HTR2A 13 46871568 0.27 (0.08) 0.0007 
rs9526245 C HTR2A 13 46871832 0.27 (0.08) 0.0007 
LY2216684 analysis (n=157) 
rs12121815 G KCNK2 1 215187382 0.65 (0.21) 0.0027 
rs11841433 A HTR2A 13 46860598 -0.46 (0.15) 0.0029 
rs1328674 A HTR2A 13 46867572 -0.45 (0.16) 0.0043 
rs498917 A ADRA1A 8 26862186 0.38 (0.14) 0.0065 
rs580644 A ADRA1A 8 26862973 0.38 (0.14) 0.0065 
rs9534501 A HTR2A 13 46865841 0.22 (0.11) 0.0409 
rs9567743 G HTR2A 13 46866665 0.22 (0.11) 0.0409 
rs731779 C HTR2A 13 46877903 0.27 (0.11) 0.0197 
rs9316235 A HTR2A 13 46871568 0.17 (0.10) 0.0927 
rs9526245 C HTR2A 13 46871832 0.17 (0.10) 0.0927 
Placebo analysis (n=162) 
rs2770298 G HTR2A 13 46872712 0.43 (0.12) 0.0006 
rs747107 A SLC6A2 16 55661809 0.41 (0.12) 0.0009 
rs2770296 G HTR2A 13 46866425 0.41 (0.12) 0.0011 
rs3785151 C SLC6A2 16 55678607 -0.43 (0.14) 0.0020 
rs9316235 A HTR2A 13 46871568 0.35 (0.12) 0.0037 
rs9534501 A HTR2A 13 46865841 0.34 (0.12) 0.0055 
rs9567743 G HTR2A 13 46866665 0.34 (0.12) 0.0055 
rs731779 C HTR2A 13 46877903 0.34 (0.14) 0.0137 
rs9316235 A HTR2A 13 46871568 0.35 (0.12) 0.0037 
rs9526245 C HTR2A 13 46871832 0.35 (0.12) 0.0037 
s.e.: standard error 
8.3.3.4. Linear mixed elastic net analysis 
The linear mixed elastic net analysis did not select any SNPs that are associated with change 
in MADRS-TS over time in the full sample. Model convergence was slow: a single cross-
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validation iteration for a single tuning parameter combination took from a few hours up to 
three days to run. Parallelizing the cross-validation steps did speed the process up, but 
given the relatively small size of the dataset we considered that this was slow. Moreover, 
the endpoint elastic net with a larger tuning parameter grid could be run in two hours 
without parallelizing cross-validation. In addition to computational time, we encountered 
more software weaknesses when estimating the linear mixed elastic net. For some tuning 
parameter combinations the model failed to converge in some cross-validation folds but did 
converge in others. The non-convergence occurred across the range of tuning parameter 
values and was not specific to either low or high values of tuning parameters. An additional 
issue was the specification of the tuning parameter grid. If the elastic net penalty is too 
strong (high 𝜆) all genetic variables are removed from the model, but a penalty that is too 
weak (𝜆 close to zero) retains all SNPs. The range of 𝜆 that allows variable selection 
depended heavily on 𝛼, and construction of the tuning parameter grid required a 
considerable amount of manual input. For instance, when 𝛼 = 1 values of 𝜆 smaller than 
0.003 retained all genetic variables and 𝜆 values larger than 0.011 caused all genetic 
variables to be removed from the model. When 𝛼 = 0.6, the range of 𝜆 values that allowed 
variable selection was between 0.005 and 0.025 and thus clearly dependent on the value of 
𝛼. We defined the range of 𝜆 wherein variable selection can take place by trial and error for 
each level of 𝛼, again a time intensive procedure. Because of these computational issues, 
the analysis was performed on the full sample, but was not repeated in the treatment 
specific datasets.  
8.3.4. Power simulation analysis 
We simulated a single SNP for the LY2216684 treated sample, which was analysed as a 
single SNP using linear regression and in combination with all 1,138 SNPs in an elastic net 
algorithm. We estimated the power as the proportion of simulations in which the simulated 
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SNP attained a p-value below the multiple-testing threshold (p= 1.35*10-4) in linear 
regression or in which the SNP was retained by variable selection in the elastic net model. 
The results of this simulation study suggest that in this sample elastic net may have more 
power than linear regression to detect a single SNP associated with MADRS-TS (Fig.45). 
Furthermore, the power curve of linear regression is very close to, but slightly lower than 
the theoretical curve from the genetic power calculator (Purcell, Cherny, & Sham, 2003). 
For both methods the power when there is no genetic effect, (i.e. heritability equal to zero), 
is close to zero as expected, indicating that the type I error is well-controlled for in both 
analysis methods. Realistic heritability values for a single SNP are smaller than 5% and in 
this range both endpoint methods have low power to detect genetic associations in this 
sample. 
 
Figure 45. Power curve for linear regression and elastic net, and theoretical power from 




This study compared four analysis methods to identify SNPs that have a PGx effect on 
antidepressant response. We contrasted traditional statistical modelling with machine 
learning algorithms, both for a single endpoint outcome and a repeated longitudinal 
outcome.  
The elastic net machine learning approach was applied to build an algorithm that predicts 
change in MADRS-TS from baseline at the end of the trial using a combination of genetic 
variables. In the full sample, elastic net identified a set of 23 SNPs that increased the 
predictive performance of the model compared to a clinical baseline covariate model only. 
Although no SNPs reached significance in the linear regression analysis, the results of both 
endpoint analyses were consistent in terms of which SNPs provided the strongest evidence 
for association. The modest decrease in RMSE when SNPs were included in the elastic net 
implies that the genetic covariates make only a minor contribution to the prediction 
accuracy. Furthermore, penalized logistic regression has been shown to outperform single 
SNP analysis methods in detecting associations in a simulation study (Ayers & Cordell, 
2010). It is thus not contradictory that these SNPs were picked up by the elastic net but did 
not reach significance in the linear regression. Nevertheless, our results should be 
replicated in an independent dataset for confirmation, particularly because our sample size 
did not allow the data to be split into a separate training and testing subset. In the 
longitudinal setting we did not detect any SNPs that associated with change in MADRS-TS 
over time in either the traditional or machine learning analyses. 
We have used elastic net to achieve the simultaneous analysis of many SNPs in a single 
regression-like model for the purpose of variable selection and parameter interpretation, 
but the resulting model can also be used for outcome prediction. Other machine learning 
methods, for example support vector machines, may further improve prediction, but these 
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algorithms are less interpretable. In many machine learning algorithms the relationship 
between covariates and outcome is not straightforward and difficult to translate to a 
biological meaning. Elastic net has the advantage that it can be seen as a machine learning 
extension of linear regression and the interpretation of elastic net model parameters is 
similar to that of linear regression parameters. 
Although statistical learning methods can handle more covariates than subjects, the 
available sample size is a limitation of our study, as it is not large enough to allow separate 
training and testing subsets, particularly for the treatment specific samples where 𝑛 was 
approximately 160. The average RMSE across cross-validation folds provides an estimate of 
the predictive performance of the elastic net but is likely to be too optimistic. Nevertheless, 
this study was primarily interested in the variable selection property of the elastic net and 
we do not use the model for prediction purposes.  
The simulation study revealed that in this sample the elastic net has more power than the 
linear regression to detect genetic associations with the change in MADRS-TS at the end of 
the study period. However, as power is defined differently for both analyses, this result 
should be interpreted with caution. In the linear regression analysis, each SNP is modelled 
separately and power is the probability of obtaining a significant p-value for the simulated 
SNP. By contrast, elastic net analyses all SNPs in a single model and the probability of the 
simulated SNP being selected is termed power. There is thus a conceptual difference 
between the traditional statistical and machine learning approaches. Furthermore, this is a 
limited simulation study applicable only to our sample and we cannot draw the general 
conclusion that elastic net is superior to linear regression in all datasets.  
Despite the increased power of the elastic net, both methods have less than 30% power to 
detect genetic effects with 5% heritability in the treatment specific samples. A stronger 
genetic effect is unlikely, given the lack of success of previous larger studies to identify the 
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genetic associations with antidepressant response (GENDEP Investigators et al., 2013). Lack 
of power may therefore be the reason why the elastic net failed to identify any SNPs in the 
LY2216684 and placebo analyses. Yet, it cannot be ruled out that there simply is no genetic 
association with the outcome in these samples. 
The simulation study also found that the power of the linear regression analysis was slightly 
lower than that of the theoretically calculated power curve, which is most likely due to the 
fact that baseline covariates were included in the regression analysis, something the 
genetic power calculator does not take into account. 
Although theoretically feasible, the linear mixed elastic net proved to be computationally 
challenging. Simplification of the random effects structure did reduce the computational 
burden significantly, but the software suffered from additional limitations. Non-
convergence in some cross-validation folds and difficulties in specifying the tuning 
parameter grid mean this method is not robust and not practical for applied data analysis. 
We expect that the computational issues we encountered in our longitudinal analysis will 
be aggravated if more variables, for example genome-wide data, are analysed. 
Other software packages for penalized linear mixed model exist (Table 4), but we did not 
extend our study to alternative methods for longitudinal statistical learning. The available 
software packages differ in the parameter estimation algorithm and penalty used, but they 
are relatively similar. We assume that genetic associations that can be identified by one 
machine learning method but not by another, are not likely to have clinically or biologically 
relevant effect sizes. 
We conclude that elastic net offers a valuable alternative to traditional statistical methods 
for the analysis of PGx studies, given its ability to incorporate many covariates in a single 
model. Elastic net identified 23 SNPs associated with change in MADRS-TS at the study 
endpoint consistent with linear regression results. Moreover, elastic net seemed to have 
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more power in our sample than linear regression to detect these associations. The elastic 
net model can be used for prediction purposes as well as interpretation of the parameter 
estimates. Although a linear mixed elastic net model is theoretically possible, software 




9.1. Summary of thesis research 
In this thesis we have studied barriers to the use of PGx testing in clinical practice. We 
described the characteristics of a clinically useful PGx test for clozapine induced 
agranulocytosis and noted that the known PGx variants lack sensitivity to alter clozapine 
monitoring guidelines. We also examined the economic arguments for PGx testing by 
reviewing the literature and concluded that the majority of economic evaluations found 
PGx guided pharmacotherapy to be cost-effective. Freely available genetic information 
would further increase the cost-effectiveness of PGx testing. 
Furthermore, we applied machine learning techniques to analyse a gene expression 
case/control study and two clinical trials with genetic data. These statistical algorithms lend 
themselves to the analysis of large datasets, such as genome-wide and transcriptome-wide 
studies. Machine learning methods enable training multivariable models examining large 
numbers of genetic variables simultaneously, which is a strong advantage over traditional 
statistical methods. In addition, these algorithms optimize predictive ability and can readily 
be applied as polygenic PGx tests. Our studies indicated that larger datasets will be 
necessary to increase the utility of machine learning in PGx research. 
9.2. Statistical methods for pharmacogenetic research 
PGx tests that are currently used in clinical practice are mainly based on a single or a 
handful of genes with large effect sizes. Most drugs listed on the FDA Table of 
Pharmacogenomic Biomarkers in Drug Labeling indeed mention a single genetic variant on 
their label and the maximum number of genes reported per drug is seven (for valproic 
acid). Single variant successes such as the HLA associations with abacavir and 
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carbamazepine induced ADRs suggested that genetic associations with PGx outcomes 
would have large effect sizes. The effect sizes for PGx outcomes detected in GWAS are 
indeed larger than those for non-PGx complex outcomes, an observation which is not 
explained by the often smaller sample sizes of PGx studies (Maranville & Cox, 2016). Hence, 
it was expected that candidate gene studies with small samples would have sufficient 
power to detect strong PGx associations. Although this approach has been successful for 
some examples, this has not proved true in general. Many findings from candidate gene 
studies turned out to be false positives and have failed to replicate, and the success of PGx 
GWAS in detecting novel PGx variants has been modest (Ioannidis, 2013). Considering the 
failure to robustly identify strong PGx effects, we need to expand our search to common 
genetic variants with moderate or weak effect sizes. It is likely that treatment efficacy and 
safety are complex outcomes and that the genetic contribution is polygenic, i.e. a combined 
effect of weak and moderate genetic associations. Larger sample sizes will be necessary to 
identify weak genetic effects. Sample sizes of PGx GWAS have lagged far behind those of 
disease genetics studies and are often smaller than 1,000 individuals (Motsinger-Reif et al., 
2013). In the field of disease genetics, larger sample sizes have indeed led to more genome-
wide significant associations and the same can be expected for PGx studies (Gratten et al., 
2014). Alternatively, rare variants may have an effect on PGx outcomes through distinct 
mechanisms. In particular for rare ADRs such as clozapine induced agranulocytosis (chapter 
2), this seems a plausible explanation. Investigating rare variant associations requires 
appropriate study design and statistical methods (Lee, Abecasis, Boehnke, & Lin, 2014).  
In addition to larger GWAS to detect modest and weak genetic variants, PGx studies should 
examine polygenic effects. A polygenic risk score, in effect the sum of several SNP alleles 
weighted by their effect size in a discovery sample, summarizes genome-wide genetic 
effects in a single continuous variable (Dudbridge, 2013). This score can subsequently be 
used to predict phenotypes in a replication sample. For example, polygenic risk scores from 
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schizophrenia, bipolar disorder and major depressive disorder explain 18.4%, 2.8% and 
0.6% of variance in case/control status in these disorders, respectively (Psychiatric GWAS 
Consortium Bipolar Disorder Working Group, 2011; Ripke et al., 2013; Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014). Polygenic risk scores can 
also be constructed for and used to predict PGx outcomes. Applied to antidepressant 
response, no significant prediction from polygenic risk scores was obtained, though the 
authors commented that the study might be underpowered (García-González et al., 2017). 
As sample sizes increase, the predictive ability of polygenic risk scores may improve and 
achieve meaningful prediction accuracy for antidepressant response. 
As an alternative to polygenic risk scores, machine learning and deep learning methods can 
be employed to model polygenic effects. Machine learning algorithms allow the 
simultaneous analysis of large numbers of correlated genetic variants. These methods 
enable an approach that is not possible via traditional statistical model as the latter struggle 
with correlated variables. Furthermore, traditional statistical methods such as linear and 
logistic regression require the number of predictor variables to be small in comparison to 
the number of individuals in the sample. Machine learning techniques provide a solution to 
this problem and can even be applied to datasets with more variables than subjects. 
Moreover, as machine learning algorithms are trained by optimizing prediction accuracy, 
they can readily be applied as polygenic biomarkers to guide treatment. These methods are 
also more flexible than polygenic risk scores as machine learning algorithms can model non-
linear multivariable effects while polygenic risk scores are linear combinations of single SNP 
effects. Another advantage is that it is relatively straightforward to include additional 
predictors such as demographic and clinical variables in machine learning models. In 
addition, many algorithms return variable importance scores, which can be used to identify 
relevant genetic variants. 
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In this thesis, we have applied machine learning to genetic (chapter 7 and 8) and gene 
expression studies (chapter 6). Both sources of data result in datasets with large numbers 
of variables, but each type has its own advantages and disadvantages. The invariability of 
genetic code is an attractive property of genetic data as it means that an individual only 
needs to be genotyped once to obtain information that remains relevant throughout their 
life. The same variables, i.e. genotypes, can be used to study many different phenotypes. 
Moreover, each somatic cell in the body contains the entire genetic code and a simple 
saliva sample is sufficient to collect it. Although missing genotypes can sometimes be 
imputed based on LD with observed genotypes, missing observations are inevitable in a 
genetic dataset. This is not a major problem in GWAS, but many machine learning methods 
require complete data and thus imputation techniques must be used to estimate missing 
information. On the other hand, gene expression scores are dynamic over time, so have to 
be measured at specific time points when used to study treatment response or safety. This 
means that transcriptomic data are only relevant for a limited period of time. Though the 
dynamic nature of this type of data also has its advantages as gene expression can change 
in response to variations in the patient’s condition. For example, changes in gene 
expression following the administration of a drug might predict the development of an 
ADR. Furthermore, gene expression is tissue and cell specific. Although gene expression in 
blood cells can easily be measured, other tissues which are less accessible might be more 
relevant to the outcome studied. For instance, for a PGx study of antipsychotic response 
gene expression in the brain might be most informative but virtually impossible to obtain. 
Gene expression can be summarized in a continuous score and by definition there are no 
missing observations in the data. These characteristics mean that transcriptomic data are 
particularly suitable for machine learning.  
Since machine learning and deep learning methods are capable of analysing large numbers 
of predictors simultaneously, they are not only convenient for the analysis of genetic or 
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transcriptomic datasets, but can also be used to build integrative multi-omics prediction 
models combining several large datasets. When it comes to predicting a PGx outcome, 
other sources of information than genetics could be relevant. Demographic and clinical 
descriptives, as well as transcriptomic, proteomic or metabolomic variables may contain 
some prediction signal and machine learning algorithms can be used to combine predictors 
from various sources to achieve maximal predictive accuracy. A limitation of this approach 
is the fact that whereas genetic information is invariable over time and can be stored for 
future use, other variables have to be measured at the time of testing and results might not 
be available immediately. For example, it may take days or weeks between sample 
collection and the reporting of gene expression scores. Nevertheless, combining several 
sources of information could result in more precise prediction models for treatment 
efficacy and safety and advance our understanding of the mechanisms underlying PGx 
outcomes.  
9.3. Challenges to pharmacogenetic research and implementation 
The crucial limitation for successful PGx studies will be obtaining large sample sizes. Not 
only do participants of PGx efficacy studies need to suffer from the same disease, but they 
also need to be treated with the same drug. This means the eligible patient population is 
smaller than for studies of disease genetics, particularly when there is a wide range of 
treatments available. Most patients treated with a drug achieve average response and 
contribute little information. Moreover, PGx studies investigating ADRs have more stringent 
recruitment criteria as they require patients who have developed the ADR. Usually, patients 
are recruited to a study because they are treated with the specific drug, and few suffer 
from an ADR. Collecting large samples can prove extremely difficult when the ADR under 
study is rare.  
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Secondly, heterogeneity in the phenotype may reduce the power to detect genetic 
associations and underestimate effect sizes (Manchia et al., 2013). Phenotypic 
heterogeneity and misdiagnosis is a limitation in disease genetics, but also applies to PGx 
studies. For example, in a clinical trial evaluating PGx screening prior to abacavir use, HLA-
B*5701 was associated with immunologically confirmed hypersensitivity reaction (odds 
ratio = 0.03), but the association with clinically diagnosed hypersensitivity reaction was 
substantially weaker (odds ratio = 0.4) (Mallal et al., 2008). It is thus important to 
unambiguously define the PGx outcome studied.  
It is important to keep in mind that statistical significance is not sufficient for a PGx marker 
to be of clinical relevance. A genetic association may be significant, but if it does not 
translate to accurate predictions it lacks clinical utility as a PGx test. In order to make an 
impact on pharmacotherapy, a PGx test needs to provide reliable results and thus sufficient 
precision in terms of PPV and NPV. For instance, the HLA-B*5701 association with abacavir 
has 100% NPV, meaning that all test negative patients can safely be treated with abacavir. 
In contrast, a PGx test using a polymorphism in HLA-DQB1 to predict clozapine induced 
agranulocytosis identifies one in five agranulocytosis cases and test negative patients 
benefit from only 20% risk reduction, which is not enough to disregard the risk of this ADR 
and change blood monitoring requirements. It is unlikely that common variants with weak 
effect sizes will achieve clinically significant effect sizes on their own. Rather, hope lies in 
the combination of multiple genetic variants with other information such as clinical 
variables to achieve higher prediction accuracy. Still, PGx associations with effect sizes 
below clinical relevance can be useful to elucidate the mechanisms of drug efficacy and 
safety. 
An additional barrier to the implementation of PGx tests is the level of evidence that is 
required before a PGx effect is considered proven. The highest standard of evidence is a 
randomized controlled trial, though these are expensive to conduct and time-consuming. 
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The PGx community needs to discuss the necessity of randomized clinical trials and which 
other forms of evidence, for example observational studies, can be taken into account 
(Pirmohamed, 2014). Nevertheless, it is foresighted to incorporate PGx studies in the design 
of clinical trials or to genotype participants. The pharmaceutical company AstraZeneca 
plans to sequence the genome of 500,000 trial participants as part of a large genetic project 
investigating rare genetic variants associated with disease and treatment response 
(Ledford, 2016). 
Since health care budgets are limited, there are economic considerations to be made 
before a PGx test is used in clinical practice. Our literature review in chapter 4 revealed that 
over half of economic evaluations found PGx testing was cost-effective. However, one in 
four economic studies concluded that PGx guided treatment was not cost-effective, which 
highlights the necessity of assessing the economic consequences of a PGx test prior to 
implementation in clinical practice. As the cost of genetic testing decreases, it is expected 
that more PGx tests will be cost-effective. 
Once the clinical relevance and economic feasibility of robust PGx associations have been 
established, PGx testing can be implemented in standard clinical practice. This means that 
patients outside of the research setting need to be genotyped. It is important that 
genotyping results are available quickly as not to delay the start of drug treatment. 
Furthermore, in the case of polygenic prediction algorithms, a large number of genetic 
variants need to be typed. As PGx testing becomes a more widely used health care 
application, genome-wide genotypes or even whole genome sequences may be added to 
electronic health records and genetic information will immediately be available at no 
additional cost at the time of prescribing.  
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9.4. Future perspectives 
Studies with larger sample sizes will be required to improve our chances of identifying novel 
PGx variants with moderate or weak effect sizes. Not only will larger sample sizes have 
more power to detect weak effects in GWAS, they will also enhance the potential of 
machine learning and increase prediction accuracy. Furthermore, advanced deep learning 
algorithms could be trained on PGx datasets. Since neural networks have outperformed 
other algorithms in many research areas, they might also excel in predicting PGx outcomes. 
Given the narrow recruitment criteria for PGx studies it will not be easy to collect large 
samples. International collaboration can help to achieve this goal. For example, the Clinical 
Pharmacogenetics Implementation Consortium (CPIC), the International Warfarin 
Pharmacogenetics Consortium (IWPC) and the Pharmacogenomics Research Network 
(PGRN) bring together researchers from various countries to join forces on PGx studies 
(Giacomini et al., 2017).  
As well as larger samples, future studies should also collect more information on the study 
participants. Clinical, demographic, genetic, transcriptomic, epigenetic, proteomic and 
metabolomic data can be combined to build integrative multi-omics prediction models. 
Though not a PGx study, the LIBD data analysed in chapter 6 serves as an example of how 
multiple sources of data can be combined in a single analysis. The LIBD dataset originates 
from a study investigating differences in post-mortem brains between schizophrenia 
patients and control subjects. We used gene expression scores from the DLPFC brain region 
to train a classification algorithm for schizophrenia case/control status. In addition to the 
DLPFC, gene expression and methylation levels were measured in the hippocampus and 
caudate and the subjects were genotyped, and these datasets will be released to the 
scientific community at a later stage of the BrainSeq project (Schubert et al., 2015). Thus, 
gene expression scores and methylation data from the three brain regions studied could be 
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combined in a multi-omics machine learning analysis to classify schizophrenia patients from 
controls. The capacity of machine learning algorithms to include large numbers of variables 
in a single model enables such integrative analyses where large scale omics datasets are 
combined in a hypothesis-free way. 
The clinical utility of a PGx biomarker depends partly on the predictive precision of the test 
and its cost-effectiveness. In chapter 2 we have investigated the characteristics that a PGx 
test for clozapine induced agranulocytosis should have in order to be of clinical relevance. 
However, there is no widely agreed on threshold for what constitutes a clinically acceptable 
agranulocytosis risk. A cost-effectiveness study may provide an indication as to the 
minimum PPV and NPV levels that are required for PGx test to be economically worthwhile. 
These cost-effective PPV and NPV benchmarks can be used to inform the discussion on 
clinically relevant prediction accuracy of a PGx test. In addition to health economics, many 
other clinical and ethical arguments play a role in the debate on clinical implementation of 
PGx tests. This observation is highlighted by the fact that haematological monitoring of 
patients on clozapine is not cost-effective when compared to a no monitoring strategy, yet 
monitoring is compulsory in many countries (Girardin et al., 2014). 
Furthermore, it is important that cost-effectiveness assessments are updated regularly. 
When the input parameters, for example the range of drugs on the market, evolve, the 
cost-effectiveness of a treatment strategy might change, which is true not only for 
economic evaluations of PGx tests but for all health care interventions. Newly discovered 
genetic biomarkers and the price of genetic testing are factors specific to PGx testing that 
might influence the cost-effectiveness of PGx-guided treatment. We explored the impact of 
freely available genetic information in chapter 4 and concluded that this variable indeed 
plays a notable role in the cost-effectiveness of PGx testing. However, it may not always be 
straightforward to estimate the consequences of changing input parameters on the cost-
effectiveness conclusions, in particular as these parameters can evolve concurrently and 
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can interact with each other. Hence, cost-effectiveness should be re-evaluated when the 
circumstances of PGx testing change. Up-to-date economic evaluations are necessary to 
accurately inform the allocation of health care budgets.  
In conclusion, to advance the field of PGx larger studies will be necessary. Traditional 
statistical approaches as well as machine learning and deep learning techniques will be 
useful to unravel the mechanisms of non-response and ADRs and to build accurate 
multivariable prediction models. It is likely that polygenic effects, i.e. a combination of 
multiple genetic variants with weak effect sizes, underlie PGx outcomes. Although weak 
genetic markers have little predictive power on their own, algorithms combining multiple 
genetic variants, possibly also including other sources of information, might achieve high 
prediction accuracy. More accurate predictions will improve the clinical utility and cost-
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